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Abstract 
The ETS transcription factor family members are involved in multiple cancers, including prostate cancer. 
Whilst extensive literature exists on the highly prevalent TMPRSS2-ERG gene fusion, the role of other ETS 
factors in prostate cancer is less well understood. ELF3 has been ascribed both oncogenic and tumour 
suppressive roles in prostate cancer and has been highlighted as a regulator of epithelial cell differentiation 
in other tissues. The overarching aim of this project was to elucidate the role of ELF3 in the context of both 
normal prostate development and prostate cancer. 
This study details an extensive expression profile of ELF3 in prostate epithelial cell lines, primary prostate 
cell subpopulations and prostate tissue. ELF3 expression was restricted to the basal compartment of 
epithelial glands, specifically to the committed basal cell subpopulation of the basal epithelial hierarchy. 
Appropriate cell models were used to investigate the role of ELF3 in the prostate. By silencing ELF3 in BPH-
1 and PC3 cells, ELF3 was established as a regulator of the cell cycle. This manifested as a decrease in 
colony forming ability, migration and cell viability caused by G2 cell cycle arrest. Furthermore, manipulating 
ELF3 expression altered the differentiation status of cell lines and primary cells, highlighting that a balance 
of ELF3 expression is required to maintain proper differentiation of the epithelial hierarchy. Finally, a possible 
link of ELF3 to more advanced prostate tumours using tissue microarray analysis, a potential association 
with neuroendocrine differentiation and putative survival advantage of ELF3 expression in cancer vs normal 
cells, was identified. 
These results suggest that ELF3 acts as an oncogene in the prostate cancer setting. However, its 
importance in normal prostate epithelial cell growth and differentiation has also been demonstrated. Work 
should now focus on identifying appropriate downstream effectors that could be targeted to exploit these 
properties for prostate cancer treatment.   
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1. Introduction  
1.1 Function and anatomy of the prostate 
The prostate is a male secretory gland comprised of a series of glandular epithelial acini and muscular 
stroma. It is responsible for producing proteins, such as prostatic acid phosphatase (PAP) and prostate 
specific antigen (PSA) and secreting the fluid which constitutes semen via ducts which lead to the urethra. 
The prostate is located below the bladder, surrounding the urethra, and is in close proximity to a collection 
of nerves called the prostatic plexus which is responsible for controlling urinary output as well as erection 
and ejaculation. As a result of this position, enlargement of the prostate can lead to both urinary and sexual 
symptoms (Figure 1.1). The prostate can be divided into separate zones, each with its own propensity for 
disease. The peripheral zone is found at the base of the prostate and forms ~70% of the tissue. This area 
is where the majority of prostate cancers (PCa) arise (>70%) and can be assessed during a digital rectal 
examination. The central zone lies just below the bladder. Prostate tumours rarely arise from the central 
zone however they are associated with an aggressive phenotype and poor prognosis (Lee et al., 2011).  
Finally, the transitional zone is located in front of the central zone surrounding the urethra and is the site 
where the majority of benign enlargement of the prostate occurs, known as benign prostatic hyperplasia 
(BPH) (McNeal, 1981). 
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Figure 1.1. The zonal anatomy of the prostate. 
The prostate gland is situated below the bladder, surrounding and linking the urethra to the ejaculatory duct. The prostate 
consists of four zones; the peripheral zone, anterior zone, central zone and transitional zone, each of which has its own 
propensity for prostate pathology. Reprinted from (Sathianathen et al., 2018), with Copyright permission from Springer 
Nature. 
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1.2 Cellular organisation of the normal prostate 
The normal prostate epithelium is composed of an hierarchy of cells that can be split into a basal 
compartment, which is attached to the basement membrane (BM), and a luminal compartment, which is the 
inner layer lining the lumen (Figure 1.2). Androgen-independent basal cells comprise the proliferative 
compartment of the adult prostate and can be distinguished by their expression of specific cytokeratins (CK) 
including CKs 5 and 14 (Schalken and van Leenders, 2003), and other cell markers such as p63 (Signoretti 
et al., 2000), CD44 (Terpe et al., 1994) and bcl-2 (McDonnell et al., 1992). The fully differentiated luminal 
cells are the secretory cells of the prostate. These are androgen-responsive, expressing high levels of the 
androgen receptor (AR) and PSA. Luminal cells also express CKs 8 and 18 (Schalken and van Leenders, 
2003) and CD57 (Liu et al., 1997b). Distinct differentiation states have been found within the basal 
compartment, adding another level of complexity and heterogeneity to the prostate epithelium. The base of 
the hierarchy consists of normal basal stem cells (SC) which are largely quiescent (Oldridge et al., 2012). 
Some SCs asymmetrically divide into a proliferative, intermediate progenitor cell population which are 
termed transit amplifying (TA) cells. A third population committed to differentiation called committed basal 
(CB) cells completes the basal hierarchy (Oldridge et al., 2012, Isaacs and Coffey, 1989). Significantly, 
several studies have shown that both basal and luminal cells derive from the same rare SC precursors found 
in the basal compartment, providing further evidence for the presence of a differentiation hierarchy in the 
prostate (Isaacs and Coffey, 1989, Hudson et al., 2001, Lang et al., 2001b, van Leenders et al., 2001).  
A rare neuroendocrine (NE) cell population is also scattered throughout the basal compartment of the 
prostate epithelium. These granular cells secrete peptide hormones such as serotonin and chromogranin A 
(ChrA) that regulate epithelial cell proliferation and differentiation (di Sant'Agnese, 1998, Rumpold et al., 
2002). On the opposite side of the basal basement membrane lies the network of fibromuscular stroma 
which includes smooth muscle cells, fibroblasts, collagen fibres, endothelial cells and nerve fibres (Barron 
and Rowley, 2012). The stroma is important for maintaining prostate tissue growth and homeostasis through 
interactions with epithelial cells and secretion of growth factors. 
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Figure 1.2. Differentiation hierarchy of the normal prostate. 
The normal human prostate epithelium is composed of an hierarchical differentiation pathway. SCs differentiate into rapidly 
dividing transit amplifying cells by asymmetric division and thus also maintain themselves. Multipotent transit amplifying 
cells differentiate into committed basal cells, which then commit to terminal differentiation into secretory luminal cells. This 
tightly regulated pathway generates a highly organised glandular structure consisting of the luminal layer, the basal layer 
attached to the basement membrane and the surrounding stroma. Adapted from (Archer et al., 2017). 
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1.3 Disorders of the prostate 
1.3.1 Benign prostatic hyperplasia 
There are a number of disorders of the prostate which have all been linked by some means to the 
development of PCa. BPH involves an androgen-dependent abnormal increase in proliferation of the 
epithelial and stromal cells within the prostate (Roehrborn, 2008). This disorder primarily occurs in the 
transitional zone and can result in the obstruction of urine in the urethra which can be somewhat alleviated 
by transurethral resection of prostate (TURP) (Simpson, 1997). Like PCa, the presence of BPH increases 
with age, with 88% of autopsies of men over 80 presenting with BPH (Boyle, 1994). There is accumulating 
evidence that inflammation plays a key role in the development of BPH. The presence of immune cell 
infiltrates and cytokines in BPH lesions has been observed and this is thought to promote tissue remodelling 
and further proliferation and enlargement (Kramer et al., 2007, Bostanci et al., 2013, Fibbi et al., 2010). 
1.3.2 Prostatic intraepithelial neoplasia 
Prostatic intraepithelial neoplasia (PIN) is defined by accumulating abnormalities in the prostatic epithelium 
with progressive similarities to adenocarcinoma. These include an increase in proliferation in luminal 
epithelial cells and a decrease in basal cells (Shen and Abate-Shen, 2010). Whilst it does not increase the 
levels of prostate PSA, the presence of PIN is considered an early stage of carcinogenesis and the majority 
of patients presenting with PIN develop cancer within 10 years. The incidence of PIN also increases with 
age, but predominantly occurs in the peripheral zone of the prostate. Tissue with high-grade PIN lesions 
share both morphological and genetic similarities to PCa (Bostwick et al., 2004). 
1.3.3 Prostatitis 
Inflammation of the prostate, known as prostatitis, is divided into four categories; acute and chronic bacterial 
prostatitis, most commonly caused by E.coli and Enterococcus spp, asymptomatic inflammatory prostatitis 
and chronic prostatitis, also known as chronic pelvic pain syndrome (CPPS) (Murphy et al., 2009, Cai et al., 
2011). It is estimated that 15% of US males will be affected by symptomatic prostatitis in their lifetime 
(Krieger, 2004). However, the presence of inflammation in prostatic biopsies and TURPs suggest that the 
prevalence of asymptomatic prostatitis may be much higher and that inflammation may be an important 
factor in prostate carcinogenesis (De Marzo et al., 2007, Nickel et al., 1999, Nickel et al., 2008). 
1.4 Prostate cancer 
1.4.1 Epidemiology and risk factors 
PCa is the most common cancer of men in the UK, accounting for 26% of all new cancer cases. It is currently 
the second most common cause of cancer-related death (13%), following lung cancer and it is estimated 
that 1 in 8 males in the UK will develop the disease in their lifetime (Cancer Research UK, 2016). 
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Epidemiological and genetic studies have defined clear risk factors. PCa is most highly associated with age, 
with over a third of new cases found in men ≥75 (Figure 1.3). PCa is also more prevalent in black males 
than white males, with Asian males possessing significantly lower risk (Quinn and Babb, 2002). 
Other PCa risks include familial factors which was first explored by Morganti et al. in 1956, and describes 
several members of the same family developing the disease due to environmental factors, genes or a 
combination of the two, accounting for 10-20% of all PCa cases (Morganti et al., 1956, Stanford and 
Ostrander, 2001). Hereditary PCa is a subset of familial PCa caused by the Mendelian inheritance of rare 
susceptibility genes (Potter and Partin, 2000). Hereditary PCa is considerably more prevalent in relatively 
younger diagnosed patients, accounting for 43% of cases diagnosed below the age of 55. There are now 
over 70 susceptibility loci that confer an increased risk for PCa, identified through genome wide association 
studies (Eeles et al., 2013). An example of susceptibility genes that are of current interest are BRCA1 and 
BRCA2, gene mutations of which are most widely associated with a predisposition for breast cancer. BRCA2 
mutations have now been confirmed as a risk factor for early and aggressive PCa and patients show poorer 
outcomes following localised PCa treatment than those who do not harbour mutations (Mottet et al., 2017, 
Castro et al., 2015). Phase II clinical trials have found patients with BRCA2 mutations and other DNA repair 
defects respond favourably to PARP inhibitors such as olaparib, highlighting the need for stratified therapies 
(De Felice et al., 2017). 
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Figure 1.3. Prostate cancer is highly associated with age. 
The average number of new cases per year and incidence rate with age from 2013-2015, compiled by Cancer Research 
UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-
cancer/incidence#heading-One. 
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1.4.2 Diagnosis and grading  
PSA testing of men over 50 remains the gold standard for the screening of PCa. Normal levels of PSA in 
the blood is <4ng/ml, however this figure rises naturally with age. Although the introduction of PSA testing 
led to a dramatic increase in PCa incidence in the late 1980s, this method of detection remains imperfect. 
PSA levels not only rise in the incidence of PCa but also due to infection, prostatitis and BPH (Obort et al., 
2013). Furthermore, although PSA is termed a prostate-specific protein, detectable expression has also 
been found in other tissues including the breast, lung, ovary and salivary glands (Smith et al., 1995). PSA 
detection and subsequent PCa diagnosis can often lead to the overtreatment of many patients. Several 
alternative biomarkers specific to PCa have been investigated, such as PCA3 and TMPRSS2:ERG (Romero 
Otero et al., 2014, McGrath et al., 2016). However, PSA still remains the most advantageous screening 
method to date. 
Following high level PSA detection, multiple transrectal ultrasound (TRUS) biopsies are usually taken. The 
Gleason grading system is the most widely used technique for grading prostate carcinomas (Gleason, 1966). 
H&E stained histological sections of prostate are graded according to the most common patterns of cells 
observed under the microscope. The system has been updated in recent years to reduce ambiguity between 
grades for pathologists (Figure 1.4) (Epstein, 2010). Patterns are graded 1-5 by their degree of differentiation 
and visual abnormalities compared to normal prostate tissue, with 1 representing normal glandular 
structures and 5 representing abnormal sheets of undifferentiated tissue. The sum of the most common 
(primary) and second most common (secondary) patterns produces the total Gleason score. A new 
classification system divides patients into the grade groups defined in Figure 1.4 (Epstein et al., 2016). The 
Gleason system has been a powerful tool in predicting prognosis and aiding the decision of treatment 
options. Furthermore, the upgraded classification has resulted in a reduction in overtreatment of Gleason 6 
cancers (as more aggressive patterns are now associated with a Gleason score of 7) and distinguishes the 
prognostic differences in Gleason scores 3 + 4 and 4 + 3 (Epstein et al., 2016). However, its limitations 
include the absence of consideration of the heterogeneity of PCa, as several different Gleason patterns 
have been found in single prostate tumours (Humphrey, 2004). Discovery of a PCa-specific biomarker 
capable of determining progression and aggressiveness would aid to avoid overtreatment and allow for a 
more appropriate treatment regime for individual patients. 
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Figure 1.4. Gleason grading system of prostate adenocarcinoma. 
Updated Gleason grading system of prostate adenocarcinomas. Histological patterns are scored 1 to 5 according to degree 
of disorder. Reprinted from (Epstein, 2010), with Copyright permission from Elsevier. 
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1.4.3 Treatment of localised prostate cancer 
A patient with low Gleason grade, localised PCa has the option to either receive treatment or undergo active 
surveillance (Kollmeier and Zelefsky, 2012). Both tumour grade and patient preference will impact this 
decision.  
As some low Gleason grade adenocarcinomas will never progress, overtreatment of these men is an 
ongoing problem. A case for active surveillance as an alternative option is growing, whereby the patient 
receives routine PSA level checks and biopsies. The inability to determine which patients will undergo 
disease progression is a cause for reservation. However, the quality of life of the patient following treatment 
must also be taken into consideration (Bul et al., 2013, Klotz, 2006, Xia et al., 2012, Bellardita et al., 2014).  
If immediate treatment is favoured, options include surgical removal of the prostate, known as radical 
prostatectomy (RP), radiotherapy or focal treatment. The most common treatment is RP, which risks 
undesirable side effects, most notably incontinence and impotence.  
Radiotherapy is an option for local and locally advanced PCa in conjunction with hormone therapy, and can 
be delivered by external beam radiation therapy (EBRT) or directed brachytherapy. EBRT includes three-
dimensional conformal radiation therapy (3D-CRT) and image-guided intensity-modulated radiation therapy 
(IMRT) (Heidenreich et al., 2014a). IMRT is presently favoured due to the capacity for higher doses of 
radiation without increasing off-target toxicity (Bauman et al., 2012). Brachytherapy involves direct radiation 
of the prostate by either a temporary high dose implant or permanent low dose radioactive seeds. An 
advantage to brachytherapy is the limited radiation to the surrounding tissues, whereas EBRT risks rectal 
toxicity (Crook, 2011). However, many authors have demonstrated that a high dose of radiation is required 
for a better outcome in patients (Zelefsky et al., 2001, Kupelian et al., 2005). A ten year follow-up study 
monitoring patients undergoing active surveillance, RP or EBRT found there was no significant difference in 
PCa-related deaths (Hamdy et al., 2016). However, RP and ERBT were associated with lower risk of disease 
progression and metastases compared to active surveillance. 
At present there are various focal therapies for PCa available which aim to target a tumour directly and limit 
damage to the surrounding tissue in order to avoid the undesirable side effects of the alternative therapies 
already discussed. Given PCa is often a multifocal disease, focal therapy is generally selected for patients 
considered low-risk of progression, where the tumour is restricted to one lobe and unifocal (Eggener et al., 
2010). High-intensity focused ultrasound (HIFU) utilises targeted thermal damage with magnetic resonance 
imaging (MRI) as guidance (Napoli et al., 2013). It is delivered transrectally and so avoids invasive surgery. 
As HIFU is a relatively new therapy, there is a lack of studies with long term follow up. However, the current 
cancer-free survival rates and low rates of serious side effects are promising (Cordeiro et al., 2012, Ramsay 
et al., 2015). Extreme low temperature and thawing cycles characterise cryotherapy which can be used to 
treat localised PCa or as salvage therapy following relapse (de la Taille et al., 2000). A transperineal argon 
gas or liquid nitrogen probe is used, guided by TRUS (Nomura and Mimata, 2012).  Cryoablation is a 
relatively invasive treatment and also requires warming of the surrounding tissues to avoid damage (Cohen 
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and Miller, 1994). Photodynamic therapy (PDT) involves intravenous injection of photo-sensitive drugs which 
specifically act in the prostate by administration of light. This therapy induces necrosis of tumour material 
and largely avoids damaging other tissues (Koudinova et al., 2003). However, since the drug is administered 
intravenously, patients must avoid direct sunlight for a period of time depending on the half-life of the drug 
used (Moore et al., 2009). Results from a recent clinical trial show that after 3.5 years follow up, 75% of 
patients maintained complete tumour ablation in the treated lobe (Noweski et al., 2018).  
1.4.4 Metastasis and epithelial-to-mesenchymal transition 
Metastasis is the cause of over 90% of deaths from solid tumours (Valastyan and Weinberg, 2011, Gupta 
and Massague, 2006). Despite local therapy, up to 40% of men will develop metastatic PCa, most commonly 
to the bone (Beltran et al., 2011). Activation of invasion and metastasis is one of the hallmarks of cancer 
described by Hanahan and Weinberg, where transformed cells progress through a coordinated series of 
steps, coined the invasion-metastasis cascade, summarised in Figure 1.5 (Hanahan and Weinberg, 2000, 
Hanahan and Weinberg, 2011).  
Following formation of a primary tumour, cells undergo a number of changes to facilitate local invasion of 
the BM and surrounding stroma. Epithelial-to-mesenchymal transition (EMT) is a process which occurs 
during normal organ development and wound healing (Thiery et al., 2009). EMT has also become 
recognised as a major mechanism by which transformed epithelial cells acquire the ability to invade 
surrounding tissue and disseminate to form distant metastases. It is a molecular switch from an epithelial 
cell phenotype to a mesenchymal cell phenotype, culminating in the loss of cell polarity and tight junctions 
between cells. The most well characterised alteration is the loss of epithelial cell marker E-cadherin and 
induced expression of mesenchymal cell marker N-cadherin, which results in the loss of cell-to-cell contacts 
and promotes a migratory mesenchymal cell phenotype (Valastyan and Weinberg, 2011). This switch in 
gene expression is controlled by several master transcription factors of EMT including Snail, Slug, ZEB1/2 
and Twist (Thiery et al., 2009). EMT transcription factors are capable of promoting a cell phenotype which 
facilitates almost the entirety of the invasion-metastasis cascade. Mesenchymal-to-epithelial transition 
(MET), the reversal of EMT, may occur at distant tumour sites to permit establishment of invading tumour 
cells (Polyak and Weinberg, 2009).  
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Figure 1.5. The invasion-metastasis cascade. 
Schematic detailing the stages of the invasion-metastasis cascade. A metastatic cell must invade the local tissue and enter 
the circulation via intravasation. Should the cell survive transit, it must then invade the distant tissue site and adapt in order 
to survive and form metastatic lesions in the new foreign microenvironment. Reprinted from (Valastyan and Weinberg, 
2011), with Copyright permission from Elsevier. 
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Whilst bone is the most prominent site of PCa metastases, occurring in 90% of patients with advanced PCa, 
they are also commonly known to occur in the lymph nodes, lungs and liver (Bubendorf et al., 2000, Kelly 
and Yin, 2008). This tropism for bone is thought to be regulated by chemokines. Chemokines are a class of 
chemotactic cytokine which are important for immune cell development and recruitment of immune cells to 
sites of inflammation. The chemokine CXCL12 is highly expressed at sites of PCa metastases, including 
bone (Mognetti et al., 2013). Its receptor, CXCR4, has been shown to be expressed in PCa cell lines as well 
as increased expression in tissue sections derived from primary prostate tumours and mestastases 
compared to normal prostate (Sun et al., 2003, Akashi et al., 2008, Chetram et al., 2011).  
The surrounding stroma, both locally in the prostate and at sites of metastases, provide factors such as 
cytokines and growth factors, which interact with tumour cells and cooperatively facilitate invasion into the 
circulation from the primary tumour and also survival at the new tumour site (Josson et al., 2010, Morrissey 
and Vessella, 2007). The tumour-associated stroma (known as “reactive stroma”) demonstrates changes in 
composition which can be distinguished from normal stroma, such as a switch from largely smooth muscle 
cell content in normal prostate stroma to a more myofibroblast and fibroblast cell content in reactive stroma 
(Tuxhorn et al., 2002). This process is thought to be regulated in part by TGF-β and Wnt signalling, which 
are also known regulators of EMT (Barron and Rowley, 2012).  
1.4.5 Treatment of metastatic prostate cancer  
High-grade and metastatic PCa is generally treated with pharmacological drugs which aim to deprive the 
tumour of androgens which are essential for growth, known collectively as androgen-deprivation therapy 
(ADT). The standard categories of ADT are as follows: 
1) Anti-androgen therapy: prevents activation of target genes by interacting with the AR, e.g. 
bicalutamide (Iversen et al., 2000). 
2) Oestrogen treatment: prevents testosterone production by inhibiting 5-α reductase, e.g. 
diethylstilbestrol (McLeod, 2003). 
3) Gonadotrophin-releasing hormone (GnRH) agonist: inhibits androgen production by 
desensitising hormone feedback systems in the pituitary, initially used in conjunction with anti-
androgens to prevent tumour flare, e.g. goserelin (Peeling, 1989). 
4) GnRH antagonist: binds to GnRH receptor and inhibits testosterone production, e.g. degarelix 
(Shore, 2013). 
Many different agents have been trialled with different mechanisms of action. Oestrogen therapy via 
diethylstilbestrol (DES) was the first hormonal therapy used for PCa in the 1960s. However, the overall 
mortality rate among patients treated with DES was higher due to increased cardiovascular disease, 
highlighting the need for alternative treatments (McLeod, 2003). GnRH agonists, such as goserelin, are used 
at present, which avoid the need for surgical castration (Peeling, 1989, Heidenreich et al., 2014b, Seidenfeld 
et al., 2000). The use of nonsteroidal anti-androgen therapy such as bicalutamide for locally advanced PCa 
does not have significant survival benefits over castration but does provide the patient with a better quality 
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of life (Tyrrell et al., 1998, Iversen et al., 2000, Iversen, 2003). Other agents include GnRH antagonists, 
which have been shown to decrease testosterone and PSA levels at a much faster rate than GnRH agonists 
(Klotz et al., 2008, Trachtenberg et al., 2002).  
1.4.6 The androgen receptor and the emergence of castration-resistant prostate cancer  
Androgens are necessary factors for pre- and post-natal development and growth of the prostate 
(Kellokumpu-Lehtinen et al., 1979, Aumuller, 1991). The AR is a member of the nuclear receptor superfamily 
and is a vital transcriptional regulator for both the normal prostate and PCa. The AR is expressed by luminal 
epithelial cells, which comprise the bulk of a prostate tumour and are therefore the main target of ADT. 
In its unactivated form, the AR exists in the cytoplasm in complex with several proteins from the heat shock 
protein family. Upon ligand binding, most commonly to dihydrotestosterone (DHT), the AR undergoes a 
conformational change which triggers nuclear translocation. Here, the AR binds to the promoter/enhancer 
regions of genes which contain androgen response elements (ARE) such as PSA and PAP. AR-mediated 
transcription can be positively and negatively regulated in several ways. This includes interaction with co-
regulators which modulate histones and either promote/prevent AR binding, and also by interaction with 
other transcription factors (Heinlein and Chang, 2004).  
Patients with high grade PCa undergoing androgen-ablation treatment may show promising tumour 
regression and lowering of PSA initially. However, they eventually become hormone resistant and the cancer 
recurs, known as castration-resistant prostate cancer (CRPC). Several androgen-related mechanisms of 
resistance have been investigated including: 
1) AR mutations: mutations can result in a receptor that is more sensitive to small amounts of 
hormone and increase sensitivity to other steroid hormones and molecules (Taplin et al., 1999). 
2) AR variants: several AR splice variants have been identified in CRPC patients. Variants lacking a 
ligand-binding domain result in constitutive activation of the AR (Watson et al., 2010).  
3) AR amplification: multiple copies of the AR gene resulting in an increase of AR protein (Linja et 
al., 2001). 
An alternative hypothesis for the emergence of CRPC suggests that androgen-independent, and therefore 
ADT-resistant, cell populations of the prostate epithelium can survive treatment and subsequently 
reconstitute the tumour with other androgen-independent cells (Shen and Abate-Shen, 2010). 
1.4.7 Treatment of CRPC 
Therapy for CRPC includes treatment with cytotoxic chemotherapy agents such as docetaxel or cabazitaxel, 
which target rapidly dividing cells. Unfortunately, not all PCa patients respond to chemotherapeutic agents 
and others often become resistant, as the survival benefit with current agents is between a few months to 2 
years (Seruga and Tannock, 2011, Bahl et al., 2013, Pezaro et al., 2014). Several novel therapies have now 
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been developed which are not curative but aim to prolong progression-free survival and improve quality of 
life, these include:  
1) Abiraterone acetate: second-line anti-androgen that inhibits CYP17A, an enzyme involved in 
androgen synthesis (de Bono et al., 2011). 
2) Enzalutamide: second-line anti-androgen that inhibits AR signalling by powerful blockade of the 
AR (Scher et al., 2012). 
3) Sipuleucel-T: a personalised immunotherapy whereby the patients antigen-presenting cells are 
externally activated by granulocyte-macrophage colony stimulating factor (GM-CSF) which is fused 
to PAP as the antigen. The vaccine is then infused into the patient to stimulate an immune response 
against PAP-expressing cells (Kantoff et al., 2010, Anassi and Ndefo, 2011). 
4) Radium-223 dichloride: an α-emitting radionuclide with a tropism for bone metastases (Deshayes 
et al., 2017). 
The median life expectancy of a patient with CRPC is 2 years despite the development of these next 
generation therapies, which only increase life expectancy by a matter of months relative to a placebo (de 
Bono et al., 2011, Kantoff et al., 2010, Scher et al., 2012). Ongoing clinical trials aim to determine the best 
time at which to introduce these drugs during disease progression and the combinations which yield the 
greatest effects possible (James et al., 2016, James et al., 2017, Attard et al., 2018). Although the principal 
focus of drug design has been on androgen depletion, the use of these drugs has in fact now been linked 
to an increased risk of developing advanced PCa by the U.S. Food and Drug Administration  (FDA) 
(Thompson et al., 2003, Andriole et al., 2010, FDA, 2011). Resistance suggests that AR-positive cells are 
not the only important cell type within the tumour. These current PCa drugs have been designed to target 
androgen-responsive luminal cells which comprise the bulk of a tumour, whilst overlooking the AR-negative 
basal cell populations which includes a stem-like population. 
1.5 Cancer stem cells 
The cancer stem cell (CSC) hypothesis proposes that only a subpopulation of cells within a tumour is able 
to initiate, propagate and maintain tumour growth (Greaves, 2010). In addition to self-renewal and 
multipotency, CSCs also have dysregulated proliferation and differentiation. Thus, a CSC can maintain itself, 
whilst also differentiating into the distinct heterogeneous cell types that constitute the bulk of a tumour 
(Figure 1.6). These bulk tumour populations are considered non-tumourigenic, although it should be noted 
that CSC properties may not only be originally acquired by normal tissue SCs but also by a more 
differentiated cell type within the hierarchy. The original cell type which is targeted for genetic mutation and 
transformation, whether or not it is a SC, is known as the cell of origin. Since CSCs are the only cells capable 
of driving tumour growth, these cells therefore require targeting to achieve long term cancer therapy. 
However, consistent with normal tissue SCs, CSCs possess inherent resistance mechanisms which allow 
them to evade standard cancer treatments including chemotherapy and radiation (Alison et al., 2012, 
Morrison et al., 2011, Ishii et al., 2008).  
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Figure 1.6. The cancer stem cell hypothesis and progression of prostate cancer. 
This model shows the progression from a normal prostate differentiation hierarchy to the deregulated growth of a prostate 
tumour. Although it is more likely for the cancer stem cell to arise from a normal stem cell, due to its longevity and self-
renewal properties, this model does not exclude the possibility that a progenitor cell could become the cancer stem cell 
following a series of mutations. This cancer stem cell is then able to maintain tumour growth and differentiate into the 
different cell types that compose the tumour. In addition, it is possible for other mutations to occur within bulk tumour cells 
altering their behaviour and contributing to a more aggressive cancer phenotype. Taken from (Archer et al., 2017). 
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Multiple studies, going back over a hundred years implied the existence of CSCs (Maitland and Collins, 
2014). The first “modern age” evidence presenting CSCs as the cause and maintenance of cancer was 
elegantly demonstrated in acute myeloid leukaemia (AML) by John Dick’s laboratory in 1994 (Lapidot et al., 
1994). Since then our understanding of CSCs has been refined and their identification in multiple other 
leukaemias and solid tumours has supported the CSC hypothesis of cancer (Visvader and Lindeman, 2008). 
However, accumulating evidence for the CSC hypothesis has posed significant challenges, including the 
identification of markers that can accurately distinguish CSCs and expedite isolation of these relatively rare 
cells from a complex tumour environment. The two functional caveats for identifying CSCs are that they 
must 1) be tumourigenic, forming heterogeneous tumours reminiscent of those from which they were derived 
and 2) be serially transplantable when xenografted in mice. An array of markers, including CD133, CD44, 
CD24 and ALDH1, have been used to isolate CSCs from different solid tumours. Moreover, as there is no 
single CSC marker for each tumour type, multiple markers are generally used to isolate as homogeneous a 
population as possible. These markers usually include normal SC markers of the same tissue (Park et al., 
2007). Whilst it has previously been hypothesised that CSCs constitute a rare population of tumour cells, 
studies in melanoma have shown that the current models could be significantly underestimating the size of 
the CSC population. In NOD/SCID mice the proportion of cells with tumourigenic capacity was 0.1-0.0001%, 
which rose to 25% in more immunocompromised NOD/SCID/IL2Rγnull mice (Quintana et al., 2008). 
However, the original hypothesis seems true in tumours of other tissues such as human pancreatic 
adenocarcinoma, lung squamous cell carcinoma, lung adenocarcinoma, and head and neck squamous cell 
carcinoma (HNSCC). In these tumours, the CSC population only accounted for 0.0028-0.04% of total tumour 
cells in NOD/SCID/IL2Rγnull mice (Ishizawa et al., 2010). The proportion of tumour cells with a CSC 
phenotype is therefore likely to be a quality that is dependent on tissue of origin and cancer subtype within 
that tissue, and in some cases tumour grade may also be important (Marcato et al., 2011, Thirant et al., 
2011). Although serial transplantation in mice is considered to be the gold standard as the means of 
identifying CSCs, this data also highlights the host’s immune response and differences in vital growth factors 
as limiting factors in studying CSCs in model systems.  
1.5.1 A basal cell is the cell of origin of prostate cancer  
Substantial evidence exists for a basal SC origin of PCa. By introducing ERG expression and constitutive 
PI3K signalling into the basal and luminal epithelial cells of mice, Lawson et al. demonstrated that whilst 
luminal cells were unresponsive, the basal population was able to form fully differentiated tumours 
reminiscent to those seen in humans (Lawson et al., 2010). Significantly, evidence from human prostate 
cells also indicates a basal SC origin of PCa. The CD44+/CD133+/α2β1hi markers in basal cells identify normal 
prostate SCs (Collins et al., 2001, Richardson et al., 2004). These cells showed self-renewal and 
differentiation properties, were highly proliferative and reconstituted prostate glands in vivo (Richardson et 
al., 2004). To isolate primary prostate CSCs which constitute approximately 0.1% of tumour cells from PCa 
biopsies the same markers were used; cells were first selected for high α2β1 integrin expression by rapid 
adhesion to collagen I-coated plates and CD133+ cells were then enriched from α2β1hi cells (Collins et al., 
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2005). These CD133+/α2β1hi cells exhibited enhanced proliferative potential and secondary colony-forming 
efficiency in vitro compared to other populations, i.e. they were able to expand and self-renew through 
several generations as the proportion of CD133+ cells remained constant. As well as possessing the 
fundamental SC properties, the cells also demonstrated classic cancer cell characteristics of invasion and 
anchorage-independent growth, confirming that the cells were of tumour origin.  Furthermore, CD133+/α2β1hi 
cells were able to differentiate into AR+ luminal cells, recapitulating the characteristics of a primary prostate 
tumour (Collins et al., 2005). It should also be noted that these cells are normally studied at as low a passage 
as possible, minimising any changes that may occur due to long-term culture. Patrawala et al also 
demonstrated that primary human PCa CD44+ basal cells had increased tumourigenic and proliferative 
capabilities in vitro and in vivo than CD44- cells (Patrawala et al., 2006).  Then, similarly to Lawson, Goldstein 
et al. confirmed that human benign basal cells, but not luminal cells, could produce tumours with a luminal 
phenotype in NOD/SCID/IL2Rγnull mice following AKT, ERG and AR expression (Goldstein et al., 2010). 
Furthermore, it was recently shown by high-throughput RNA sequencing that a basal SC phenotype was 
associated with more aggressive types of PCa (Smith et al., 2015). Various combinations of markers 
including CD133, CD49f, CD44 and Trop2 are commonly used to detect prostate CSCs (Trerotola et al., 
2010, Patrawala et al., 2006, Goldstein et al., 2010). 
In contrast, Wang et al identified castration-resistant Nkx3.1-expressing cells (CARNs) which  were defined 
as a subset of luminal cells in the mouse prostate (Wang et al., 2009). These cells comprised 1% of cells in 
the total prostate and were able to survive following androgen deprivation. CARN cells were proposed to be 
the origin of PCa, due to the presence of high grade PIN and carcinoma lesions following PTEN deletion 
and their ability to form organoids in culture (Wang et al., 2009, Chua et al., 2014). Similarly, luminal 
progenitors have also been found in other mouse models of PCa (Korsten et al., 2009, Liu et al., 2011, 
Agarwal et al., 2015). However, the normal mouse and human prostates display significant differences. For 
instance, the murine prostate consists of a single layer of epithelia where luminal cells contact the basement 
membrane directly, and has a lower basal cell content compared to human. It is therefore possible that the 
development of PCa differs between the two species and this CARN progenitor could be a unique cell found 
in mice. However, a putative luminal CSC was found in the BM18 xenograft model derived from a human 
PCa bone metastasis (Germann et al., 2012). A quiescent population of cells co-expressing stem-like 
(NANOG or ALDH1A1) and luminal (NKx3.1 and CK18) markers was able to reconstitute a tumour in the 
presence of androgen following previous castration. However, these specific cells were not selected and 
serially transplanted into different mice, so it remains unclear whether the cells truly have tumour-initiating 
properties.  It should also be noted that this xenograft model only represents one patient and it is well known 
that PCa is a very heterogeneous disease. Furthermore, the xenograft had been passaged many times 
since it was established in 2005 and is likely to have evolved significant changes since then (McCulloch et 
al., 2005). Critically, a luminal CSC has yet to be isolated from a primary human prostate tumour (Collins et 
al., 2005). 
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1.6 Cancer stem cells and treatment resistance in prostate cancer  
The CSC hypothesis also logically explains the development of metastases. Complex sequencing studies 
have shown that the cancer cell clones present in a primary prostate tumour are also present in metastases 
(Hong et al., 2015, Haffner et al., 2013). Theoretically, in order to maintain the founder mutations present in 
the original tumour through to metastasis, this must be carried out by a primitive, long-lived cell that is 
capable of both clonal expansion and the ability to accumulate further abnormalities that allow the cell to 
develop independence from the extracellular matrix and migrate to extraprostatic sites (Gundem et al., 
2015). Prostate CSCs possess enhanced invasive qualities in comparison to other tumour cell populations 
(Smith et al., 2015, Klarmann et al., 2009). Successfully targeting the CSC population alongside cytotoxic 
hormone therapies to kill the rapidly dividing tumour bulk may be curative, and should prevent the initiation 
of lethal secondary metastases (Figure 1.7). However, heterogeneity within the CSC population itself makes 
drug design for the rare CSC population even more challenging (Guenechea et al., 2001, Greaves, 2010). 
Furthermore, CSCs are thought to be the cause of cancer recurrence following radiation and chemotherapy, 
and the emergence of CRPC following ADT (Frame and Maitland, 2011, Rane et al., 2012). This seems 
logical, given that a characteristic of normal SCs is their robustness and inherent resistance to toxic 
substances. The quiescent nature of SCs poses a further challenge, since most cancer therapies target 
actively dividing cells. So, whilst conventional cancer therapies reduce the bulk population of tumour cells, 
these treatments consequently have the potential to enrich for CSCs (Dylla et al., 2008, Freitas et al., 2014, 
Li et al., 2008).  
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Figure 1.7. Prostate cancer cell response and resistance to treatment. 
Whilst current PCa therapies can effectively eradicate the differentiated luminal cells which compose the bulk of the tumour, 
cancer stem cells can survive via extensive therapy resistance mechanisms. The CSCs are then able to initiate the growth 
of new tumours and metastases and may themselves have evolved to thrive in the post-treatment microenvironment. The 
discovery of novel CSC-directed therapies may be curative and eliminate all tumour cells in conjunction with conventional 
therapies. Taken from (Archer et al., 2017). 
  
36 
1.6.1 Drug efflux transporters and anti-apoptotic molecules  
Normal SCs and CSCs express drug efflux transporters of the ABC transporter superfamily that can 
efficiently pump chemotherapeutic drugs out of the cells (Moitra et al., 2011). ABCG2 has been shown to 
be expressed in prostate CSCs and is more highly expressed in prostate tumours which have recurred 
following treatment compared to non-recurrent tumours, suggesting that the transporter does indeed play a 
part in drug resistance in PCa (Pascal et al., 2007, Guzel et al., 2014). There have been numerous clinical 
trials for ABC inhibitors, but outcomes have been poor due to high toxicity and low efficacy (Fletcher et al., 
2010). Many CSCs also express anti-apoptotic molecules, essentially allowing them to bypass signals which 
would ordinarily lead to cell death. This includes members of the Bcl2 family (Madjd et al., 2009, Konopleva 
et al., 2002) and inhibitor of apoptosis (IAP) family (Liu et al., 2006). Affymetrix gene-expression arrays 
comparing the gene expression of human primary prostate CSCs and committed basal cells fractionated 
from benign and cancerous prostate tissue showed that SCs and CSCs also have significantly higher 
expression of IAP family members survivin and BIRC6 (Birnie et al., 2008). 
1.6.2 DNA damage response  
Enhanced DNA damage response is another characteristic of CSCs, which allows them to survive exposure 
to radiation and chemotherapy. Under normal circumstances, when DNA damage is irreversible, cell death 
pathways are activated, resulting in the upregulation of pro-apoptotic molecules. However, given the DNA 
damage repair mechanisms and upregulation of cell cycle checkpoint molecules in CSCs, they are able to 
survive such genotoxic stresses (Maugeri-Sacca et al., 2012). In glioma, CD133+ CSCs were more resistant 
to radiation than the CD133- tumour cell populations. Inhibitors of checkpoint kinases Chk1 and Chk2 
induced radiosensitivity, demonstrating that glioma CSCs have a permissive DNA damage checkpoint in 
response to radiation (Bao et al., 2006). In cell line models, prostate CSCs also have increased expression 
of DNA damage repair molecules (Yan and Tang, 2014, Kim et al., 2013). In human prostate tissue the 
CD133+/α2β1hi CSCs exhibited higher levels of heterochromatin, which rendered them more resistant to the 
lethal double strand breaks induced by radiation. (Frame et al., 2013). Radio-sensitivity could be induced by 
combination treatment with the histone deacetylase (HDAC) inhibitor Trichostatin A, i.e. CSC therapy 
resistance in this case is defined at the chromatin level. Radiotherapy produces reactive oxygen species 
(ROS), causing oxidative stress and subsequently DNA damage in cells. Breast CSCs possess low levels 
of ROS compared to normal SCs due to increased expression of free radical scavengers and thus survive 
following radiation (Diehn et al., 2009).  
1.6.3 The tumour microenvironment and CSC niche 
As well as possessing several mechanisms that confer drug resistance, CSCs may also persist due to 
signals from the local microenvironment. The normal SC niche is a distinct area within a tissue that supports 
and provides SCs with the factors they require to maintain stemness (Li and Xie, 2005). A special niche may 
also exist for CSCs (Sneddon and Werb, 2007). For instance, CSCs are often found in niches in close 
proximity to vasculature, where VEGF-secreting endothelial cells can promote CSC-induced angiogenesis 
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and metastasis (Beck et al., 2011, Alvero et al., 2009, Veeravagu et al., 2008). The stroma surrounding solid 
tumours is altered from its normal state, sometimes referred to as “reactive stroma” in the prostate (Dakhova 
et al., 2009, Thalmann et al., 2010). The reactive stroma (or cancer-associated fibroblasts, CAFs) isolated 
from primary prostate tumours was sufficient to induce tumorigenesis in selected basal cells from the benign 
BPH-1 cell line, resulting in tumour formation in immunocompromised mice (Taylor et al., 2012). Additionally, 
with help from the reactive stroma, PCa cells are able to continuously adapt to their environment promoting 
EMT which allows cells to become motile and disseminate. This inevitably results in invasion and metastasis 
with a particular tropism for bone (Thalmann et al., 2010, Josson et al., 2010, Scheel and Weinberg, 2011, 
van der Pluijm, 2011).  The innate plasticity of CSCs, which allows them to thrive in distant environments 
from the original tumour also makes them a difficult therapeutic target. Treatments to target the surrounding 
microenvironment may also be required to treat PCa more effectively (Bracarda et al., 2011). 
1.6.4 Other CSC targets 
Given the extensive therapy resistance mechanisms of CSCs discussed above, it is therefore likely that both 
the CSC and clonal evolution models occur in unison in PCa (Greaves and Maley, 2012). Whilst the tumour 
is probably initiated by a long-lived CSC, following treatment, the selection pressures will dictate which CSCs 
will mutate and thrive and cause metastases by clonal evolution. This makes the continually adapting CSCs 
an essential but challenging target. Inhibitors of key developmental pathways such as Wnt, Notch and 
Hedgehog, all crucial for CSC maintenance, are currently being tested (Morrison et al., 2011, Alison et al., 
2012, Takebe et al., 2011). For instance galiellalactone, a STAT3 inhibitor which blocks the binding of 
activated STAT3 to target gene DNA, decreased the proportion of ALDH+ cells in PCa cell lines, another 
commonly used CSC marker (Hellsten et al., 2011). Other inhibitors of the STAT3 pathway have also proved 
successful in human primary PCa cultures and xenograft models (Kroon et al., 2013). Siltuximab (anti-IL-6) 
and LLL12, a specific inhibitor of activated STAT3, supressed the colony forming ability of prostate CSCs. 
Following ex vivo treatment, LLL12 also prevented tumour initiation of a xenograft derived from a castrate-
resistant patient (Kroon et al., 2013).  
It should be noted that since these pathways are also crucial in many normal cell types, including SCs, the 
off-target effects and toxicity must be carefully monitored. Two phase 2 clinical trial targeting CSCs in late 
stage pancreatic cancer (ALPINE trial) and small cell lung cancer (PINNACLE trial) have so far provided 
disappointing results (OncoMed Pharmaceuticals, 2016, OncoMed Pharmaceuticals, 2017). The lack of 
success with tarextumab, a Notch2 and Notch3 receptor inhibitor, to produce a beneficial response in 
patients is most likely due to the off-target side effects of blocking this critical signalling pathway. However, 
encouragingly, NF-κB pathway blockade by parthenolide treatment has been shown to decrease the viability 
of human primary prostate CSCs without affecting the normal SC population, highlighting that selective cell 
death of prostate CSCs may be possible (Birnie et al., 2008).  
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1.7 Transcriptional regulation in the prostate 
To maintain normal prostate homeostasis, a delicate balance of cell renewal, differentiation and cell death 
within the prostate epithelium must occur. This equilibrium is dictated by specific gene expression patterns 
which are in part controlled by transcription factors. 
As mentioned previously, androgens and the AR are essential for both prostate development and 
maintenance of the adult prostate. Specifically, androgens are required for the survival of adult luminal 
epithelial cells, as demonstrated by involution–regeneration experiments in rats (English et al., 1987). Other 
important factors include Nkx3.1 and FoxA1, which are also required for normal prostate luminal cell 
differentiation (Dutta et al., 2016, Gao et al., 2005). In addition, p63 is essential for maintaining the basal 
progenitor cell populations of the prostate (Signoretti et al., 2005).   
There are several key signalling pathways involved in the development and maintenance of the complex 
differentiation hierarchy of the prostate including Notch, Wnt and Hedgehog signalling (Leong and Gao, 
2008, Deng et al., 2016, Simons et al., 2012, Shaw and Bushman, 2007). These vital signalling pathways 
are also involved in regulating SC survival (Shahi et al., 2011, Bisson and Prowse, 2009, Chang et al., 2011). 
It should be noted that signals from the surrounding stroma also play an important role in prostate cell 
differentiation and homeostasis (Hall et al., 2002, Berry et al., 2008).  
1.8 ETS transcription factors control of cell differentiation and the stem cell 
phenotype in prostate cancer 
The E26 transformation-specific (ETS) family of transcription factors are critical for the control and regulation 
of a variety of cellular processes such as haematopoiesis, differentiation, survival, and the immune response 
(Kastner and Chan, 2008, Russell and Garrett-Sinha, 2010, Kar and Gutierrez-Hartmann, 2013, Scott et al., 
1994). Notably, ETS factors are also important in the maintenance of SCs of different tissues (Hock et al., 
2004, Chen et al., 2005). Many ETS factors are ubiquitously expressed in several different cell types, whilst 
some factors are restricted to specific cell lineages and tissues (Oikawa and Yamada, 2003). ETS proteins 
are exclusively found in metazoans and there are at least 30 human genes, which have been divided into 
specific subfamilies according to the gene homology of their characteristic ETS domains (Table 1.1). All 
ETS family members contain the unique 85 amino acid ETS DNA-binding domain (Figure 1.8) which consists 
of a winged-helix-turn-helix (WHTH) structure and binds to core purine-rich sequences of GGAA/T in DNA 
target genes. This domain is also involved in protein-protein interactions which regulate DNA binding 
(Sharrocks, 2001). ETS factors vary widely outside the ETS domain and variations within the ETS domain 
itself between the transcription factors can affect the proteins that can bind and also how they are regulated, 
demonstrating the vast potential for regulation within this family.  
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Figure 1.8. Domain structure of ETS factors which have proposed roles in prostate cancer. 
The amino acid number and positions of known domains of ETS factors which have been shown to have a role in PCa are 
displayed above. ETS factors are characterised by a unique 85 amino acid long sequence known as the ETS DNA binding 
domain (ETS). A subset of ETS factors also possess a pointed domain (Pointed) involved in protein-protein interactions. 
The transactivation domain (TAD) is essential for activation of transcription factor activity.  Other regions important for DNA 
binding have also been identified such as the serine-rich region (SRR) of ETS1 and the AT hook domain (AT) of ELF3. 
ELF3 also contains a serine- and aspartic acid-rich domain (SAR) which may play a role in cellular transformation. It should 
also be noted that some ETS factors such as ERG, ETS1 and ELF3 have been found to possess auto-inhibitory regions 
flanking the ETS domain. N = N-terminus, C = C-terminus. Taken from (Archer et al., 2017). 
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ETS Subfamily Family Members (alternative names) 
ERG ERG, FLI1, FEV 
ERF ERF (PE2), ETV3 (PE1) 
ETS ETS1, ETS2 
ELG GABPα 
PDEF PDEF (SPDEF, PSE) 
TEL ETV6 (TEL), ETV7 (TEL2) 
SPI PU.1 (SPI), SPIB, SPIC 
ESE ELF3 (ESE1, ESX), ESE2 (ELF5), ESE3 (EHF) 
ELF ELF1, ELF2 (NERF), ELF4 (MEF) 
TCF ELK1, ELK4 (SAP1), ELF3 (NET, SAP2) 
PEA3 
ETV4 (PEA3, E1AF), ETV5 (ERM), ETV1 (ER81), 
ETV2 (ER71) 
 
Table 1.1. ETS transcription factor subfamilies. Taken from (Archer et al., 2017). 
 
A subset of ETS factors including ETS1, ETS2, ETV6 and ELF3 also possess a pointed (PNT) domain at 
their N-terminal which is important for protein-protein interactions and can further influence the 
transcriptional regulation of target genes (Figure 1.8). For instance, the PNT domain of ETS1 acts as a 
docking site for signalling molecule ERK2 (Seidel and Graves, 2002). Also, the PNT domain of ETV6 allows 
it to form oligomers which are important for the function of fusion proteins found in many leukaemias (Jousset 
et al., 1997, Mackereth et al., 2004). Overlapping functions and redundancy in promoter occupancy have 
been found between ETS proteins, making investigation of native biological interactions challenging 
(Hollenhorst et al., 2007, Oikawa and Yamada, 2003). Many ETS factors were discovered due to their 
integral roles in leukaemias and cancers, and a number of ETS family members have since been linked to 
various different cancers (Zelent et al., 2004, May et al., 1993, Panagopoulos et al., 1994, Golub et al., 1996, 
de Nigris et al., 2001). In PCa, ERG is the most overexpressed oncogene in patient tumour samples and 
the TMPRSS2-ERG fusion, which can be formed by translocation or interstitial deletion, is a suspected driver 
of tumourigenesis and progression (Adamo and Ladomery, 2015, Tomlins et al., 2008, Taylor et al., 2010). 
Additional key roles for other members of the ETS family in PCa are emerging in the literature (Li et al., 
2012, Sementchenko et al., 1998, Turner et al., 2011, Shatnawi et al., 2014, Longoni et al., 2013, Albino et 
al., 2012).   
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1.8.1 Aberrant expression of ETS factors 
ETS1 is the founding member of the ETS transcription factor family (Laudet et al., 1993). Its expression in 
cancers other than prostate is generally associated with negative prognosis and is most frequently linked to 
high grade tumours and metastasis (Takai et al., 2000, Nakayama et al., 2001). Studies of primary prostate 
tissue have shown that ETS1 expression is also associated with poorly differentiated, high Gleason grade 
prostate tumours as well as faster progression to castration-resistant disease following ADT (Li et al., 2012, 
Alipov et al., 2005). A series of studies by Shaikhibrahim and Wernert also identified metastasis-associated 
genes that were differentially expressed in PC3 cells after ETS1 knockdown. These were then subsequently 
correlated to primary PCa tissue by gene expression microarray (Shaikhibrahim et al., 2011a, Shaikhibrahim 
and Wernert, 2012). There is also evidence that ETS1 contributes to the castration-resistant phenotype by 
directly interacting with the AR and decreasing LNCaP sensitivity to the AR antagonist flutamide following 
ETS1 overexpression (Smith et al., 2012). Furthermore, ETS1 knockdown in C4-2 cells (a castration-
resistant progression model of LNCaP cells) resulted in decreased invasion and anchorage-independent 
growth. Angiotensin II is an important mediator of angiogenesis and is a potent upregulator of VEGF (Chen 
et al., 2013). Kosaka et al explored the effects of angiotensin II and angiotensin II type I receptor blockers 
(ARBs) in PCa cell lines (Kosaka et al., 2010). Interestingly, angiotensin II upregulates ETS1, and is inhibited 
following treatment with the ARB candesartan. Collectively the evidence shows that ETS1 is strongly 
associated with PCa metastasis and castration-resistant disease. 
Closely related to ETS1, ETS2 expression is also upregulated in PCa. Similar to ETS1, downregulation of 
ETS2 in Du145 and PC3 cells reduces colony forming ability and cell survival, both characteristics of CSCs, 
whilst increasing apoptosis (Carbone et al., 2004, Sementchenko et al., 1998). Interestingly, both ETS1 and 
ETS2 are highly expressed in androgen-insensitive and more invasive PCa cell lines PC3 and Du145, but 
are expressed at lower levels in androgen-sensitive (luminal) cell lines LNCaP and VCaP, providing further 
evidence that ETS2 expression is associated with more malignant disease (Sementchenko et al., 1998, 
Shaikhibrahim et al., 2011b). An early study by Liu et al using a series of PCR primers showed that ETS2 
mRNA was expressed in 5 tumour foci derived from frozen tissue sections from one patient (Liu et al., 
1997a). On the other hand, ETS1 was only expressed in one of these tumour foci. This suggests that 
individual ETS factor expression may arise in independent tumour foci and thus display different expression 
patterns between focuses. These studies highlight that PCa is a heterogeneous disease with intra- and inter-
patient heterogeneity. Interestingly, ETS2 can regulate telomerase action. Telomerase is a reverse 
transcriptase which maintains the elongation of telomeres on chromosomes permitting an extended life 
span. Telomerase is essential during development and remains active in long-lived cells, namely germ cells 
and some SCs, whilst it is downregulated in most other cell types. Telomerase is also present in >85% of 
human cancers (Hiyama and Hiyama, 2002). ETS2 is an activator and repressor of hTERT, the enzymatic 
component of telomerase, by binding to different ETS binding sites within its promoter (Dwyer and Liu, 
2010). This was found in breast cancer cell lines, and ETS2 knockdown resulted in decreased cell survival 
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(Xu et al., 2008). Since ETS2 is often overexpressed in PCa, its regulation of telomerase and therefore 
potential of maintaining cell survival, a CSC characteristic, in prostate cells could be of importance.  
1.8.2 ETS fusion genes 
The TMPRSS2-ERG fusion gene is formed in 50% of PCas between the androgen-regulated promoter of 
the transmembrane protease TMPRSS2 and the ETS factor (ERG) gene, both encoded on chromosome 21 
(Tomlins et al., 2005, Clark et al., 2008). There have been 14 distinct variants of the TMPRSS2-ERG 
transcript reported in literature, which can result in the translation of either normal full-length ERG, various 
N-terminal truncations of ERG and one which encodes a TMPRSS2-ERG fusion protein (Clark et al., 2007, 
Tu et al., 2007, Wang et al., 2006). The most common isoform is that between TMPRSS2 exon 1 and ERG 
exon 4. Significantly, most of these transcripts retain the ETS DNA binding domain of ERG, together with 
the PNT domain and C-terminal transactivation domain, ultimately resulting in the overexpression of a 
functional ERG protein. The incidence of the fusion in precancerous prostate intraepithelial neoplasia (PIN) 
lesions suggests it could be an early event in PCa development (Carver et al., 2009a). Some fluorescent in 
situ hybridisation (FISH) and immunohistochemistry (IHC) studies have correlated fusion positive prostate 
tumours with poor prognosis and disease recurrence (Perner et al., 2006, Rajput et al., 2007, Huang et al., 
2014) . Increased copy number of the TMPRSS2 or ERG loci, as well as fusion formation by deletion rather 
than translocation, has also been linked to poor prognosis (Fine et al., 2010, Mehra et al., 2008, Attard et 
al., 2008). To add to the complexity, PCa is a heterogeneous, multifocal disease (Arora et al., 2004, Bostwick 
et al., 1998, Wise et al., 2002). Reverse transcriptase (RT) PCR and FISH studies of prostate tumours have 
revealed that multiple independent TMPRSS2-ERG rearrangements can occur in a single patient in separate 
tumour foci (Cooper et al., 2015, Mehra et al., 2007, Clark et al., 2007, Clark et al., 2008).  
The TMPRSS2-ERG fusion results in overexpression of ERG oncoprotein. Whilst ERG is not expressed in 
the normal prostate, it is consistently overexpressed in a large subset of prostate tumours, corresponding 
to the frequency of fusion positive patients (Tomlins et al., 2008). ERG overexpression has been proposed 
to be an inducer of epithelial-to-mesenchymal transition (EMT), increased migration and invasion, and 
subsequently metastasis through the upregulation of associated target genes (Leshem et al., 2011, Gupta 
et al., 2010, Carver et al., 2009b). ERG target genes include activation of FZD4, MMP1, VEGFR2 and 
repression of E-cadherin, all of which directly promote EMT and invasion (Adamo and Ladomery, 2015).  
Additionally, ERG stimulates the expression of the chemokine receptor CXCR4. Its ligand, CXCL12, is highly 
expressed in bone marrow, resulting in the chemoattraction of PCa cells to bone, the most common site of 
metastasis (Singareddy et al., 2013, Cai et al., 2010, Carver et al., 2009b). Two ChIP-seq studies in PCa 
cell lines showed that ERG disrupts the expression of androgen-regulated genes such as PSA in 
cooperation with epigenetic-modifying enzymes HDAC1 and EZH2 (Yu et al., 2010, Chng et al., 2012). ERG 
overexpression also promotes c-myc expression, as well as downregulating prostate-specific differentiation 
associated genes (Sun et al., 2008). This disruption of androgen-regulation retains cells in a de-differentiated 
progenitor state that is thought to promote invasion and metastasis (Figure 1.9).  
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Figure 1.9. Proposed mechanisms of ETS factor-induced de-differentiation of prostate cancer 
epithelial cells. 
The majority of the discussed ETS factors may play a role in prostate cell differentiation. It appears that in PCa these factors 
are regulated in a manner which disrupts the normal differentiation pathway and allows cells to remain in a progenitor state 
which allows them to possess stem-like qualities promoting cancer growth and spread. I) ERG is overexpressed in PCa 
patients who possess the TMPRSS2-ERG fusion gene. ERG has been shown to both activate genes which initiate EMT 
and repress luminal-associated genes, characteristics associated with cancer stem cells. II) PDEF expression may be lost 
in terminally differentiated luminal cells due to miR-204 expression in cancer cells. PDEF loss results in an invasive cell 
phenotype associated with less differentiated cells. III) Microarray data shows ELF3 is more highly expressed in 
differentiated committed basal cells compared to SCs from both benign and cancerous primary prostate tissue. This 
suggests ELF3 expression may promote prostate SC differentiation (work in this thesis). IV) Knockdown of ESE3 results in 
the upregulation of EMT markers and downregulation of luminal cell marker Nkx3.1. Together with characteristic SC 
functions such as colony forming ability, this suggests that ESE3 loss may promote a SC phenotype. (SC = stem cell, TA 
= transit amplifying cell, CB = committed basal cell). Taken from (Archer et al., 2017). 
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Initial mouse models to investigate the effects of TMPRSS2-ERG utilised ERG cDNA driven by the prostate-
specific modified probasin promoter. Although some studies observed the development of PIN lesions 
following ERG overexpression (Klezovitch et al., 2008, Tomlins et al., 2008), others required concomitant 
PTEN deletion to observe a disease phenotype (King et al., 2009, Carver et al., 2009b), probably  due to 
the different genetic backgrounds of the mice used. Since the TMPRSS2-ERG fusion is suspected to be an 
early event in PCa initiation and evidence from mouse models suggests that other mutation events such as 
PTEN loss are also required for cancer progression, it is reasonable to hypothesise that these initial events 
are likely to occur in long-lived, self-renewing cells where mutations can accumulate. Casey et al produced 
a bacterial artificial chromosome (BAC) by recombination to express the ERG gene under the control of the 
TMPRSS2 promoter (Casey et al., 2012). Once again PIN lesions and progression to carcinoma were only 
evident in mice with an additional heterozygous PTEN deletion. They observed a more genuine, cell specific 
expression pattern of TMPRSS2-ERG which revealed expression in not only the EpCAM+/Sca-1-/NKx3.1+ 
luminal cells but also in a fraction of the EpCAM+/Sca-1+/p63+ basal/progenitor cell population. The Sca-1+ 
(stem cell antigen-1) basal cells from TMPRSS2-ERG mice possessed greater sphere-forming and colony-
forming ability than their counterparts from wild-type mice, illustrating that TMPRSS2-ERG positive stem-
like cells have increased self-renewal capabilities.   
The study by Casey et al. highlighted the importance of investigating critical genetic aberrations in the 
individual cell populations of the prostate as opposed to total epithelial cells, which may mask any variations 
found in the rarer basal epithelial cell populations, including SCs (Casey et al., 2012). Polson et al examined 
this further by growing epithelial cells from human prostate biopsies in culture and fractionating the cell 
populations into SC, TA and CB populations based on CD133 and α2β1 expression as discussed previously 
(Polson et al., 2013, Collins et al., 2005). Using FISH, RT-PCR and southern blotting the status and 
expression of TMPRSS2-ERG in the SC fraction from primary patient samples was demonstrated. They 
also showed that prostate basal epithelial cells, particularly SCs, do not express AR or the oestrogen 
receptor (ER), and therefore demonstrated that TMPRSS2-ERG must be regulated in these cells in an 
androgen-independent manner (Maitland et al., 2011, Polson et al., 2013). There was also heterogeneity in 
the expression patterns of TMPRSS2-ERG. For instance, in one patient TMPRSS2-ERG was expressed in 
both the SC and TA populations and lost in the CB population. Most commonly, whilst TMPRSS2-ERG was 
expressed in the SC population, in several patients fusion expression was lost in TA cells and regained in 
CB cells. This can be explained by a phenomenon called monoallelic expression, whereby one inherited 
allele of a gene is preferentially expressed and the other is silenced (Chess, 2012). In cases of genetic 
abnormality where one allele is normal and the other mutated, such as TMRPSS2-ERG, the mechanism of 
monoallelic expression becomes significant. Silencing of a mutated allele may prevent the early removal of 
a potential cancer-initiating clone thereby allowing a higher chance of accumulating additional necessary 
mutations required for cancer progression.  
TMPRSS2 fusions can also occur with other ETS factors, albeit at much reduced frequencies. Along with 
ERG, TMPRSS2 fusions to ETV1 and ETV4 were also discovered by Tomlins et al. in PCa cell lines and 
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primary tissue (Tomlins et al., 2005, Tomlins et al., 2006). The presence of the fusions again coincides with 
the overexpression of the corresponding ETS factor and each appears to be mutually exclusive in most 
cases (Svensson et al., 2011). Unlike ERG, ETV1 and ETV4 are located on different chromosomes from 
TMPRSS2 and fusions are therefore formed solely by translocation rather than interstitial deletion. This may 
be relevant when deducing the prognostic significance of different fusions, given that TMPRSS2-ERG 
fusions formed by deletion are associated with poor prognosis (Mehra et al., 2008). The propensity of ETS 
factors to form tumourigenic fusions has also led to the discovery of several other non-TMPRSS2 ETS factor 
fusions in PCa (Barros-Silva et al., 2013, Helgeson et al., 2008, Tomlins et al., 2007). The incidence of 
several mutually exclusive ETS factor fusions in PCa, which is also the case in Ewing’s sarcoma, is an 
occurrence which should be investigated. This may be an example of redundancy seen in ETS factors, 
where in the absence of one fusion another may be able to exert the same effects.  
1.8.3 Epithelial-specific ETS factors 
Within the ETS transcription factor family there is a subset of genes whose expression is limited to epithelial 
cells. ESE2, ESE3 and ELF3 (also known as ESE1) are highly related and form a distinct gene subfamily. 
PDEF is another epithelial-specific ETS factor, although it differs from the others due to its preferential 
binding to GGAT core sequences in target genes, as opposed to the more common GGAA (Oettgen et al., 
2000). This relatively new category of ETS factors, the first of which was discovered in 1997, display 
important roles in epithelial cell differentiation. Notably, there is now mounting evidence that several of these 
factors play a role in PCa.   
1.8.3.1 PDEF 
Prostate-derived ETS factor (PDEF) is most highly expressed in the prostate but is also found at lower levels 
in other hormone-regulated organs including the breast, ovaries and salivary glands and also in the lung 
and intestine (Oettgen et al., 2000, Noah et al., 2010). PDEF protein is exclusively expressed in the 
terminally-differentiated secretory luminal cells of normal prostate epithelium and has a role in the 
differentiation of intestinal progenitor cells into the secretory cell types of the intestinal epithelium (Oettgen 
et al., 2000, Gregorieff et al., 2009). Consistent with this expression pattern, PDEF was first described as 
an upregulator of PSA both in the presence of and independently of androgen (Oettgen et al., 2000). In PCa, 
loss of PDEF expression is associated with more aggressive tumours, and patients with PDEF- tumours 
have a decreased survival rate compared to PDEF+ patients (Turner et al., 2011, Ghadersohi et al., 2011). 
Several studies have shown PDEF loss to enhance the migratory and invasive phenotype of PCa cell lines 
and thus have tumour suppressor qualities upon its re-expression (Johnson et al., 2010, Turner et al., 2011, 
Gu et al., 2007). This coincides with evidence found in other cancers showing loss of PDEF protein 
expression, including colon and breast cancer (Moussa et al., 2009, Steffan and Koul, 2011, Feldman et al., 
2003). In PCa, PDEF expression loss is in part regulated by microRNA miR-204 expression (Turner et al., 
2011). 
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Conversely, some studies claim PDEF expression increases in prostate and breast cancers compared to 
their normal tissues and induces invasiveness of a non-tumourigenic breast epithelial cell line when co-
expressed with tyrosine kinases ErbB2 and CSF-1 (Gunawardane et al., 2005, Sood et al., 2007). This 
dichotomy can be explained since the studies that show PDEF to be a tumour suppressor in breast cancer 
are of the more invasive basal cell subtype and those that describe it as an oncogene are of the more 
differentiated luminal subtype (associated with better prognosis). This implies that in different cancer cell 
subtypes, PDEF can influence tumour growth in different ways. Since PDEF is normally expressed in luminal 
cells in the prostate and associated with luminal cell markers such as PSA, loss of protein expression could 
potentially result in cells dedifferentiating, which would correlate with an increase of invasiveness (Figure 
1.9). Whether PDEF knockdown in more differentiated (luminal) PCas could be beneficial therapeutically 
remains to be seen, but this seems to be the situation in breast cancer (Buchwalter et al., 2013).  Using this 
rationale, one would therefore expect PDEF expression to be lost in more aggressive, less differentiated 
PCas (high Gleason grade) resulting in suppression of luminal markers such as PSA. If PDEF loss also 
promotes a stem-like phenotype in PCa cells then EMT and invasion (also properties of CSCs) should be 
seen. These proposals are yet to be experimentally demonstrated.  
1.8.3.2 ELF3  
ELF3 (also known as ESE1, ESX, and Jen) is mainly expressed in epithelial-rich tissues such as the gut, 
kidneys, bladder and prostate (Tymms et al., 1997, Oettgen et al., 1997, Bock et al., 2014). Two papers 
have been published describing a role for ELF3 in PCa with conflicting views. Shatnawi et al described ELF3 
as a repressor of PCa. By interfering with AR DNA binding, ELF3 could repress the upregulation of AR target 
genes known to be drivers of PCa (Shatnawi et al., 2014). Knockdown of ELF3 using siRNA induced AR 
target gene expression resulting in increased cell migration and proliferation of the PCa cell line LNCaP. 
Furthermore, overexpression of ELF3 repressed tumour growth in an LNCaP xenograft model. ELF3 protein 
loss was also associated with PCa progression by IHC from tissue sections, although the patient cohort was 
relatively small.  
In contrast, Longoni et al described ELF3 as a driver of PCa (Longoni et al., 2013). They observed high 
ELF3 expression at the mRNA level in several patient datasets. Immunohistochemical staining for ELF3 in 
207 tumours revealed that 63% of tumours significantly expressed the protein, whereas ELF3 was poorly 
expressed in normal tissues. ELF3 mRNA was also more highly expressed in metastases compared with 
primary prostate tumours. The mechanism by which ELF3 drives PCa was proposed to be a positive 
feedback loop with the transcription factor NF-κB, a known upregulator of ELF3 (Rudders et al., 2001, Grall 
et al., 2005). This required pro-inflammatory IL1-β stimulation for NF-κB activation and subsequent ELF3 
induction, which was then able to sustain NF-κB activation. ELF3 induction resulted in an increased 
malignant phenotype of LNCaP and 22RV1 cell lines by increasing colony forming ability in soft agar, anoikis 
resistance and cell migration. Xenograft tumours produced by ELF3 over-expressing 22RV1 cells in nude 
mice presented with larger and faster growing tumours and also produced metastases in the lung compared 
to control cells. However, since 22RV1 cells are known to migrate and promote angiogenesis, other cell 
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lines may have been more appropriate to validate an effect in vivo (Stieler et al., 2012). It should also be 
taken into account that both of these studies did not use a normal cell comparison as a control. Elucidating 
the roles of ELF3 in the normal prostate will aid further experiments in cancer models.  
ELF3 has oncogenic and suppressive roles in colorectal cancer (CRC). It can upregulate β-catenin and 
subsequently activate downstream targets of the Wnt/β-catenin signalling pathway to drive colon cancer 
progression (Wang et al., 2014). ELF3 expression can also directly promote the apoptotic effects of non-
steroidal anti-inflammatory drugs (NSAIDs) in CRC (Lee et al., 2008). An explanation for these conflicting 
findings is that ELF3 could be under similar regulation to that of PDEF in cancer where it has different roles 
in different cell types. ELF3 also plays major roles in epithelial cell differentiation, including the terminal 
differentiation of keratinocytes as well as a high expression in the most differentiated cells of the normal 
human urothelium (Cabral et al., 2003, Bock et al., 2014). Furthermore, a recent study has shown that ELF3 
is linked to differentiation of the human embryonal carcinoma stem cell line NCCIT, after differentiation was 
promoted using retinoic acid treatment. This treatment resulted in the downregulation of early differentiation 
transcription factor OCT4 and upregulation of ELF3 (Park et al., 2014). OCT4 is important for maintaining 
the pluripotency and self-renewal characteristics of SCs and its expression has been linked to enhanced 
malignant phenotype of cells and cancer progression in glioma, bladder and PCa (Du et al., 2009, Linn et 
al., 2010, Chang et al., 2008).  
When Affymetrix gene-expression arrays of 15 BPH and cancer tissues obtained from patients, comparing 
prostate SC/CSC (CD133+/α2β1hi) gene expression to the committed basal cell population (α2β1lo), 581 genes 
associated with cancer and inflammation were found to have significantly altered expression in the CSC 
population (Birnie et al., 2008). This information has allowed investigation of specific targets and pathways 
to further our understanding of prostate cell heterogeneity and CSC biology and identify potential therapeutic 
targets for PCa (Maitland and Collins, 2008). Here, ELF3 was found to have consistently higher expression 
in committed basal cells compared to SCs. Since low expression of ELF3 was found in both benign and 
malignant SCs across all patients, ELF3 may be involved in SC differentiation (Figure 1.9). Using the 
different fractions of primary prostate epithelial cells to investigate ELF3 should provide a more precise 
account of its roles in prostate cell differentiation and PCa and will be addressed in this study. 
1.8.3.3 ESE3 
ESE3 is an epithelial-specific ETS factor belonging to the same subfamily as ELF3. The ESE3 ETS DNA-
binding domain shares 84% homology with ELF3 (Kas et al., 2000). However, each has a distinct PNT 
domain, suggesting that whilst they may bind to similar target genes, their effects could ultimately vary 
depending on the protein-protein interactions achieved via their PNT domains. This was shown for prostate-
specific promoters PSA and PSMA (prostate-specific membrane antigen). The PSMA promoter was 
upregulated 3-fold in the presence of ELF3, whilst ESE3 had no effect. Conversely, ESE3 was able to 
activate the PSA promoter over 2-fold whereas ELF3 repressed the PSA promoter (Kas et al., 2000). This 
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study was carried out in (non-prostate) HEK-293 cells, and so studies in more appropriate prostate models 
should be carried out to determine if ESE3 and ELF3 have opposing roles in prostate cell differentiation. 
In a microarray analysis of 59 primary prostate tumour samples and 14 normal prostate samples, differential 
ETS factor protein expression in PCa has been evaluated. ERG, ELF3 and ESE3 were the most 
dysregulated genes, with ERG and ELF3 upregulated and ESE3 downregulated in cancer samples 
compared to normal prostate (Kunderfranco et al., 2010). This study found a tumour-suppressor role for 
ESE3 in PCa as a result of its ability to regulate the expression of Nkx3.1; a tumour-suppressor commonly 
lost in PCa partly by heterozygous deletion of the gene located at chromosome 8p21.2 (Bowen et al., 2000, 
Vocke et al., 1996). Knockdown of ESE3 in LNCaP and LHS cells (normal prostate epithelial cells [PrECs] 
which have been immortalised via hTERT and SV40 large T antigen expression) resulted in reduced Nkx3.1 
transcription. Since Nkx3.1 is also an androgen-regulated marker of prostate epithelial cell differentiation 
(Iwata et al., 2010), downregulation of ESE3 and upregulation of ELF3 and ERG may act in concert to 
produce similar effects. 
To complement this theory, a study by the same group further examined the role of ESE3 suppression in 
PCa cells (Albino et al., 2012). ESE3 shRNA knockdown in immortalised PrECs and RWPE-1 cells resulted 
in the upregulation of EMT markers vimentin and twist-1 as well as downregulation of epithelial cell marker 
E-cadherin. Furthermore, ESE3 repression induced both colony-forming ability in soft agar and sphere-
forming ability, both hallmarks of SCs. Gene set enrichment studies of 3 independent datasets of primary 
prostate tumours indicated that ESE3 suppression is found in approximately 25% of tumours and can occur 
both cooperatively or independently of ERG overexpression. The highest upregulated gene sets in tumours 
with ESE3 suppression include EMT, adhesion and cytoskeleton remodelling related genes (Albino et al., 
2012). Therefore, since loss of ESE3 downregulates luminal cell markers and appears to induce stem-like 
properties it could be speculated that this would allow the de-differentiation of luminal cells and/or block the 
differentiation of basal cells (Figure 1.9).  
1.9 Models of the prostate 
1.9.1 Prostate epithelial cell lines  
To understand the mechanisms which contribute to prostate cell differentiation and the development and 
progression of cancer, a number of models of the prostate exist, each with their own advantages and 
disadvantages.  A range of human-derived cell lines are available for studying the normal and malignant 
prostate, most of which are detailed in an extensive two-part review (Sobel and Sadar, 2005). Cell lines are 
a good model of study as they are obtainable without the need for comprehensive ethical considerations, 
they can be genetically modified and easily transfected and can be grown in culture almost indefinitely. 
However, as a consequence of immortalisation and long-term culture, cell lines have adapted to life outside 
the patient by a series of genetic and epigenetic changes (Lee et al., 2006, Izadpanah et al., 2008, Kawai 
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et al., 1994, Meissner et al., 2008). This demonstrates that whilst cell lines are suitable models for initial 
studies, they do not fully represent what occurs in a patient.  
1.9.2 Primary prostate epithelial cultures  
Primary prostate cultures derived from patient tissue are valuable models of study as they not only represent 
an individual patient as unaltered as possible, but also represent the heterogeneity found between patients 
in a disease. However, it should be noted that patient biopsies may not be easy to source and requires 
ethical permission. Furthermore, they are expensive to maintain and in order to keep cultures as near to the 
patient as possible they can only be grown for a limited time.  
1.9.3 3D models of the prostate  
2D in vitro models are limited due to the fact that they do not grow in a fashion which recapitulates the 
normal tissue architecture. Notably, prostate cell lines and primary cells can also be grown in 3D cultures. 
Resuspension of cells in a solid matrix such as matrigel promotes growth of spheroids which can recapitulate 
the architecture of prostate acini (Pellacani et al., 2014, Lang et al., 2006, Lang et al., 2001a). More 
specifically, a basal and luminal bilayer with a hollow lumen in the centre.  
1.9.4 In vivo models of the prostate 
As PCa only occurs naturally in elderly canines, alternative routes of study are required for in vivo 
investigation of PCa (Leav and Ling, 1968). In vivo models of PCa include the transplantation of cell lines 
and primary cells into immunocompromised mice (known as xenografts) such as NOD/SCID or RAG2-/-
IL2RγC-/- (Stephenson et al., 1992, Shultz et al., 1995, Lawrence et al., 2013, Taurozzi et al., 2017). There 
are also transgenic mouse models of PCa available, with TRAMP and LADY amongst the most commonly 
used (Greenberg et al., 1995, Kasper et al., 1998). However, as discussed previously (Section 1.5.1), it must 
be taken into consideration that the mouse prostate bears significant differences to the normal human 
prostate. Further limitations include a non-fully-functioning immune system and interference of the host’s 
cells with the human tumour. As such, it is important to note that mouse models may not fully represent what 
would occur in a human patient with regards to potential drug efficacy and toxicity.  
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1.10 Aims of research 
The current treatment regimen for advanced PCa is not curative and a shift away from ADT, towards novel 
therapies which take into consideration the heterogenous cell populations present in a prostate tumour is 
needed. 
The role of ELF3 in the prostate is currently controversial, with literature describing both oncogenic and 
tumour suppressor roles (Longoni et al., 2013, Shatnawi et al., 2014). Furthermore, ELF3 was significantly 
downregulated in the SC subpopulation compared to the CB subpopulation derived from benign and 
cancerous prostate tissue, suggesting an additional link to prostate cell differentiation (Birnie et al., 2008). 
The main aims of this study were to investigate ELF3 expression in the prostate and elucidate its roles in 
both normal prostate development and malignancy. The specific objectives were as follows: 
 
1) Identify the pattern of ELF3 expression in prostate epithelial cell lines and primary prostate 
subpopulations at the protein level. 
 
2) Determine whether ELF3 is differentially expressed between benign and cancerous prostate tissue. 
 
3) Explore the roles of ELF3 in the normal and malignant prostate by manipulating its expression 
through knockdown and overexpression. 
 
4) Investigate potential regulatory pathways by observing global gene changes following ELF3 gene 
expression knockdown.  
 
The complex regulation of the prostate epithelial differentiation hierarchy is not fully understood and so a 
further understanding of the mechanisms involved in cell differentiation is key to developing novel long term 
therapies for advanced PCa. By resolving these questions and furthering our understanding of prostate 
epithelial cell development and maintenance, we could clarify the conflicting findings in literature and 
contribute to our understanding of PCa. 
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2. Materials and Methods 
2.1 Mammalian cell culture 
2.1.1 Maintenance of cell lines 
Cell lines were maintained in T-25 or T-75 tissue culture flasks (Corning or Sarstedt) at 37°C with 5% CO2 
and were sub-cultured by washing in phosphate buffered saline (PBS) and then incubation with 0.05% (v/v) 
trypsin-EDTA in PBS at 37°C. Trypsin was inactivated with R10 media. Cells were collected and washed in 
PBS and centrifuged at 1500 RPM for 5 minutes. Depending on the growth rate of each cell line, they were 
passaged at a ratio of 1:3-1:20. Cells were also harvested for analysis by this method unless otherwise 
stated. A summary of cell lines used in this study and culture conditions are shown in Tables 2.1 and 2.2. 
 
Cell Line Culture Conditions Reference 
PNT1a R10 (Cussenot et al., 1991) 
PNT2-C2 R10 (Berthon et al., 1995) 
BPH-1*  R5 (Hayward et al., 1995) 
P4E6** K2 (Maitland et al., 2001) 
PC3  H7 (Kaighn et al., 1979) 
Du145 R10 (Sobel and Sadar, 2005) 
LNCaP R10 (Horoszewicz et al., 1983) 
22RV1 R10 (Sramkoski et al., 1999) 
HEK-293T D10 (DuBridge et al., 1987, Pear et al., 1993) 
U-87 MG D10 (Ponten and Macintyre, 1968) 
* Gifted from Simon Hayward 
** Derived in York 
 
Table 2.1. Cell lines and their culture conditions. 
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Media Constituents 
R10 Roswell Park Memorial Institute-1640 (RPMI, 
Gibco),10% (v/v) foetal calf serum (FCS) (Gibco) 
and 2mM L-Glutamine (Gibco) 
R5 RPMI, 5% (v/v) FCS, 2mM L-Glutamine 
K2 Keratinocyte Serum-Free Medium (KSFM, 
Invitrogen), 2% (v/v) FCS, 2mM L-Glutamine, 
50µg/ml bovine pituitary extract (Gibco), 5ng/ml 
human epidermal growth factor (EGF) (Gibco) 
H7 Ham’s F-12 medium (Lonza), 7% (v/v) FCS, 
2mM L-Glutamine 
D10 Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Gibco), 10% (v/v) FCS, 2mM L-Glutamine 
 
Table 2.2. Culture media constituents. 
2.1.2 Primary prostate tissue processing and cell culture 
A detailed account of primary prostate tissue processing and cell culture is described in Frame et al. (2016). 
Prostate tissue was obtained from patients with ethical permission and consent by a tissue procurement 
officer (Ethics Number: 07/H1304/121). Tissue received was anonymised and derived from either BPH by 
TURP or targeted needle core biopsies of tumours and adjacent normal tissue following RP. Cancer cores 
were taken from palpable tumours when possible or alternatively from cancerous areas detected by MRI 
and TRUS biopsies. The tissue was submerged in transport media, composed of RPMI with 5% (v/v) FCS 
and 100U/ml antibiotic/antimycotic solution (100 IU/ml penicillin, 100µg/ml streptomycin and 0.25 µg/ml 
fungizone (ABM, Invitrogen)) and maintained at 4°C during transport.  
Upon arrival, tissue fragments were chopped into small pieces with a scalpel. A small piece was submerged 
in formalin for paraffin-embedding whilst the rest was digested in collagenase (200U/mg, Worthington 
Biochemical Corporation) in 2.5ml KSFM and 5ml R10. After incubation overnight at 37°C on an orbital 
shaker at 80 RPM, the digested tissue was then triturated through a 5ml pipette followed by a blunt cannula 
(0.813mm x 2.5mm, Covidien) and centrifuged at 1500 RPM for 10 minutes. The supernatant was removed 
with a Pasteur pipette and cells washed with 10ml PBS and centrifuged at 1500 RPM for 4 minutes. Cells 
were then incubated in 5ml trypsin at 37°C for 30 minutes on an orbital shaker at 80 RPM, trypsin inactivated 
with 5ml of R10 and centrifuged at 1500 RPM for 4 minutes. The supernatant was removed and cells 
resuspended in 5ml stem cell media (SCM) which consisted of KSFM, bovine pituitary extract (50µg/ml), 
human EGF (5ng/ml), granulocyte macrophage colony stimulating factor (1ng/ml, Miltenyi Biotec), stem cell 
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factor (2ng/ml, First Link UK Ltd), leukaemia inhibitory factor (2ng/ml, Chemicon), cholera toxin (100ng/ml, 
Sigma Aldrich) and L-Glutamine (2mM).  
Primary cells were cultured on collagen-I coated 10cm dishes (BD Biosciences) with murine STO fibroblast 
feeder cells (irradiated) and maintained with fresh SCM every other day and passaged at a ratio of 1:2-1:4 
by trypsinisation. Following the first passage after processing, STOs were no longer used.  
2.1.3 Irradiation of murine fibroblasts 
Murine STO fibroblasts were added to primary epithelial cell cultures as a feeder culture. To ensure STOs 
did not overwhelm the primary cell cultures, they were treated with a 60Gy dose of radiation. Irradiation of 
STOs was routinely carried out by Fiona Frame and Dominika Butler using an X-RAD iR225 irradiator. STOs 
were maintained in T-175 tissue culture flasks (Sarstedt) in D10, harvested by trypsinisation at 90% 
confluency and centrifuged at 1500 RPM for 5 minutes. They were then sub-cultured at a ratio of 1:20. STOs 
that were to be irradiated were resuspended in 25ml KSFM per T-175 flask. Irradiated STOs were kept at 
4°C until use for up to 5 days.  
2.1.4 Cryopreservation of cell cultures  
Cultured cells to be transferred to liquid nitrogen for long term storage were harvested via trypsinisation and 
centrifuged at 1500 RPM for 5 minutes. They were then resuspended at a concentration of 1-2x106 cells/ml 
in freezing medium (10% (v/v) dimethyl sulfoxide (DSMO), 20% (v/v) FCS in RPMI) and transferred into 2ml 
cryovials (Greiner Bio-One). Cells were stored at -80°C for 24 hours before transferring to liquid nitrogen.  
2.1.5 Live cell count using haemocytometer  
Live cell number was determined using Trypan Blue Stain (0.4%, Sigma Aldrich). 10µl Trypan Blue was 
mixed with 10µl cell suspension and cells counted using a haemocytometer (Neubauer). Number of 
unstained cells was equivalent to live cell number. 
2.1.6 Enrichment of basal cell subpopulations from primary cell cultures 
The prostate differentiation hierarchy is composed of three basal cell subpopulations. TA and CB cells were 
enriched for from primary prostate epithelial cell cultures by using cell surface markers, as described 
previously by Collins et al. and Frame et al. TA cells are α2β1-integrinhigh and CB cells are α2β1-integrinlow 
(Collins et al., 2001, Frame et al., 2016). α2β1-integrin expression allows enrichment by collagen adherence. 
Collagen-I coated 10cm dishes were blocked with heat inactivated, filtered 0.3% (w/v) bovine serum albumin 
(BSA) in PBS at 37°C for 1 hour and washed once with PBS. The number of blocked plates was half the 
number of plates of cultured cells to be enriched. Primary cultures were harvested by trypsinisation and 
resuspended in SCM. 3ml of cell suspension was added to each blocked plate and incubated for 20 minutes 
at 37°C. The media was collected, together with three 3ml PBS washes, and centrifuged at 1500 RPM for 
5 minutes; this constitutes the CB subpopulation. The adherent cells were then trypsinised and pelleted and 
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these constitute the TA subpopulation. The TA and CB subpopulations were then harvested for protein or 
plated onto collagen-I coated plates for knockdown experiments (CB cells only) or vorinostat treatment. 
2.1.7 Vorinostat treatment of primary cells  
Primary prostate epithelial cells (whole population, TA or CB) were plated at a density of 5 x 105 onto 
collagen-I coated 6 well plates and left to adhere overnight. Cells were treated with Vorinostat at a 
concentration of 0.625μM, 2.5μM or 10μM for 4 hours or 24 hours before harvesting for protein analysis. 
2.2 Cell transfection 
2.2.1 siRNA transfection of prostate cell lines 
Silencer Select siRNAs (ThermoFisher Scientific) were used to knock down ELF3 expression in prostate 
epithelial cell lines and primary cells. Cells were plated at a density of 4 x 104 – 3 x 105 and left to adhere 
overnight. A 10μM stock of ELF3 siRNA (siELF3, Assay ID: s4623) or scrambled siRNA (siSCR, Negative 
control no. 1) was added to OptiMEM reduced serum medium to produce mix 1 and Lipofectamine RNAiMAX 
(Invitrogen) was added to OptiMEM to produce mix 2 (Table 2.3). The mixtures were added together at a 
ratio of 1:1 and incubated for 15 minutes at room temperature. The transfection mix was then added 
dropwise into media of wells. Cells were harvested at various time points for protein analysis and functional 
assays (Section 2.7).  
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Plate Size 
Mix 1 Mix 2 Total 
Transfection 
Mix/well (μl) 
Media 
Volume 
(ml) 
OptiMEM 
(μl) 
10μM 
siRNA (μl) 
OptiMEM 
(μl) 
RNAiMAX 
(μl) 
6 well 125 2.5 125 7.5 250 2 
12 well 50 1 50 3 100 1 
24 well 25 0.5 25 1.5 50 0.5 
 
Table 2.3. Components of siRNA transfection mixes for cell lines. 
2.2.2 siRNA transfection of primary prostate cells 
Cell were plated at a density of 3 x 104 – 2 x 105 in 12-well or 6-well collagen-I coated plates and left to 
adhere overnight. Transfection mixes were prepared as follows; siELF3 or siSCR (stock concentration of 
10μM) was added to OptiMEM reduced serum medium to produce mix 1 and Oligofectamine transfection 
reagent was added to OptiMEM medium to produce mix 2 (Table 2.4) and tubes were incubated for 10 
minutes at room temperature. All reagents were equilibrated to room temperature before use. The tubes 
were then added together and incubated for a further 25 minutes at room temperature. Media was aspirated 
from cells and OptiMEM was added to each well. The siRNA/Oligofectamine mixture was then added 
dropwise to wells and cells were incubated for 4 hours at 37°C. The transfection mixture was then removed, 
cells were washed once in PBS and 2ml of SCM was added. Cells were harvested from 6 well plates at 72 
hours post-transfection for protein analysis and from 12 well plates at 72 hours for cell cycle analysis. 
 
Plate 
Size 
Mix 1 Mix 2 
OptiMEM 
Volume (μl) 
Total 
Transfection 
Mix/well (μl) 
Total 
Media 
Volume 
(ml) 
OptiMEM 
(μl) 
10μM 
siRNA 
(μl) 
OptiMEM 
(μl) 
Oligofec
tamine 
(μl) 
6 well 245 5 66 4 175 320 2 
12 well 122.5 2.5 33 2 87.5 160 1 
 
Table 2.4. Components of siRNA transfection mixes for primary cells. 
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2.3 Mammalian cell RNA analysis 
2.3.1 RNA extraction 
An RNeasy Mini Kit (QIAGEN) was used to extract RNA from mammalian cells as per manufacturer’s 
instructions. Briefly, up to 5x106 cells were harvested by washing in PBS and incubated at 37°C with 0.05% 
trypsin-EDTA. Trypsinisation was stopped with R10 medium and cells were pelleted by centrifugation at 
1500 RPM for 5 minutes. The supernatant was removed and the remaining cell pellet was lysed in 350µl of 
Buffer RLT with 1:100 (v/v) β-mercaptoethanol (β-Me) and vortexed. The lysate was transferred to a 
QIAshredder spin column in a 2ml collection tube (QIAGEN) and centrifuged at 13,000 RPM for 2 minutes 
to homogenise the samples. 350µl of 70% ethanol was added to the homogenate and transferred to an 
RNeasy Mini spin column. The mixture was centrifuged at 13,000 RPM for 15 seconds and the flow-through 
discarded. The column was washed with 350µl of Buffer RW1 and centrifuged at 13,000 RPM for 15 
seconds. DNase digestion was performed by preparing a master mix of 10µl DNaseI stock solution and 
70µl of Buffer RDD per sample and mixed by inverting the tube a few times. 80µl of the mix was added to 
each column and incubated at room temperature for 10 minutes. 350µl of Buffer RW1 was added to the 
each column and centrifuged at 13,000 RPM for 15 seconds. Each column was transferred to a fresh 
collection tube and washed with 500µl Buffer RPE and centrifuged at 13,000 RPM for 15 seconds. A final 
wash was carried out with 500 µl Buffer RPE and centrifuged at 13,000 RPM for 2 minutes. The columns 
were then transferred to a fresh collection tube and centrifuged at 13,000 RPM for 1 minute to remove any 
residual ethanol. To elute the RNA, each column was placed in a 1.5ml Eppendorf and 30µl RNase-free 
water was added directly to the column and centrifuged at 13,000 RPM for 1 minute. A NanoDrop ND-1000 
spectrophotometer (ThermoFisher Scientific) was used to determine RNA quality and concentration. RNA 
samples were kept at -80°C for long term storage.  
2.3.2 cDNA synthesis and PCR purification 
Equal quantities of RNA were reverse transcribed into complementary DNA (cDNA) for each experiment 
(5µg of cell line RNA, 15-270ng primary cell RNA). Two master mixes were prepared as shown in Table 2.5 
(all components from Invitrogen). The appropriate volume of RNA was added to PCR tubes and samples 
were made up to 10µl with sterile molecular biology grade water (Sigma Aldrich). 2µl of Mastermix 1 was 
added to each sample and incubated at 65°C for 5 minutes. Samples were then put on ice and 8µl of 
Mastermix 2 was added and mixed by pipetting. The samples were then incubated at 25°C for 10 minutes, 
42°C for 50 minutes and 72°C for 15 minutes on a GeneAmp PCR Sytem 9700 (Applied Biosystems).  
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Mastermix Component (concentration) Volume per sample (µl) 
1 
Random hexamer primer (50ng/μl) 1 
dNTP (10mM)  1 
2 
5x First Strand Buffer  4 
DDT (0.1M) 2 
RNase OUT (40U/µl) 1 
Superscript III (200U/µl) 1 
 
Table 2.5. Mastermix components for cDNA synthesis. 
The QIAquick PCR purification Kit (QIAGEN) was used to remove excess dNTPs and salts from the cDNA 
samples. 100µl of Buffer PB was added to the 20µl cDNA reactions and transferred to a QIAquick spin 
column. The samples were centrifuged at 13,000 RPM for 45 seconds. The flow-through was discarded and 
the column washed in 750µl of Buffer PE and centrifuged 13,000 RPM for 1 minute. The flow-through was 
discarded and the column was centrifuged again at 13,000 RPM for 1 minute. The column was then 
transferred to a 1.5ml Eppendorf and the column incubated with 30µl of water (Sigma Aldrich) for 1 minute 
before eluting the cDNA by centrifugation at 13,000 RPM for 1 minute. A NanoDrop ND-1000 
spectrophotometer was used to determine cDNA quality and concentration. cDNA samples were kept at -
80°C for long term storage. 
2.3.3 Quantitative reverse-transcriptase PCR (qRT-PCR) 
Quantitative reverse-transcriptase PCR (qRT-PCR) was carried out using a CFX96 Real-Time PCR 
Detection System (Bio-Rad). Reactions were prepared in a dedicated PCR hood with 5µl SsoFast Probes 
Supermix (Bio-Rad) or Taqman Gene Expression Master Mix (Applied Biosystems), 0.5µl TaqMan assay 
probe (ELF3: Hs00963881_m1,  Applied Biosystems) (GAPDH: qHsaCEP0041396, Bio-Rad)  and 1.5µl 
ddH2O. 3µl cDNA was added outside the hood to make a total reaction volume of 10µl. A standard curve 
was used for absolute quantification of gene expression. 5-fold serial dilutions of pGEM-TEasy-ELF3 
plasmid (obtained from Prof Jenny Southgate, University of York) were prepared with a known number of 
copies of ELF3. Each sample and standard were run in triplicate on MicroAmp Optical 96 well plates (Applied 
Biosystems) and covered with StarSeal Advanced Polyolefin Film (STARLAB). 
Results were analysed using the Bio-Rad CFX Manager 2.0. The standard curve equation was used to 
determine the expression in unknown samples. Relative quantification was also carried out on a selection 
of samples using the delta-delta CT method, with GAPDH as the housekeeping gene.  
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2.4 Gene expression microarray analysis 
2.4.1 Sample preparation 
RNA was extracted from cells using the RNeasy Mini Kit (QIAGEN) according to Section 2.2.1. Sample sets 
were in triplicate and included untransfected, mock transfected, siSCR and siELF3 BPH-1 and PC3 cells. 
The RNA integrity number (RIN) of all samples was 9.8 or above (analysed by the University of York 
Bioscience Technology Facility using an Agilent Bioanalyzer). Each sample was carried out in duplicate to 
also obtain protein for western blot analysis. ELF3 knockdown was verified at the protein level before 
microarray analysis.  
2.4.2 Data analysis 
An Affymetrix Clariom D gene expression microarray was performed by Eurofins Genomics on RNA 
extracted from the samples described above. Transcriptome Analysis Console (TAC) Software 4.0 was used 
to analyse the data (ThermoFisher Scientific). A significance threshold of 2-fold increase or decrease and a 
p-value <0.05 was used. Gene ontology (GO) analyses were carried out using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) and visualised using REViGO. 
Data was also analysed by an external bioinformatician (Alastair Droop). He used LIMMA (Linear Models 
for Microarray and RNA-seq Data) within the R numerical environment, with a false discovery rate threshold 
of 0.025 after empirical Bayes smoothing of the standard errors (Ritchie et al., 2015, R Core Team, 2014).  
Multidimensional scaling (MDS) showed that BPH-1 and PC3 cells are different from each other and 
samples within each set are consistent and can therefore be compared (Figure 2.1).  
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Figure 2.1. Multidimensional scaling of microarray samples. 
Multidimensional scaling (MDS) of BPH-1 and PC3 samples analysed by gene expression microarray. Produced by 
Alastair Droop. Sample sets were in biological triplicate and included untransfected, mock transfected, siSCR and siELF3 
of BPH-1 and PC3 cells. 
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2.5 Protein analysis 
2.5.1 Protein extraction  
Cells were harvested using trypsin and the resulting pellets were lysed in radioimmunoprecipitation assay 
(RIPA) buffer or CytoBuster lysis buffer (Novagen) with the addition of protease inhibitors (cOmplete™, Mini, 
EDTA-free Protease Inhibitor Cocktail, Roche). Phosphatase inhibitors were also added if appropriate 
(PhosSTOP Roche). Cells lysed in CytoBuster were incubated on ice for 5 minutes and then centrifuged at 
13,000 RPM for 5 minutes. The supernatant was then transferred into a new 1.5ml microcentrifuge tube as 
the whole cell lysate. Cells lysed in RIPA buffer were incubated at 4°C for 20 minutes on a cyclical spinner. 
Samples were then spun at 14,000 RPM for 10 minutes at 4°C and the supernatant kept as the whole cell 
lysate. 
2.5.2 Protein quantification  
A Bicinchoninic acid (BCA) assay (Thermofisher Scientific) was used to quantify protein concentration from 
whole cell lysates according to the manufacturer’s instructions. Standards of known concentrations of BSA 
were made in the same lysis buffer as the unknown samples. 10μl of each standard or unknown sample 
were added to a 96 well plate in triplicate. 200μl of the pre-made BCA assay working solution was then 
added to each well and the plate was incubated at 37°C for 30 minutes. The plate was cooled down to room 
temperature and then read on a POLARstar OPTIMA microplate reader (BMG Labtech) for absorbance at 
562nm. A standard curve was generated from the BSA standards and protein concentration of unknown 
samples was calculated from the line of best fit.  
2.5.3 Cytoplasmic and nuclear fractionation 
5x106 cells (PNT1a, PNT2-C2, BPH-1, P4E6, LNCaP, PC3) were harvested and washed twice in cold PBS. 
The supernatant was discarded and the cell pellet was resuspended in 500μl of hypotonic buffer (20mM 
Tris-HCl pH 7.4, 10mM NaCl, 3mM MgCl2) and transferred to a pre-chilled 1.5ml microcentrifuge tube. The 
lysate was then incubated on ice for 15 minutes. 25μl of 10% NP40 was added and mixed by vortexing for 
10 seconds. The lysate was centrifuged at 3000 RPM for 10 minutes at 4°C. The supernatant was removed 
and kept as the cytoplasmic fraction. The remaining cell pellet was then was then resuspended in 50μl cell 
extraction buffer (100mM Tris-HCl pH 7.4, 2mM NaVO4, 100mM NaCl, 1% (v/v) Triton X-100, 1mM EDTA, 
10% (v/v) glycerol, 1mM EGTA, 0.1% (w/v) SDS, 1mM NaF, 0.5% (w/v) sodium deoxycholate, 20mM 
Na4P2O7). The lysate was incubated on ice for 30 minutes with vortexing at 10 minute intervals. They were 
then centrifuged at 12,000 RPM for 30 minutes at 4°C. The supernatant was transferred to a fresh Eppendorf 
as the nuclear fraction. Lysates were kept at -80°C for long term storage.  
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2.5.4 SDS-PAGE gel electrophoresis 
8-12% Tris-SDS acrylamide gels were prepared using the Bio-Rad Protean II system. 20-30µg of protein 
lysate was added to 4x Laemmli Sample Buffer (Bio-Rad) and heated to 95°C for 5 minutes. Up to 50µl of 
samples were added to wells with the Precision Plus Protein Kaleidoscope ladder (Bio-Rad) in a separate 
lane to determine size of proteins. Proteins were subjected to electrophoresis at 50V for 30 minutes, followed 
by 100V for 90 minutes. 
2.5.5 Western blot 
Immobilon-P membrane (Millipore) was activated by immersion in methanol for 30 seconds, and washed in 
dH2O. Gels were placed onto the membrane and transferred using the Bio-Rad Protean II system in transfer 
buffer (48mM Tris, 39mM glycine, 10% (v/v) methanol) at 100V for 90 minutes. Membranes were then 
blocked with 5% (w/v) non-fat skimmed milk (Marvel) at room temperature for 1 hour. Primary antibody 
diluted in 1% (w/v) Marvel or 5% (w/v) BSA in TBST (150mM NaCl, 50mM Tris-HCl pH7.5, 0.1% (v/v) Tween 
20) was added and incubated overnight at 4°C; a list of primary antibodies used is shown in Table 2.6. The 
following day, membranes were washed in TBST buffer three times for 5 minutes. Membranes were 
incubated with secondary antibodies (goat anti-rabbit IgG HRP-linked, Cell Signalling Technologies or goat 
anti-mouse IgG HRP-linked, Affinipure) for 1 hour at room temperature at a working concentration of 
1:10,000. After washing in TBST three times for 10 minutes, the BM Chemiluminescence Blotting Substrate 
(Roche) was used to develop the membranes. Solution A was added to Solution B at a dilution of 1:100 and 
added to the membrane for 2 minutes. The excess was removed and the membranes were exposed to 
hyperfilm ECL (GE Healthcare) and processed using an X-ray processor (SRX-101A, Konica Minolta) or a 
GeneGnome (Syngene). 
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Antibody Manufacturer Catalogue no. Species 
Working 
Concentration 
Diluent 
ELF3 Abcam Ab133621 Rabbit mono 1:1000-1:5000 1% Milk 
CK5 Abcam Ab52635 Rabbit mono 1:2000 1% Milk 
CK18 Sigma Aldrich C8541 Mouse mono 1:2000 1% Milk 
E-cadherin Abcam Ab1416 Mouse mono 1:250 1% Milk 
Total β-
catenin 
Sigma Aldrich C2206 Rabbit poly 1:4000 1% Milk 
Active β-
catenin 
Cell Signalling 
Technology 
(CST) 
8814S Rabbit poly 1:1000 5% BSA 
NSE Abcam Ab53025 Rabbit poly 1:500 1% Milk 
PLK1 CST 4513 Rabbit mono 1:1000 5% BSA 
CDC25C CST 4688 Rabbit mono 1:1000 5% BSA 
Cleaved 
caspase 3 
CST 9661 Rabbit poly 1:1000 5% BSA 
Cyclin B1 CST 4135 Mouse mono 1:1000 5% BSA 
p-Cyclin B1 
(Ser133) 
CST 4133 Rabbit mono 1:1000 5% BSA 
p21 CST 2947 Rabbit mono 1:1000 5% BSA 
GAPDH Abcam Ab9485 Rabbit poly 1:10,000 1% Milk 
Actin  Merck 04-1040 Rabbit mono 1:10,000 1% Milk 
 
Table 2.6. Antibodies used for protein detection by western blot. 
2.5.6 Western blot stripping 
Once membranes had been exposed they were washed in TBST four times for 5 minutes and then incubated 
in stripping buffer (0.0625M Tris-HCl pH6.8, 2% (w/v) SDS, 0.007% (v/v) β-Me) for 30 minutes at 50°C on 
a rocker. The membrane was then washed in TBST six times for 5 minutes and blocked in 5% Marvel for 1 
hour at room temperature before incubating with the primary antibody overnight at 4°C.   
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2.6 Paraffin-embedding and sectioning of prostate tissue 
2.6.1 Preparation of prostate tissue for paraffin-embedding 
Small segments of prostate tissue biopsies and TURPs were submerged in formalin overnight. The following 
day, the tissue was moved to a histocassette and placed in 70% ethanol until paraffin embedding. Filter 
paper was added to the histocassette to avoid small pieces of tissue being lost through the gaps. 
2.6.2 Preparation of cell pellets for paraffin-embedding 
BPH-1 cells were grown in a monolayer in a 10cm dish until confluent. Cells were detached via incubation 
with trypsin and collected by centrifugation at 1500 RPM for 5 minutes. The pellet was then washed once in 
PBS and transferred to a 1.5ml microcentrifuge tube. Cells were centrifuged at 6500 RPM for 2 minutes and 
the pellet was resuspended in 225μl of blood plasma with 5.6μl of 1M calcium chloride added. 22.5μl of 
thrombin (120 NIH-U/ml, Sigma) was added to the cell mixture, stirred with a pipette tip and left to coagulate 
for a few minutes.  
A histocassette was set up as follows; a layer of filter paper at the bottom, a sponge layer with a hole cut 
out of the middle to insert the coagulated cell pellet followed by another filter paper on top. The assembled 
histocassette was then placed in formalin to replicate fixation of prostate tissue. After four hours (the pellet 
did not require as long as tissue for the formalin to penetrate) the histocassette was moved to 70% ethanol 
until paraffin embedding.  
2.6.3 Paraffin-embedding of cell pellets and prostate tissue 
Prepared tissues and cell pellets in histocassettes were transferred from storage 70% ethanol into fresh 
70% ethanol for 10 minutes. Histocassettes were then placed in 100% ethanol 3 x 10 minutes, propan-2-ol 
2 x 10 minutes and xylene 4 x 10 minutes. Excess xylene was blotted on blue roll. Four paraffin wax pots 
were melted in an oven at 60°C the previous evening and the histocassettes were placed in each pot for 15 
minutes consecutively. The samples were then removed from the histocassette and placed and orientated 
in metal moulds partially filled with molten wax from an urn. The lid of the histocassette (with label) was 
placed on top of the sample and the mould was filled up with molten wax. The samples were set on a cold 
plate for 20 minutes and removed from the mould. Samples were stored at room temperature until 
sectioning.  
2.6.4 Sectioning of paraffin-embedded samples 
SuperFrost Plus Slides (ThermoFisher Scientific) were first coated in 3-Aminopropyltriethoxysilane (APES) 
as follows: submerged in 2% APES in acetone for 1 minute, 2 x acetone washes, 2 x distilled water washes 
and placed on a slide dryer overnight. 
Paraffin-embedded tissues and cell pellets were sectioned on a Leica RM2235 microtome. Sections were 
5μm thick and placed on APES coated slides and placed on a slide dryer overnight.  
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2.7 Immunostaining 
2.7.1 Immunohistochemistry (IHC) – prostate tissue and cell pellets 
Paraffin-embedded prostate tissue sections were baked at 45°C for 20 minutes on a slide dryer. 
Deparaffinisation and rehydration were performed by immersing slides in the following baths; xylene 2 x 10 
minutes, xylene 1 x 1 minute, 100% ethanol 3 x 1 minute and 70% ethanol 1 x 1 minute. Slides were then 
washed for 5 minutes under running tap water. Heat-induced epitope retrieval (HIER) was carried out in 
sodium citrate buffer (pH 6) using the 2100 Antigen Retriever (Aptum Biologics) pressure cooker overnight. 
Slides were washed three times in PBS for 5 minutes on an orbital shaker. A PAP pen (Dako) was used to 
create a hydrophobic barrier around each tissue section, which was subsequently blocked in 10% (v/v) FCS 
in PBS for 1 hour at room temperature in a dark, moist box. The block was removed and sections were 
incubated in primary antibody diluted in 10% (v/v) FCS in PBS overnight at 4°C in the box (Table 2.7).  
The following day, slides were washed three times in PBS for 5 minutes and treated with 3% (v/v) hydrogen 
peroxide in PBS for 30 minutes to remove endogenous peroxidases. Slides were rinsed in PBS and then 
incubated with the secondary biotinylated antibody diluted in 10% (v/v) FCS in PBS for 30 minutes at room 
temperature. After washing three times in PBS for 5 minutes, they were then incubated with the tertiary 
antibody (streptavidin-HRP) diluted in 10% FCS for 30minutes at room temperature. Slides were washed 
twice in PBS for 5 minutes and sections were then incubated with diaminobenzidene (ImmPACT DAB 
peroxidase substrate, Vector Laboratories) until sections started to turn brown (10 seconds – 2 minutes). 
Following rinsing in distilled water and then running tap water for 5 minutes, sections were counterstained 
with haematoxylin for 3 seconds, rinsed with water and then dehydrated through the following baths; 70% 
ethanol 1 x 1 minute, 100% ethanol 3 x 1 minute and xylene 2 x 1 minute. The slides were then mounted 
with DPX (Sigma Aldrich) and covered with a coverslip.  
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Antibody 
Primary (P)/ 
Secondary 
(S) /Tertiary 
(T) 
Manufacturer Cat no. Species 
Working 
Dilution 
ELF3 P Abcam Ab97310 Rabbit poly 1:1000 
p63 P Dako M7317 Mouse mono 1:500 
HMW-CK P Dako M0630 Mouse mono 1:800 
Nkx3.1 P Menapath MP-422-CR01 Rabbit poly 1:800 
AMACR P Dako M3616 Rabbit mono 1:100 
Rabbit anti-
mouse 
biotinylated 
S Dako E0354 Rabbit poly 1:200 
Goat anti-
rabbit 
biotinylated 
S Dako E0432 Goat poly 1:500 
Streptavidin-
HRP 
T Dako P0397  1:100 
 
Table 2.7. Antibodies used for protein detection by immunohistochemistry.  
2.7.2 IHC using the ImmPRESS Excel Amplified HRP Polymer Staining Kit 
The ImmPRESS Excel Amplified HRP Polymer Staining Kit (anti-rabbit IgG kit: MP-7601, anti-mouse IgG 
kit: MP7602, Vector Laboratories) was employed to amplify signal of potentially weakly expressed antigens. 
Baking, deparaffinisation, hydration and antigen retrieval was carried out as described in section 2.5.1. All 
further reagents used were provided in the kit.  
The following day sections were incubated with BLOXALL blocking solution for 10 minutes to quench 
endogenous peroxide activity and subsequently washed in running water for 10 minutes. Sections were then 
blocked in 2.5% normal horse serum for 20 minutes. The block was removed and sections were incubated 
in primary antibody diluted in 2.5% normal horse serum overnight at 4°C in a dark moist box.  
Slides were washed three times in TBST for 5 minutes and then incubated with Amplifier Antibody for 15 
minutes followed by another two washes in TBST for 5 minutes. Sections were then incubated with 
ImmPRESS Excel Reagent for 30 minutes and washed once in TBST and then in dH2O for 5 minutes. Equal 
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volumes of ImmPACT DAB EqV Reagent 1 and 2 were combined and added to sections until they turned 
brown (10 seconds – 2 minutes). Sections were then rinsed in dH2O followed by running tap water. Slides 
were counterstained with haematoxylin for 3 seconds, rinsed with water and dehydrated and mounted as 
described in section 2.5.1.  
2.7.3 Immunocytochemistry (ICC) – fixed cells 
Cells were plated onto 8 well chamber slides and left to adhere overnight (~10,000 cells/well). Corning 
Biocoat collagen-I coated slides were used for primary prostate cells whilst uncoated Falcon culture slides 
were used for cell lines (Corning). Following two PBS washes, cells were then fixed with either 200μl 4% 
paraformaldehyde (PFA) pH 7.4 for 10 minutes at room temperature or 1:1 methanol:acetone for 30 seconds 
at room temperature. After washing in PBS three times for 5 minutes, cells were permeabilised using 200μl 
0.5% (v/v) Triton X-100 in PBS for 10 minutes at room temperature. Following a further three PBS washes 
for 5 minutes, cells were then blocked in 10% (v/v) goat serum in PBS for 1 hour at room temperature. Cells 
were then incubated with primary antibody diluted in 10% goat serum overnight at 4°C. Secondary antibody 
only controls were performed by incubating in 10% goat serum only overnight. Primary and secondary 
antibodies used are shown in Table 2.8. 
The following day, slides were washed three times in PBS for 5 minutes and incubated with 200μl secondary 
antibody at a dilution of 1:1000 in 10% goat serum. Cells were washed a final five times with PBS for 5 
minutes whilst protected from light and the chambers were then removed. Nuclear staining was performed 
using Vectashield mounting medium with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories) and 
slides covered with a coverslip (22x50mm, SLS) and sealed with clear nail varnish.  
Slides were analysed on a Leica DMIL LED fluorescent microscope or a Zeiss LSM 880 confocal 
microscope. 
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Antibody 
Primary (P)/ 
Secondary(S) 
Manufacturer Cat no. Species 
Working 
Dilution 
ELF3  P Abcam Ab133621 Rabbit mono 1:1000 
ELF3 P Santa Cruz sc-376055 Mouse mono 1:50-1:500 
ELF3 P Sigma Prestige HPA003479 Rabbit poly 1:50 
Ki67 P Abcam Ab15580 Rabbit poly 1:800 
Active β-
catenin 
P Cell Signalling 
Technology 
8814S Rabbit poly 1:600 
Cytokeratin 5 P Abcam Ab52635 Rabbit mono 1:500 
Cytokeratin 18 P Sigma C8541 Mouse mono 1:800 
Tubulin P Abcam Ab7291 Mouse mono 1:250 
Phospho-
histone 3 
P Merck 06-570 Rabbit poly 1:500 
Goat anti-rabbit 
IgG Alexa Fluor 
568 
S Invitrogen  A-11036 Goat poly 1:1000 
Goat anti-
mouse IgG 
Alexa Fluor 488 
S Invitrogen A-11029 Goat poly 1:1000 
 
Table 2.8. Antibodies used for protein detection by immunocytochemistry. 
2.8 Lentiviral cloning and virus production 
2.8.1 attB sequence flanking of ELF3 
Invitrogen Gateway Cloning Technology (ThermoFisher Scientific) was utilised to produce lentiviral vectors 
for ELF3 overexpression, which is based on bacteriophage lambda att site recombination. For the desired 
sequence to be incorporated into the vector, it was first flanked with attB sequences via two rounds of PCR 
amplification and gel extraction. A reaction mix of 20μl was prepared according to Tables 2.9 and 2.10. PCR 
reactions were performed using the Phusion polymerase kit (New England Biolabs) and all components 
were kept on ice. Thermocycling conditions were as follows; 98°C for 30 seconds, 30 cycles of 98°C for 10 
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seconds, 66°C for 30 seconds and 72°C for 30 seconds, with a final extension of 72°C for 10 minutes on 
the GeneAmp PCR System 9700 (Applied Biosystems). Plasmid DNA template pGEMT-easy-ELF3-WT was 
provided by Prof Jenny Southgate and pEGFP-ELF3-ΔAT was provided by Prof Arthur Gutierrez-Hartmann. 
Component Volume per sample 
5x HF Phusion Buffer  4 
Forward primer (10μM) 1 
Reverse primer (10μM) 1 
dNTPs (10mM) 0.4 
DNA template 100ng 
Phusion polymerase  0.1 
Nuclease free H2O Up to 20μl 
 
Table 2.9. Components used for attB flanking of ELF3 by PCR. 
 
 
Primer Name Description Sequence 
ELF3-overhang Outer ELF3 and inner attB sequence 
F: 5’ – CAAAAAAGCAGGCTCCAT 
GGCTGCAACCTGTGAG – 3’ 
R: 5’ – CAAGAAAGCTGGGTCTCA 
GTTCCGACTCTGGAGAA – 3’ 
Outer attB Outer attB sequence 
F: 5’ – GGGGACAAGTTTGTACAA 
AAAAGCAGGCT – 3’ 
R: 5’ – GGGGACCACTTTGTACAA 
GAAAGCTGGGT – 3’ 
 
Table 2.10. Primer sequences for sequential attB flanking of ELF3. 
2.8.2 Gel extraction 
PCR products were run on a 1% (w/v) agarose gel in Tris-acetate EDTA (TAE) buffer with SYBR Safe DNA 
gel stain (Invitrogen) at 60V for 90 minutes. Bands were visualised, excised into a 2ml microcentrifuge tube 
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and DNA was recovered using the QIAquick Gel Extraction kit (QIAGEN). Briefly, the amount of gel was 
weighed and the appropriate volume of QG buffer was added (100μl for every 100mg of gel). Tubes were 
incubated at 50°C for 10 minutes and vortexed every 3 minutes until the gel dissolved. An equal volume of 
isopropanol was then added to the tubes and mixture was transferred to a QIAquick column and centrifuged 
for 1 minute at 13,000 RPM. 500μl of Buffer QG was added and centrifuged for a further minute and the 
flow through discarded. The column was centrifuged for 1 minute at 13,000 RPM to remove residual buffer 
and then placed into a clean 1.5ml microcentrifuge tube. 30μl Sigma water was added to the column and 
left standing for 4 minutes before eluting the DNA by centrifuging for 1 minute at 13,000 RPM.  
2.8.3 BP reaction 
The BP recombination reaction was performed by adding 25ng of the ELF3-attB PCR product to 150ng of 
the empty DONR vector (pDONR221) and Sigma water to make a total volume of 8μl. The BP clonase was 
thawed on ice and 2μl was added to each sample. The samples were incubated overnight at 25°C using 
the GeneAmp PCR Sytem 9700 (Applied Biosystems) and then stopped using 1μl of proteinase K 
(Invitrogen) before transformation into DH5α competent cells (Section 2.6.4). 
2.8.4 Transformation and bacterial cultures 
MAX Efficiency DH5α competent cells (Invitrogen) were thawed on ice for 20 minutes. Meanwhile, lysogeny 
broth (LB) agar plates containing the appropriate antibiotic were warmed to 37°C. DONR vectors were 
selected on kanamycin plates (30μg/ml) whilst Destination vectors were selected on carbenicillin plates 
(50μg/ml). The recombination reaction mixture was added to the competent cells, mixed by swirling the 
pipette tip and incubated on ice for 30 minutes. The mixture was heat shocked at 42°C for 45 seconds in a 
waterbath and incubated on ice for a further 2 minutes. 200μl of S.O.C media (ThermoFisher Scientific) 
without antibiotic was added and the mixture was incubated at 37°C whilst shaking at 225 RPM for 1 hour. 
The transformation mixture was then spread on warmed agar plates using a glass spreader and incubated 
overnight at 37°C. 
Single colonies were picked and used to inoculate a 5ml LB broth with the appropriate antibiotic and 
incubated at 37°C for 16-18 hours with shaking at 225 RPM. Glycerol stocks of each clone were generated 
by adding 850μl of bacterial culture to 150μl of glycerol into a cryovial before vortexing and storing at -80°C. 
2.8.5 Miniprep 
Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (QIAGEN) using the manufacturer’s 
instructions. Briefly, bacterial cells from overnight cultures were harvested by centrifuging at 3000 RPM for 
10 minutes at room temperature in a Heraeus Megafuge 1.0R centrifuge (Thermo Scientific). Cells were 
then resuspended in 250μl Buffer P1 and transferred to a microcentrifuge tube. 250μl Buffer P2 was added 
and mixed by tapping the tube until the mixture became viscous. After 5 minutes at room temperature, 350μl 
of Buffer N3 was added, mixed immediately and thoroughly by inverting the tube until the mixture became 
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white and cloudy. Tubes were then centrifuged at 13,000 RPM for 10 minutes and the resulting supernatant 
was transferred to a QIAprep spin column and centrifuged at 13,000 RPM for 1 minute. The flow-through 
was discarded and the column was washed with 500μl of Buffer PB. Columns were centrifuged at 13,000 
RPM for 1 minute and the flow through was discarded. Columns were then washed in 750μl of Buffer PE. 
The flow-through was discarded and the columns were centrifuged again at 13,000 RPM for 1 minute to 
remove any remaining wash buffer. The QIAprep column was transferred to a clean 1.5ml microcentrifuge 
tube, 50μl of Sigma water was added and allowed to absorb into the column for 1 minute. DNA was eluted 
by centrifuging for 1 minute at 13,000 RPM. DNA concentration and quality was calculated by a NanoDrop 
ND-1000 spectrophotometer (Thermo Scientific). 
2.8.6 LR reaction  
The LR recombination reaction was performed by adding 1μl of the empty Destination vector (pDest298 or 
pDest159) at 100ng/μl to 1μl of the pENTR vector produced during the BP reaction (pDONR227-ELF3-WT 
clone 7) at 50ng/μl into a PCR tube. 1μl of Sigma water was added to the reaction and finally 1μl of LR 
Clonase which was thawed on ice. The reaction was incubated overnight at 25°C using the GeneAmp PCR 
Sytem 9700 (Applied Biosystems) and then stopped using 1μl of proteinase K (Invitrogen) before 
transformation into DH5α competent cells (Section 2.6.4). 
2.8.7 PCR 
PCR amplification was carried out to determine if ELF3 was present in plasmid clones. A reaction mix of 
20μl was prepared according to Table (Section 2.7.1). Primers used are shown in Table 2.11. PCR reactions 
were performed using the Phusion polymerase kit (New England Biolabs) and all components were kept on 
ice. Thermocycling conditions were as follows; 98°C for 30 seconds, 30 cycles of 98°C for 10 seconds, 
66°C for 30 seconds and 72°C for 30 seconds, with a final extension of 72°C for 10 minutes. Products were 
analysed on a 1% (w/v) agarose gel in TAE buffer with GelRed nucleic acid stain (1:10,000, Biotium). Size 
of bands was determined using the MassRuler Express Reverse DNA ladder (ThermoFisher Scientific). 
Gels were visualised using GeneSnap ID software (Syngene). 
 
Primer Sequence 
ELF3 Forward 5’ – TCGGAGGACTCCACCCTG – 3’ 
ELF3 Reverse 5’ – CCCAACCAGCTGGCCTTC – 3’ 
 
Table 2.11. ELF3 primer sequences for PCR. 
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2.8.8 Restriction digest 
Restriction digests were carried out on single selected clones. 250ng of DNA was added to 2μl of the 
appropriate buffer and 1μl of enzyme (EcoRI, BamHI or PvuII, New England Biolabs). Reactions were made 
up to 10μl in Sigma water and incubated at 37°C for 1 hour. The products were subjected to gel 
electrophoresis on a 1% (w/v) agarose gel in TAE buffer with GelRed nucleic acid stain (1:10,000) at 60V 
for 90 minutes.  
2.8.9 Plasmid transfection 
HEK-293T cells were transfected with several clones of each generated ELF3-overexpressing plasmid using 
X-tremeGENE HP DNA transfection reagent (Roche). 3 x 105 cells were plated on 6 well poly-L-lysine 
(0.1mg/ml, Sigma Aldrich) coated plates and left to adhere overnight. A total reaction volume of 200μl was 
prepared. All reagents were warmed to room temperature before use consisting of 2μg of plasmid and 6μl 
of X-tremeGENE HP DNA transfection reagent, topped up with Opti-MEM reduced serum media. The 
transfection mix was incubated for 45 minutes at room temperature before adding dropwise to wells. GFP 
expression was examined on a Leica DMIL LED fluorescent microscope at 24 and 48 hours post-
transfection. 
2.8.10 Lentivirus production and concentration 
Lentivirus production was carried out in HEK-293T cells which had been modified from HEK-293T cells by 
transformation with SV40 large T antigen. This modification results in a highly transfectable cell line which 
is beneficial for lentivirus production (Pear et al., 1993). 7.5 x 105 HEK-293T cells were plated into 6 well 
poly-L-lysine coated plates and left to adhere overnight. The following day 2ml of fresh D10 media was 
added to wells 2 hours before transfection. The transfection mixture was prepared to a total volume of 200μl. 
All reagents were warmed to room temperature before use. Reduced serum Opti-MEM was added to a 1.5ml 
microcentrifuge tube. The plasmid mix was then added and gently mixed. This was composed of the desired 
Destination vector (2μg/well) and the viral packaging plasmids pVSV-G (0.5μg/well) and psPAX2 
(1.5μg/well). X-tremeGENE HP DNA transfection reagent (Roche) was then added at a ratio of 3:1 
(12μl/well) and mixed gently. The transfection mixture was incubated at room temperature for 45 minutes 
and then added dropwise to wells.  
The viral supernatant was collected at 48 hours post-transfection and filtered using a Millex-HV 0.45μm 
PVDF syringe filter (Merck). The virus was concentrated using PEG-it precipitation solution. 1ml of PEG-it 
solution was added for every 4 volumes of filtered viral supernatant and incubated at 4°C overnight. The 
supernatant was centrifuged at 1500G for 30 minutes at 4°C, transferred to a new vial and residual virus 
was centrifuged at 1500G for a further 5 minutes. The resulting pellets were resuspended and combined in 
PBS at 1:10 of the original volume. This was then aliquoted into cryovials and stored at -80°C.  
The control pDest298-GUS plasmid was provided by Alberto Taurozzi. 
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2.8.11 Lentivirus titre 
5 x 104 P4E6 cells were transduced in suspension with 10-fold serial dilutions of concentrated virus between 
a range of 1:10 and 1:100,000. Cells were plated onto 24 well plates and the media was changed 16 hours 
after transduction. Cells were analysed at 48 hours post-transduction by flow cytometry on a CyAn ADP 
(Beckman Coulter). Results were analysed using Summit software. The population of interest was gated on 
using FS Lin/SS Log and singlets were gated on using pulse width. The GFP-positive population was gated 
on using FITC Log. Viral titre was determined using dilutions which produced between 1 and 20% of GFP-
positive P4E6 cells. Viral titre was calculated using the following formula: 
 
𝑇𝑖𝑡𝑟𝑒 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔 𝑐𝑒𝑙𝑙𝑠 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 × (% 𝐺𝐹𝑃 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 ÷ 100)
𝑣𝑜𝑙𝑢𝑚𝑒
 
 
2.8.12 Lentiviral transduction of primary prostate epithelial cells 
3 x 105 primary prostate epithelial cells were transduced in suspension with pDest298-GUS, pDest298-
ELF3-WT or pDest298-ELF3-ΔAT at a ratio of three infectious particles for each cell. The cells were plated 
onto a 10cm dish topped up with 5ml of SCM. The media was changed 16 hours post-transduction, changed 
every two days thereafter until the 10cm dishes were 90% confluent. The cells were then used for various 
functional assays.  
1 x 104 primary prostate epithelial cells were transduced in suspension with pDest159-GUS, pDest159-
ELF3-WT or pDest159-ELF3-ΔAT at a ratio of three infectious particles for every one cell. The pDest159-
GUS virus was provided by Alberto Taurozzi. The cells were plated onto a collagen-coated chamber slide 
(Corning) and topped up with 200ul of SCM. The media was changed 16 hours post-transduction and cells 
were fixed in 4% PFA the following day.  
2.9 Cell function assays 
2.9.1 Cell viability assay 
AlamarBlue quantitatively measures cell viability since actively metabolising cells can reduce its active 
ingredient resazurin to a fluorescent molecule (resorufin) which can be subsequently analysed on a plate 
reader. Cells were plated in 24 well plates in triplicate at a density of 4 x 104 BPH-1 cells/well and 6 x 104 
PC3 cells/well and left to adhere overnight in 500μl media. The following day cells were transfected 
according to section 2.6.11. At days 1, 2 and 3, 50μl of alamarBlue reagent (diluted 1:10 in the corresponding 
media for each cell line) was added to each well and incubated at 37°C for 2 hours. Fluorescence intensity 
was determined using a microplate reader (Polarstar Optima, BMG Labtech) at excitation/emission values 
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of 544/590nm. As cells were approaching confluency at day 3, they were trypsinised and replated at the 
original plating density, viability was analysed on days 4, 5 and 6.  
2.9.2 Cell adhesion assay 
To assess the effect of ELF3 knockdown on cell adhesion, BPH-1 cells following knockdown were detached 
by incubation with trypsin and replated in a 6-well plate at three different densities; low (40,000), medium 
(100,000) and high (300,000). Cells were left to adhere for 4 hours at which point non-adherent cells were 
washed off and adherent cells were trypsinised and counted using the Vi-Cell Cell Viability Analyser 
(Beckman Coulter).  
2.9.3 Wound healing assay following ELF3 knockdown in prostate epithelial cell lines 
Cells were plated onto 12 well plates in triplicate (2 x 105 BPH-1, 2.5 x 105 PC3 per well) and left to adhere 
overnight. Cells were transfected the following day according to Section 2.5.1. At 24 hours post-transfection, 
a wound was made in the confluent monolayer using the end of a blue tip. Images were taken at zero hours 
using an EVOS XL transmitted light microscope (AMG) at 10x. The end point was determined by monitoring 
the wounds until the first triplicate set of one condition (mock, siSCR or siELF3) had closed. The average 
width of the wounds was determined between 10 points using Image J software. Percent wound closure 
was calculated at the end point relative to zero hour images.   
2.9.4 Wound healing assay following ELF3 overexpression in primary prostate epithelial cells  
Primary prostate epithelial cells were transduced with lentiviral ELF3 overexpression vectors as described 
in Section 2.7.12. 2.1 x 104 cells were plated into each well of a 2-well insert (Ibidi) in 12 well plates in 
triplicate according to manufacturer’s instructions. The insert ensures the cell-free gap is consistent between 
wells. Cells were left to adhere overnight and the following day the inserts were removed and the plates 
were put onto the VL21 microscope (Phasefocus, www.phasefocus.com) to monitor wound closure via live 
cell real time imaging. The data was processed by Amanda Noble using Cell Analysis Toolbox (CAT) 
software and analysed by myself. 
2.9.5 Colony forming assay 
Colony forming assays were carried out by plating 200 BPH-1 or PC3 cells into 12 well plates in triplicate. 
Cells were plated 24 hours after knockdown treatment (mock, siSCR or siELF3), and were supplemented 
with fresh media every two days. At day 7, cells were stained with crystal violet (1% (w/v) crystal violet, 10% 
(v/v) ethanol in PBS). Colonies consisting of >32 cells were counted (representative of 5 population 
doublings) (Puck and Marcus, 1956, Francipane et al., 2008). 
2.9.6 Cell cycle analysis 
Cell cycle analysis was carried out by flow cytometry using the Click-iT Plus EdU Pacific Blue Flow 
Cytometry Kit (ThermoFisher Scientific) and propidium iodide according to the manufacturer’s instructions. 
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Briefly, 4 x 104 BPH-1 and 8 x 104 PC3 cells were plated onto a 12 well plate. The following day cells were 
transfected for knockdown according to section 2.6.11. On days 1, 2 and 3 post-transfection cells were 
treated with 10μM EdU. After 4 hours, cells were trypsinised and harvested and washed in 3ml 1% BSA in 
PBS. The pellet was resuspended in 100μl Click-iT fixative and incubated at room temperature for 15 
minutes away from light. Cells were washed in 3ml 1% BSA in PBS and then stored in PBS at 4°C until the 
day they were to be analysed by flow cytometry.  
Cells were centrifuged and resuspended in 100μl of 1x Click-iT saponin-based permeabilisation and wash 
reagent and incubated at room temperature for 15 minutes. 500μl of the Click-iT Plus reaction cocktail 
(438μl PBS, 10μl copper protectant, 2.5μl fluorescent dye picolyl azide, 50μl reaction buffer additive) was 
added to each tube, mixed well and incubated at room temperature for 30 minutes away from light. Cells 
were then washed in 1x Click-iT saponin-based permeabilisation and wash reagent, centrifuged and 
resuspended in 400μl of the same reagent. 50μl of RNase A (1mg/ml, Sigma) and 50μl propidium idodide 
(400μg/ml, Sigma) were added to each sample and incubated at 37°C for 30 minutes before analysing on 
the flow cytometer.  
Results were analysed using Summit software. The cell population of interest was gated using a FS Lin/SS 
Log histogram and doublets were excluded using a PE-Texas Red Lin/PE-Texas-Red Area histogram. PE-
Texas Red Area/Violet 1 Log was used to determine the proportion of cells in G1, S and G2 phases of the 
cell cycle. At least 10,000 events were collected for significance. 
A pulse-chase experiment was also set up to assess progression of cells through the cell cycle. Cells were 
treated with 10μM EdU for 4 hours (pulse) and one well was then harvested and the medium was replaced 
in duplicate wells with normal growth medium. These cells were then harvested at 24 hours (chase). Cells 
were then analysed using the above protocol. 
2.10 Statistical analyses 
Unless otherwise stated, statistical analyses were carried out using GraphPad Prism 6/7 software (San 
Diego, USA). Functional assays were carried out in technical replicate (at the same time with the same 
passage of cells, n=3) and biological replicate (at a separate time point with a different passage of cells, 
n≥3). Significance was calculated on at least three biological replicates using tests described in figure 
legends. Results were expressed as the mean with associated standard deviation unless otherwise stated. 
Statistical significance was represented on graphs as * p = 0.01 to 0.05, ** p = 0.001 to 0.01, *** p = 0.0001 
to 0.001, **** p < 0.0001. 
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3. Results 
3.1 ELF3 expression in prostate epithelial cell lines 
3.1.1 ELF3 is ubiquitously expressed in a range of prostate cell lines 
ELF3 has been ascribed both oncogene and tumour suppressor roles in the prostate (Longoni et al., 2013, 
Shatnawi et al., 2014). These reported studies focused on manipulating ELF3 expression in the prostate cell 
lines LNCaP, Du145 and 22RV1. To ascertain the expression pattern of ELF3 in all epithelial cell types in 
the prostate, qRT-PCR was carried out on a range of cell lines derived from normal prostate, benign prostate, 
localised PCa and PCa metastases (Table 3.1). The absolute transcript copy number of ELF3 was 
determined using a standard curve of serial dilutions of the pGEM-TEasy-ELF3 plasmid. The standard curve 
was then used to determine the gene expression levels of ELF3 in the prostate cell lines. ELF3 was most 
highly expressed in the normal PNT2-C2 cell line, but had relatively low expression in the PNT1a cell line 
which is also derived from normal prostate and both represent androgen-independent luminal cells. The 
intermediate BPH-1, PC3 and Du145 cell lines showed moderate expression and P4E6 (intermediate), 
LNCaP (luminal), and 22RV1 (luminal) expressed relatively low levels of ELF3 (Figure 3.1A). The level of 
ELF3 expression in each cell line was predominantly mirrored at the protein level (Figure 3.1B). These 
results demonstrate that there was no clear pattern of expression of ELF3 in relation to diagnosis or 
basal/luminal phenotype.  
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Cell Line Origin 
Selected 
Epithelial 
Hierarchy 
Markers 
Basal/Luminal 
/Intermediate 
AR 
Expression 
PSA 
Expression 
Reference 
PNT1a 
Normal 
prostate 
CK8, CK18 
Androgen-
independent 
Luminal 
- - 
(Mitchell et 
al., 2000) 
PNT2-C2 
Normal 
prostate 
CK8, CK18  
Androgen-
independent 
Luminal 
- - 
(Berthon et 
al., 1995, 
Lang et al., 
2001a) 
BPH-1 BPH 
CK5, CK8, 
CK18 
Intermediate 
 - - 
(Hayward et 
al., 1995, 
Pellacani et 
al., 2014) 
P4E6 
Localised 
PCa 
CK8, CD44 Intermediate - + 
(Maitland et 
al., 2001) 
PC3 
Lumbar 
vertebral 
bone 
metastasis 
CK5, CK8, 
CK18 
CD44 
Intermediate - - 
(Kaighn et 
al., 1979, 
van 
Leenders et 
al., 2001) 
Du145 
Brain 
metastasis 
CK5, CK8, 
CK18,  
Intermediate - - 
(Sobel and 
Sadar, 2005) 
LNCaP 
Lymph 
node 
metastasis 
CK8, CK18 Luminal + + 
(Horoszewicz 
et al., 1983) 
22RV1 
Xenograft 
of relapsed 
CWR22 
xenograft 
CK8, CK18 Luminal + + 
(Sramkoski 
et al., 1999) 
 
Table 3.1. Origin and phenotypic characteristics of prostate epithelial cell lines. 
CK = cytokeratin, AR = androgen receptor, PSA = prostate specific antigen, BPH = benign prostatic hyperplasia, PCa = 
prostate cancer. Markers of basal cells – CD44, CK5. Markers of luminal cells – CK8, CK18, AR. Expression of CK5 in 
absence of CK14 indicated an intermediate phenotype. 
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Figure 3.1. mRNA and protein expression of ELF3 in prostate epithelial cell lines. 
Expression of ELF3 was examined in a range of prostate cell lines at the mRNA and protein level. (A) 30ng of cDNA was 
analysed by qRT-PCR. A standard curve of 5-fold serial dilutions of pGEM-TEasy-ELF3 plasmid was used for absolute 
quantification of ELF3 gene expression. Colours indicate diagnosis of respective cell lines. Blue = normal, green = benign 
prostatic hyperplasia, orange = primary PCa, red = metastatic PCa, purple = derived from mouse model of PCa. (B) Protein 
expression was analysed by western blot analysis. 20µg of protein was loaded per lane onto a 10% SDS gel, transferred 
onto a PVDF membrane and probed for the indicated proteins. Tubulin was used as a loading control.  
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3.2 ELF3 expression in primary prostate epithelial cells 
3.2.1 ELF3 is more highly expressed in the committed basal cell population of primary prostate 
cultures as detected by microarray analysis 
An Affymetrix gene expression microarray was previously carried out in our lab, on enriched SC and CB 
epithelial cell populations derived from both human benign prostatic hyperplasia (BPH) and PCa tissue 
(Birnie et al., 2008). A total of seven BPH and twelve PCa tissues were processed and enriched for SC 
(α2β1hi/CD133+) and CB cells (α2β1lo/CD133-). Only treatment naïve PCa samples with a Gleason score of 
7 or above were included in the analysis as this resulted in clustering of samples based on diagnosis and 
differentiation state. The data was reanalysed to determine the expression of ELF3.  
There was a significant increase in ELF3 expression in CB cells compared to SC across three individual 
probes (Figure 3.2). However, there was no significant difference in ELF3 expression between benign and 
malignant samples when cell types were pooled. This suggests that, ELF3 expression is linked to the 
differentiation state of prostate epithelial cells regardless of diagnosis.  
  
79 
 
Figure 3.2. Affymetrix gene expression microarray data analysis from benign and malignant prostate 
suggests ELF3 is expressed at higher levels in the committed basal cell subpopulation compared to 
stem cells. 
Affymetrix gene-expression arrays were carried out on the sorted cell populations from seven benign prostatic hyperplasia 
(BPH) and twelve prostate cancer (PCa) tissues obtained from patients. (A) ELF3 gene expression was compared between 
stem cell (SC) and committed basal (CB) cell populations derived from BPH and cancer tissues. RPLPO (ribosomal protein 
lateral stalk subunit P0) and PDYN (prodynorphin) were used as positive and negative control genes, respectively. BS = 
benign stem cells, MS = malignant stem cells, BC = benign committed cells, MC= malignant committed cells. (B) Tables 
indicate the P values of individual ELF3 probes in SC vs CB (top panel) and BPH vs cancer (bottom panel). Statistical 
significance was measured using the Student’s T-test (unpaired, two-tailed). Significant values are highlighted in blue. Data 
generated by mining array from (Birnie et al., 2008).  
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3.2.2 ELF3 is expressed in the CB population of primary prostate cultures at the protein level 
To add to the RNA expression profile of ELF3 found in the microarray data, ELF3 protein expression was 
examined in primary prostate samples by SDS-PAGE and western blotting. Initial blots showed that lysates 
containing whole epithelial populations did not express ELF3 (data not shown). BPH and PCa tissues were 
then cultured and enriched for TA and CB subpopulations. ELF3 was consistently expressed in the CB 
population of both BPH (n=4) and PCa (n=4) samples (Figure 3.3). There was very little expression or no 
detection of ELF3 in the TA population of any samples. Furthermore, there was no differential expression 
between BPH and PCa.  
When performing western blot analysis on lysates derived directly from BPH tissue homogenates, ELF3 
was not detected (Figure 3.4A). This suggests the threshold of ELF3 expression is below the limit of 
detection due to the heterogeneous nature of the cells. Since the tissue homogenates contain stroma as 
well as epithelial glands and CB cells only comprise a fraction within the basal layer, this may not be 
surprising.  
Stromal cells can also be separated and cultured from prostate tissue. Lysates from six primary prostate 
stromal cultures (1 BPH and 5 PCa) showed no ELF3 expression by western blot (Figure 3.4B). As luminal 
cells are terminally differentiated, they cannot be grown in culture. Likewise, the SC population is so rare 
that upon CD133 microbead selection from six 10cm dishes only a few thousand are generally recovered. 
For these reasons the luminal and SC populations were excluded from protein analysis.  
Together these results correspond with the initial microarray data with regards to high ELF3 expression in 
the CB population and no significant difference in expression between BPH and PCa. ELF3 is also not 
expressed in prostate stroma, which may be expected as ELF3 is an epithelial-specific transcription factor 
(Oettgen et al., 1997). Since ELF3 is expressed at low levels in the SC and TA populations, the more 
primitive cell types of the prostate epithelial differentiation hierarchy, this further reinforces the hypothesis 
that ELF3 may be involved in prostate epithelial cell differentiation, either as cause or consequence. 
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Figure 3.3. Protein expression of ELF3 in the fractionated cell subpopulations from primary prostate 
benign and tumour samples.  
Western blot analysis of ELF3 protein expression in the TA and CB cell subpopulations of primary BPH and PCa samples. 
20µg of protein was loaded per lane onto a 10% SDS gel, transferred onto a PVDF membrane and probed for the indicated 
proteins. Actin was used as a loading control. p = passage number. G = Gleason score of cancer sample. 
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Figure 3.4. Protein expression of ELF3 in prostate tissue homogenates and stromal cells. 
Western blot analysis of ELF3 expression in lysates derived from (A) BPH tissue homogenates (provided by Mandy Noble) 
and (B) enriched stromal cells cultured from tissue (provided by Katrina Reilly). 20µg of protein was loaded per lane onto a 
10% SDS gel, transferred onto a PVDF membrane and probed for the indicated proteins. GAPDH was used as a loading 
control. Tables show patient details for each corresponding lane. HFF = human foreskin fibroblast cell line. G = Gleason 
score. 
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3.3 Cellular and tissue localisation of ELF3 
3.3.1 ELF3 is expressed in both the cytoplasmic and nuclear compartments of prostate epithelial 
cells 
To accurately determine the function of ELF3 in prostate cells it was important to establish its cellular 
localisation. To achieve this, ICC was carried out on fixed cell lines. Despite testing three antibodies and 
different methods of optimisation, it was concluded that these antibodies were unsuitable for ICC. 
BPH-1 cells with ELF3 knockdown were used as a negative control and stained using two commercially 
available antibodies (Ab133621, Abcam and sc-376055, Santa Cruz). Figures 3.5A & B show that whilst 
there was significant ELF3 knockdown, as detected by western blot, there was no corresponding decrease 
in ICC staining, which is positive in all samples and presents with a pan-cellular pattern. A third commercial 
antibody was then tested (HPA003479, Sigma). BPH-1 cells were plated, transfected and stained on 
hydrochloric acid-treated coverslips to avoid the need to detach (Figure 3.5C). However, similar results were 
observed. As an additional control the three antibodies were also tested on an ELF3-negative cell line, U-
87 MG, with PNT2-C2 cells as a positive control. The Santa Cruz antibody showed low/negative staining in 
both cell lines, whilst the Abcam and Sigma antibodies were positive in both cell lines (Figure 3.6). U-87 MG 
negativity was verified by western blot (Figure 3.6B). As 4% paraformaldehyde was initially used for cell 
fixation, an alternative method of 50:50 methanol:acetone was also performed to observe whether this would 
reduce background staining and improve specificity (Figure 3.7). In this case PC3 cells were chosen as 
ELF3 high cells, PNT1a as ELF3 low cells and HEK-293 as ELF3 negative cells. However, whilst PC3 cells 
showed high expression compared to PNT1a, there was still some staining present in the HEK-293 cells 
suggesting there was non-specific binding occurring.  
To overcome this issue, an alternative technique to determine protein localisation was employed. A cell 
fractionation protocol was used on a panel of prostate cell lines, which involved a hypotonic buffer to extract 
cytoplasmic proteins and the remaining nuclear pellet was subsequently lysed with a whole cell extraction 
buffer (Figure 3.8). Western blot analysis revealed that ELF3 was predominantly expressed in the nucleus 
of all cell lines, with some present in the cytoplasm. Furthermore, the resulting expression pattern between 
cell lines was consistent with that from the whole cell lysates (Section 3.3.1).  
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Figure 3.5. Testing ELF3 antibodies for immunocytochemistry using BPH-1 cells with ELF3 
knockdown.  
BPH-1 cells were transfected with ELF3 (siELF3) and scrambled siRNA (siSCR), fixed in 4% paraformaldehyde and 
stained using commercial ELF3 antibodies. Cells stained with (A) Ab133621 and (B) sc-376055 were transferred to 
chamber slides 24h following transfection and fixed at 48h post-transfection. (C) Cells stained with HPA003479 were 
transfected and stained directly on hydrochloric acid-treated coverslips to avoid replating of cells. Cells were fixed 24h post-
transfection. Western blots show knockdown of ELF3 for each experiment. 20µg of protein was loaded per lane onto a 
10% SDS gel, transferred onto a PVDF membrane and probed for the indicated proteins. GAPDH and Actin were used as 
loading controls.  E = ELF3 siRNA, S = Scrambled siRNA. Red or green = ELF3, Blue = DAPI. 60x oil lens. Scale bar = 
10μm. 
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Figure 3.6. Testing ELF3 antibodies for immunocytochemistry using ELF3-negative cell line U-87 
MG. 
(A) PNT2-C2 (ELF3-positive) and U-87 MG (ELF3-negative) cells were fixed on chamber slides with 4% PFA and 
subsequently stained using three commercial ELF3 antibodies; Ab133621 (Abcam), sc-376055 (Santa Cruz) and 
HPA003479 (Sigma). Ki67 was used as a positive control for antibody staining. Scale bar = 10μm (B) Western blot analysis 
indicating protein expression of ELF3 in PNT2-C2 and U-87 MG cells. 20µg of protein was loaded per lane onto a 10% 
SDS gel, transferred onto a PVDF membrane and probed for the indicated proteins. GAPDH was used as a loading control. 
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Figure 3.7. Testing ELF3 antibodies for immunocytochemistry using alternative fixation method. 
An alternative method of cell fixation was tested using three cell lines, which were chosen due to their varying degrees of 
ELF3 expression. (A) PC3 (ELF3 high), PNT1a (ELF3 low) and HEK-293 (ELF3 negative) cells were fixed using 50:50 
methanol:acetone and stained using ELF3 antibody Ab133621. Scale bar = 10μm (B) Western blot analysis of ELF3 
expression in untransfected HEK-293 cells and following ELF3 overexpression via plasmid transfection (pDest298-ELF3). 
20µg of protein was loaded per lane onto a 10% SDS gel, transferred onto a PVDF membrane and probed for the indicated 
proteins. GAPDH was used as a loading control. 
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Figure 3.8. ELF3 cellular localisation in prostate cell lines. 
A cell fractionation protocol was employed to determine the cellular localisation of ELF3 in a panel of prostate cell lines. 
Cells were harvested and lysed in a hypotonic buffer to extract cytoplasmic proteins. The remaining pellet was subsequently 
lysed with a whole cell extraction buffer to extract nuclear proteins. Western blot analysis was then carried out. 30µg of 
protein was loaded per lane onto a 10% SDS gel, transferred onto a PVDF membrane and probed for the indicated 
proteins. C = cytoplasmic fraction, N = nuclear fraction, GAPDH = cytoplasmic control, TATA-binding protein (TBP) = 
nuclear control.  
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3.3.2 ELF3 expression is restricted to the basal layer of the prostate epithelium in tissue 
Tissue staining was carried out to assess ELF3 expression in situ in benign and cancer prostate tissue. 
Paraffin-embedded BPH tissue sections were stained with ELF3 by immunofluorescence. There was a very 
distinct pattern of expression where ELF3 staining was present in the basal epithelial cell population, but 
absent from the luminal layer and surrounding stroma (Figure 3.9). p63 was used as a nuclear basal cell 
marker and high molecular weight cytokeratin (HMW-CK, recognises cytokeratins 1, 5, 10 and 14) as a 
cytoplasmic basal cell marker. Secondary antibody only controls were satisfactorily void of staining (data 
not shown). The cellular localisation of ELF3 was predominantly cytoplasmic, as shown by the colocalization 
with HMW-CK. However, low nuclear staining was also present in some cells. The fractionated western blots 
showed that ELF3 is present in the cytoplasm of cell lines, however there was higher expression in the 
nucleus. To address the possibility that expression in the nucleus was below the limit of detection in the 
tissue sections, an IHC amplification kit (ImmPRESS Excel Amplified HRP Polymer Staining Kit, Vector 
Laboratories), which utilises horseradish peroxidase micropolymers to amplify the signal, was employed to 
establish if any ELF3 signal could be visualised in the nuclear compartment of basal cells. First, BPH 
sections generated by our lab were stained using IHC with the amplification kit. Results confirmed that ELF3 
was specifically expressed in the basal layer of prostate epithelial glands and absent from luminal cells and 
stroma (Figure 3.10). With regards to cellular localisation, positive ELF3 staining was observed in both the 
cytoplasm and nucleus of basal cells. Since the staining pattern was specific only to basal cells and agreed 
with findings from western blot analyses, we were satisfied that this antibody was suitable for IHC. 
Tissue microarrays (TMAs) of both BPH (102 sections from 34 patients) and PCa (40 sections from 13 
patients) tissue were obtained from the Orchid tissue bank (in collaboration with Professor Dan Berney, 
Barts Hospital, London) to evaluate the expression of ELF3 across multiple patients. ELF3 was present in 
all BPH tissue sections from 34 patients which contained epithelial glands. Some patient sections showed 
exclusively cytoplasmic staining (Figure 3.11A) whilst others also exhibited nuclear ELF3 (Figure 3.11B). 
Results were less clear in PCa tissue. Loss of the basal cell population and expression of AMACR are 
indicators of cancer used in prostate histology and contributes to a cancer diagnosis (Humphrey, 2007). 
This marker was therefore used to distinguish areas of cancer in the PCa tissue sections. Sections of 
Gleason 6 grade PCa which contained no obvious glandular structures did not express ELF3. However, 
some sections contained glandular structures both with and without AMACR staining. For example, patient 
WXP11C exhibited histology with a Gleason score of 6 (Figure 3.12). In these sections ELF3 tended to be 
detected in the basal-like cells of AMACR negative glands. In less differentiated sections, with Gleason 
score ≥7, which had no obvious glandular structures, but were entirely AMACR positive, some did not stain 
for ELF3 (Figure 3.13A), whilst others showed positive ELF3 staining (Figure 3.13B). It was difficult to 
distinguish the cellular localisation of ELF3 expression in these more advanced cancers.  
These results suggest that ELF3 expression may initially be lost in lower grade (Gleason 6) tumours. 
Additionally, there may be a subset of higher grade prostate tumours (Gleason ≥7) which then re-express 
ELF3.  
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Figure 3.9. ELF3 expression in BPH tissue by immunohistochemistry (immunofluorescence). 
Formalin-fixed, paraffin-embedded BPH tissue was deparaffinised and rehydrated before undergoing heat-induced antigen 
retrieval in sodium citrate buffer. IHC was carried out and sections were incubated with fluorescent Alexa Fluor secondary 
antibodies. (A) ELF3 alone (Ab97310), (B) ELF3 co-stained with high molecular weight cytokeratin (cytoplasmic basal cell 
marker) and (C) ELF3 co-stained with p63 (nuclear basal cell marker). Red = ELF3, Green = HMW-CK / p63, Blue = DAPI. 
60x oil lens. Scale bar = 10μm. 
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Figure 3.10. ELF3 expression in BPH tissue using the ImmPRESS Excel Amplified HRP Polymer 
Staining Kit. 
Formalin-fixed, paraffin-embedded BPH tissue was deparaffinised and rehydrated before undergoing heat-induced antigen 
retrieval in sodium citrate buffer. IHC was carried out using the ImmPRESS Excel Amplified HRP Polymer Staining Kit 
(Vector Labs) and sections were incubated with DAB until they turned brown and then counterstained with haematoxylin. 
(A) ELF3 (Ab97310) and (B) Nkx3.1 (nuclear luminal cell control). Scale bar = 50μm. 
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Figure 3.11. ELF3 expression in BPH tissue microarrays (TMAs).  
102 tissue sections from 34 patients were stained for ELF3 expression using Ab97310 using the Vector ImPRESS Excel 
Kit. Representative images of sections from two patients are shown. (A) Patient 9C exhibits more cytoplasmic staining 
whilst (B) Patient 5A exhibits more nuclear staining. Sections were stained for Nkx3.1 as a nuclear luminal cell control. Sec 
only = tissues stained with secondary antibody only. 20x scale bar = 100μm, 40x scale bar = 50μm. (TMAs provided 
through collaboration with Professor Dan Berney, Barts and London School of Medicine and Dentistry). 
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Figure 3.12. ELF3 expression in Cancer tissue microarrays (TMAs) – Low Gleason grade prostate 
cancer. 
40 tissue sections from 13 patients were stained for ELF3 expression using Ab97310 using the Vector ImPRESS Excel 
Kit. Representative images from one patient, WXP11C (classed as Gleason grade 3+3), where AMACR positive and 
negative regions are shown. Sections were stained for AMACR as a cancer marker. Sec only = tissues stained with 
secondary antibody only. 20x scale bar = 100μm, 40x scale bar = 50μm. (TMAs provided through collaboration with 
Professor Dan Berney, Barts and London School of Medicine and Dentistry). 
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Figure 3.13. ELF3 expression in Cancer tissue microarrays (TMAs) – High Gleason grade prostate 
cancer. 
40 tissue sections from 13 patients were stained for ELF3 expression using Ab97310 using the Vector ImPRESS Excel 
Kit. Sections were stained for AMACR as a cancer marker. (A) Patient WXP10C (Gleason grade 4+3). (B) WXP7B 
(Gleason grade 4+4). Sec only = tissues stained with secondary antibody only. 20x scale bar = 100μm, 40x scale bar = 
50μm. (TMAs provided through collaboration with Professor Dan Berney, Barts and London School of Medicine and 
Dentistry).  
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3.4 The effects of ELF3 knockdown on prostate epithelial cell lines  
3.4.1 siRNA transfection maintains long-term ELF3 knockdown in prostate epithelial cell lines  
Following confirmation that ELF3 is expressed in prostate tissue, initial mechanistic studies were carried out 
using BPH-1 and PC3 cell lines. Since ELF3 is expressed in primary prostate basal epithelial cells, BPH-1 
and PC3 cells were considered the most appropriate cell lines to initially characterise the effects of ELF3 
knockdown in prostate benign and cancer cells because they both express significant levels of ELF3 
(Section 3.1.1, Figure 3.1) and do not possess the characteristics of a luminal cell phenotype (Section 3.1.1, 
Table 3.1).  
ELF3 knockdown was achieved using a siRNA oligonucleotide targeting exon 3 of ELF3 (siELF3), which 
targets all known protein coding transcripts of the ELF3 gene. A non-specific scrambled siRNA (siSCR) was 
used as a control to ensure any changes seen with ELF3 knockdown were specific. A mock transfection 
control which contained transfection reagent only was also included. SiRNAs are an efficient method of 
modulating expression as they are generally better tolerated by a range of cells, including primary cells, 
compared to plasmid transfection.  
ELF3 siRNA transfection using Lipofectamine RNAiMAX (Invitrogen) sustained knockdown for at least 6 
days post-transfection (Figure 3.14). This ensured that ELF3 expression remained at a very low level for the 
duration of all functional experiments that were carried out. The percentage of knockdown achieved was 79-
96% in BPH-1 cells and 88-100% in PC3 cells. 
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Figure 3.14. Time course of ELF3 knockdown in benign (BPH-1) and cancer (PC3) prostate epithelial 
cell lines. 
ELF3 protein expression was analysed by western blot in (A) BPH-1 and (B) PC3 cells following ELF3 knockdown over a 
6 day time course. 20µg of protein was loaded per lane onto a 10% SDS gel, transferred onto a PVDF membrane and 
probed for the indicated proteins. GAPDH was used as a loading control. Densitometry was carried out using Image J 
software. Numbers below blots indicate levels of knockdown compared to samples treated with siSCR on the same day. 
siSCR samples were normalised to 1.0. M = Mock, S = siSCR, E = siELF3. 
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3.4.2 ELF3 knockdown significantly reduces the cell viability of prostate epithelial cell lines by a 
process other than apoptosis 
An alamarBlue assay was carried out to assess the effects of ELF3 knockdown on prostate cell viability. 
Cells were analysed for six consecutive days following transfection. After obtaining the reading from day 3, 
cells were trypsinised and replated at the original starting density. This was due to the confluency of cells 
by this point in the time course and also to assess the cells ability to recover following replating. Figure 3.15 
shows that in both BPH-1 and PC3 cells, the viability of cells with ELF3 knockdown begins to decrease at 
day 3 and is significantly decreased following replating at days 4, 5 and 6. In both BPH-1 and PC3 cells the 
viability decreased by around 40% by day 6. Therefore, there is no distinct effect on benign vs. cancer cells 
in this case.  
Since the significant decrease in viability did not occur until after replating the transfected cells, it was 
hypothesised that the cells with ELF3 knockdown had disrupted adhesion capabilities. This was confirmed 
by an adhesion assay in which BPH-1 cells were transfected with mock, siSCR or siELF3 and once confluent 
were replated at three different densities (high, medium and low) and allowed to adhere for 4hrs. Results 
showed that ELF3 knockdown decreased BPH-1 cell adhesion regardless of starting density (Figure 3.16A). 
However, since there is a continued decrease in cell viability following day 3, as opposed to an increase 
which would be evident with normally proliferating cells, this suggests that there is another mechanism 
contributing to the progressive decrease in viability over time.  
To assess whether cell death was occurring by apoptosis, western blot analysis was carried out on BPH-1 
and PC3 cells using cleaved caspase 3 as a marker of apoptosis. BPH-1 cells treated with 1μM 
staurosporine for 24 hours were used as a positive control. The ELF3 expression of these samples was 
analysed at a previous time and therefore does not include the staurosporine control. Figures 3.16B & C 
show that cleaved caspase 3 was only present in staurosporine-treated cells and therefore ELF3 knockdown 
cells were not dying via apoptosis. This correlates with the observation that little cell death was observed 
down the microscope and therefore suggests the decrease in viable cell number may be due to reduced 
proliferation. 
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Figure 3.15. ELF3 knockdown decreases the viability of prostate epithelial cell lines after replating. 
AlamarBlue cell viability assays were performed 24 hours after transfection and every day for six consecutive days. Due to 
confluency, cells were re-plated after the day 3 reading at the original density of 40,000 cells for BPH-1 and 60,000 cells for 
PC3 in a 24 well plate. (A) BPH-1 cells. (n=3) (B) PC3 cells (n=3). Mock samples were normalised to 100% viability. 
Statistical significance was determined using a 2-way ANOVA with Tukey’s multiple comparison test. 
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Figure 3.16. ELF3 knockdown reduces cell adhesion but does not cause cell death via apoptosis. 
(A) An adhesion assay was performed on BPH-1 cells 48h following knockdown. Cells were trypsinised and re-plated at 
three different densities for 4 hours (High = 300,000 cells, Med = 100,000 cells, Low = 40,000 cells). Floating cells were 
washed off and adherent cells were counted using an automated cell counter. To assess cell death by apoptosis, lysates 
of (B) BPH-1 and (C) PC3 cells with ELF3 knockdown were probed for cleaved caspase 3. BPH-1 cells treated with 1μM 
Staurosporine for 24h were used as a positive control for apoptosis (+). 20µg of protein was loaded per lane onto a 10% 
SDS gel, transferred onto a PVDF membrane and probed for the indicated proteins. GAPDH was used as a loading control.  
Statistical significance was determined using a Student’s T-test (unpaired, two-tailed).  
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3.4.3 ELF3 knockdown significantly decreases cell motility in prostate epithelial cell lines 
The ability to migrate is a property of cancer cells and also a characteristic of SCs (Collins et al., 2005, 
Hanahan and Weinberg, 2000). Overexpression of ELF3 has previously been shown to increase the motility 
of PCa cell lines LNCaP and 22RV1 (Longoni et al., 2013). Cell motility was investigated using a wound 
healing assay whereby a wound is introduced to a confluent layer of cells. Images were taken at the starting 
point and after a time period to allow the cells to grow and migrate to close the wound. Width of the wound 
was measured at 10 points and compared to the width at the start point to determine % closure.  
ELF3 knockdown significantly decreased the cell motility of both BPH-1 and PC3 cells (Figures 3.17 & 3.18). 
Whilst BPH-1 % wound closure was decreased by around 60%, PC3 cells had a more modest decrease of 
around 20%. This suggests PC3 cells have alternative mechanisms regulating migration which may be 
expected since cancer cells have increased migration capabilities.  
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Figure 3.17. ELF3 knockdown decreases the migration of BPH-1 cells. 
(A) Migration of BPH-1 cells following knockdown was calculated by % wound closure (n=3). A wound was introduced to 
a confluent monolayer of cells 24 hours post-transfection. The end point was determined by monitoring the wounds until 
the first triplicate set of one condition (mock, siSCR or siELF3) had closed. Image J software was used to determine the 
average width of the wounds between 10 points. Percent wound closure was calculated at the end point relative to zero 
hour images.  (B) Representative images of wound closure at 25.5h post-injury. Scale bar = 400μm. Statistical significance 
was determined using a Student’s T-test (unpaired, two-tailed). 
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Figure 3.18. ELF3 knockdown reduces the migration of PC3 cells. 
(A) Migration of PC3 cells following knockdown was calculated by % wound closure (n=3). A wound was introduced to a 
confluent monolayer of cells 24 hours post-transfection. The end point was determined by monitoring the wounds until the 
first triplicate set of one condition (mock, siSCR or siELF3) had closed. Image J software was used to determine the average 
width of the wounds between 10 points. Percent wound closure was calculated at the end point relative to zero hour images. 
(B) Representative images of wound closure at 56h post-injury. Scale bar = 400μm. Statistical significance was determined 
using a Student’s T-test (unpaired, two-tailed). 
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3.4.4 ELF3 knockdown significantly decreases colony forming ability in prostate epithelial cell lines  
Colony forming is the ability to grow from a single cell. This is challenging for a cell which usually requires a 
network of surrounding supportive cells for growth. Thus, colony forming ability is defined as a biological 
characteristic of SCs (Collins et al., 2005). A colony forming assay was carried out by plating 200 BPH-1 
and PC3 cells into a 12 well plate in triplicate 24 hours post-transfection. Biological triplicates were also 
performed. Wells were stained with crystal violet and colonies over 32 cells were counted (5 population 
doublings defines an established colony (Puck and Marcus, 1956, Francipane et al., 2008) and the colony 
forming efficiency relative to mock transfected cells was calculated. 
ELF3 knockdown significantly decreased the colony forming ability of prostate epithelial cell lines (Figure 
3.19). BPH-1 cells with ELF3 knockdown had an 80% decrease in colonies formed, whilst PC3 cells had 
around a 65% decrease relative to mock transfected cells.  
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Figure 3.19. ELF3 knockdown decreases the colony forming ability of benign and cancer prostate 
epithelial cell lines. 
Colony forming assays were performed on (A) BPH-1 cells (n=3) and (B) PC3 cells (n=3) 24 hours post-transfection. Top 
panel: Number of colonies >32 cells formed after seeding 200 cells in a 12 well plate following knockdown relative to mock. 
Bottom panel: representative images of colonies following crystal violet staining. Control samples were normalised to 100%. 
Statistical significance was determined using a Student’s T-test (unpaired, two-tailed). 
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3.4.5 ELF3 knockdown alters the morphology and colony formation of prostate epithelial cells 
Brightfield images of BPH-1 and PC3 cells with ELF3 knockdown were taken over a 6 day time course. 
Whilst there appeared to be no difference between conditions at the 24h time point, after replating the 
morphology and colony formation of each cell line was altered. BPH-1 cells tend to initially spread out at 24 
hours after replating (24hRP) then form tight rounded colonies at 48hRP. However, with ELF3 knockdown, 
the cells were tightly packed together from 24hRP and the colonies were far more condensed at 48hRP and 
72hRP compared to the mock and siSCR controls (Figure 3.20). Furthermore, it appeared that there were 
fewer cells present at 72hRP, which could be a combination of fewer cells adhering (as discussed in Section 
3.4.2) and the cells being more tightly packed together. 
Similarly there was no difference in PC3 cells at 24h post-transfection (Figure 3.21), but in contrast, unlike 
BPH-1 cells, PC3 cells tend to grow in a scattered manner and proceed to fill the gaps rather than grow in 
distinct colonies. There was no clear difference in cell morphology in the ELF3 knockdown PC3 cells after 
replating. However, there was again a noticeable decrease in cell number.  
To further investigate the morphology of cells with ELF3 knockdown, BPH-1 and PC3 cells were stained 
with tubulin and phalloidin (Figures 3.22 and 3.23 respectively). In the mock and siSCR conditions of BPH-
1 there were clear spaces between cells (white arrows). However, siELF3 cells were much closer together 
indicating an increase in cell-cell interactions. Furthermore, the pattern of tubulin and phalloidin expression 
was much more concentrated around the edges of the colony as a whole in siELF3 cells (red arrow), as 
opposed to individual cells seen in mock and siSCR cells. These changes were not as pronounced in PC3 
cells, possibly due to differences in colony formation between PC3 and BPH-1 cells.  
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Figure 3.20. ELF3 knockdown alters the morphology of BPH-1 cells. 
Brightfield images of BPH-1 cells following knockdown. The top row indicates cells 24h post-transfection. Cells were re-
plated day 3 post-transfection and imaged for the following 72h. RP = re-plated. Scale bar = 200μM. 
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Figure 3.21. ELF3 knockdown alters the morphology of PC3 cells. 
Brightfield images of PC3 cells following knockdown. The top row indicates cells 24h post-transfection. Cells were re-plated 
day 3 post-transfection and imaged for the following 72h. RP = re-plated. Scale bar = 200μM. 
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Figure 3.22. ELF3 knockdown alters colony formation in BPH-1 cells. 
BPH-1 cells were transfected with ELF3 (siELF3) and scrambled siRNA (siSCR), fixed in 4% paraformaldehyde at day 3 
post-transfection and stained with tubulin and phalloidin. The white arrows highlight spaces between cells in mock and 
siSCR cells. The red arrow highlights the location of tubulin at the colony periphery in siELF3 cells. Green = tubulin, red = 
phalloidin, blue = DAPI. Scale bar = 20μm. 
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Figure 3.23. ELF3 knockdown does not alter colony formation in PC3 cells. 
PC3 cells were transfected with ELF3 (siELF3) and scrambled siRNA (siSCR), fixed in 4% paraformaldehyde at day 3 
post-transfection and stained with tubulin and phalloidin. Green = tubulin, red = phalloidin, blue = DAPI. Scale bar = 20μm. 
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3.4.6 ELF3 knockdown alters the expression of differentiation markers 
The biological and morphological responses to ELF3 knockdown showed a significant change in phenotype. 
To determine the potential genes controlled by ELF3, the expression of differentiation and EMT markers 
were first investigated. CK5 is a basal cell marker whilst CK18 is a marker of luminal cells. BPH-1 cells are 
a good model as they grow as heterogeneous populations, like primary cultures, and so cells express 
varying levels of CK5 and CK18. E-cadherin is an epithelial cell marker whilst active β-catenin is a marker 
for EMT. 
Western blot analysis was carried out on BPH-1 cells over a time course of 6 days after ELF3 knockdown 
(Figure 3.24A). At day 3 there was a modest increase in CK5 and decrease in CK18 expression, suggesting 
a more basal phenotype. There was an early and sustained increase of active β-catenin expression in ELF3 
knockdown cells until day 3, however by day 5 this increase in expression had diminished, suggesting it was 
an early response to ELF3 knockdown. By day 5 there was also a sustained progressive increase in CK5 
and E-cadherin expression and a decrease in CK18. 
ICC was also carried out at the day 3 time point and showed an increase in CK5 and decrease in CK18, 
confirming the change to a more basal phenotype (Figure 3.24B). The colonies also appeared to be more 
condensed and there was less cytoplasmic space evident, compared to mock and siSCR cells, which 
correlates with the phalloidin and tubulin staining (Section 3.4.5). An increase in active β-catenin was also 
seen, however it was concentrated at the cell membrane. This suggests that rather than activating the Wnt 
signalling pathway and contributing to EMT, the active β-catenin is carrying out its alternative role as an 
adaptor to E-cadherin at the cell membrane. This corresponds to the increase in E-cadherin found by 
western blot.  
In PC3 cells, western blot analysis detected a small decrease in CK18 expression at day 2 after ELF3 
knockdown but this was not sustained until day 4 (Figure 3.25A). CK5 was not detected in any of the 
conditions or time points, even following repeats. This suggests the level of expression is below the limit of 
detection and these cells are not as basal as BPH-1 cells. There was also an increase in active β-catenin 
seen at later time points than the BPH-1 cells (day 4). There was little E-cadherin detected until days 4 and 
5 in the ELF3 knockdown cells, which correlates with the results seen in BPH-1. The reduced response 
regarding differentiation and EMT markers in PC3 cells with ELF3 knockdown may reflect the reduced 
responses seen in some functional assays compared to BPH-1 cells. Furthermore, since only a few markers 
have been investigated, there may be more significant changes in other markers not studied.  
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Figure 3.24. ELF3 knockdown alters the expression of differentiation markers in BPH-1 cells. 
(A) Expression of differentiation markers was analysed by western blot in BPH-1 cells following ELF3 knockdown over a 6 
day time course. Blots indicate protein expression at day 3 and day 5 post-transfection. 20µg of protein was loaded per 
lane onto a 10% SDS gel, transferred onto a PVDF membrane and probed for the indicated proteins. GAPDH was used 
as a loading control. M = Mock transfection, S = siSCR, E = siELF3. (B) BPH-1 cells were transfected with ELF3 (siELF3) 
and scrambled siRNA (siSCR), fixed in 4% paraformaldehyde at day 3 post-transfection and stained with the indicated 
antibodies. Scale bar = 20μm.  
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Figure 3.25. ELF3 knockdown alters the expression of differentiation markers in PC3 cells.  
(A) Expression of differentiation markers was analysed by western blot in BPH-1 cells following ELF3 knockdown over a 6 
day time course. Blots indicate protein expression at day 2 and day 4 post-transfection. 20µg of protein was loaded per 
lane onto a 10% SDS gel, transferred onto a PVDF membrane and probed for the indicated proteins. GAPDH was used 
as a loading control. M = Mock transfection, S = siSCR, E = siELF3. (B) BPH-1 cells were transfected with ELF3 (siELF3) 
and scrambled siRNA (siSCR), fixed in 4% paraformaldehyde at day 3 post-transfection and stained with the indicated 
antibodies. Scale bar = 20μm.  
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3.5 Generating lentiviral vectors for ELF3 overexpression studies 
3.5.1 Invitrogen Gateway Cloning Technology strategy  
Lentivirus transduction is an efficient method of manipulating gene expression in primary cells as they are 
more likely to die from treatment with traditional transfection reagents compared to cell lines. Lentiviruses 
were favoured over retroviruses as they are able to transduce quiescent cells such as SCs and more 
differentiated less proliferative cells, which are present in the primary cultures, whereas retroviruses are 
unable to do so. Furthermore lentiviruses also generally produce a better viral titre than retroviruses (Table 
3.2) (Lewis and Emerman, 1994, Vannucci et al., 2013, Dufait et al., 2012, Howe et al., 2008).    
The Invitrogen Gateway Cloning Technology (ThermoFisher Scientific) was used to generate lentiviral 
vectors to overexpress ELF3. The system is based on bacteriophage lambda att site recombination, where 
the phage genome can be integrated into the bacterial genome using specific sites and recombination 
enzymes (Katzen, 2007). The Gateway system is an efficient method of cloning, as one recombination 
reaction allows the gene of interest to be inserted into a “DONR” vector, resulting in the generation of an 
entry clone. The entry clone can then be used to generate a series of expression clones by recombination 
with a destination vector which has a desired expression characteristic, e.g. fluorescence, tag, antibiotic 
resistance, as well as the necessary sequences for lentivirus production. The entry and expression clones 
contain antibiotic resistance genes for selection.  
For ELF3 to be integrated into the entry clone it was flanked with specific attB sequences by two rounds of 
PCR and gel extraction (Figure 3.26). The first set of primers contained the ends of the ELF3 sequence and 
the inner attB sequence, whilst the second set contained the outer attB sequence. A recombination reaction 
was carried out using BP Clonase™ in which the attB flanked ELF3 sequence was integrated into the DONR 
vector via attP sequences, resulting in the formation of attL sequences. Single clones were then selected 
on kanamycin agar plates following transformation in DH5α E.coli competent cells. Several entry clones 
were then validated by PCR, for the presence of ELF3, and then sequenced to ensure no mutations had 
been introduced during the recombination reaction. A second recombination reaction using LR Clonase™ 
was then carried out to incorporate ELF3 into two different destination vectors; one with GFP co-expressed 
with ELF3 under separate promoters (pDest298) and one with a Venus-tag at the N-terminal of ELF3 
(pDest159). The attL sequences of the entry clone permit recombination with the specific destination vector 
which contain attR sequences via LR Clonase™. Single expression clones were selected following 
transformation using carbenicillin plates.  
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 Retrovirus Lentivirus 
Gene Expression Stable & Transient Stable & Transient  
Transduce Dividing Cells   
Transduce Non-Dividing Cells X  
Integration into Target Cell Genome   
Possible Insertional Mutagenesis   
Relative Viral Titre   
 
Table 3.2. Characteristics of retroviruses and lentiviruses as vectors for gene expression. 
  
116 
 
Figure 3.26. Lentivirus cloning strategy for ELF3 overexpression. 
A summary of the steps involved in the production of ELF3-expressing lentiviral vectors using the Invitrogen Gateway 
Cloning Technology (ThermoFisher Scientific). ELF3 was first flanked with attB sequences by two rounds of PCR and gel 
extraction. This product was then inserted into a DONR vector by a BP recombination reaction. Following PCR and 
sequencing quality control checks, a second LR recombination reaction was carried out to incorporate ELF3 into two 
different destination vectors; one with GFP co-expressed with ELF3 under separate promoters (pDest298) and one with a 
Venus-tag at the N-terminal of ELF3 (pDest159). The destination vectors then underwent a series of quality control 
measures; PCR, restriction digest and HEK-293T transfection for the presence of the desired expression characteristic i.e. 
GFP/YFP expression. QC = quality control. RRE = Rev response element. LTR = long terminal repeats. WPRE = 
Woodchuck post-translational regulatory element.  
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3.5.2 Validation of ELF3 expression vectors 
The described strategy (Figure 3.26) was performed using the wildtype (WT) ELF3 gene to create 
expression vectors pDest298-ELF3-WT and pDest159-ELF3-WT (Figure 3.27). The GFP co-expression 
vector (pDest298) was used for functional experiments, whilst the Venus-tag vector (pDest159) was used 
to determine the cellular localisation of ELF3. This was to eliminate any effects the tag may have on ELF3 
functional assays.  
In the literature, the cellular localisation of ELF3 has been described as both nuclear and cytoplasmic. 
Similarly, as demonstrated in Section 3.3, ELF3 is present in both the nucleus and cytoplasm of prostate 
epithelial cells. HEK-293T transfection of pDest159-ELF3-WT resulted in predominantly nuclear YFP, and 
therefore ELF3, expression (Figure 3.28B). To investigate any distinct functions ELF3 may have in the 
cytoplasm, an ELF3 mutant was acquired which contains a deletion of the AT-hook domain of ELF3 
(obtained from Prof Arthur Gutierrez-Hartmann, University of Colorado) (Figure 3.29A). The AT-hook domain 
contains a nuclear localisation signal (NLS) and its deletion resulted in exclusively cytoplasmic expression 
(Figure 3.29C). This mutant therefore possesses no transcriptional activity. 
The four resulting constructs (pDest298-ELF3-WT, pDest159-ELF3-WT, pDest298-ELF3-ΔAT and 
pDest159-ELF3-ΔAT) underwent several quality control processes (Figures 3.28 & 3.29). RT-PCR was 
carried out to determine which clones expressed ELF3 and a restriction digest was performed to ensure the 
ELF3-positive clones were complete expression vectors (as opposed to the entry vector). Finally, HEK-293T 
cells were transfected with each clone to examine the presence of either GFP or YFP and, in pDest159 
vectors, the localisation of the YFP.  
For functional studies, a control lentivirus construct was included in analysis. The control construct 
possessed the same lentiviral backbone (pDest298), however with the integration of a non-mammalian gene 
called β-glucoronidase (GUS). This therefore mimics the effects of lentiviral transduction, without the effects 
of specific gene expression.   
118 
 
Figure 3.27. Vector maps of lentiviral ELF3 overexpression constructs.  
Lentiviral vectors constructed for ELF3 overexpression using the Invitrogen Gateway Cloning Technology (ThermoFisher 
Scientific). (A) pDest298-ELF3-WT confers GFP co-expression with ELF3 under separate promoters. (B) pDest159-ELF3-
WT confers a YFP-tag at the N-terminal of ELF3. Both vectors contain ampicillin resistance sequences for selection. RRE 
= Rev response element. LTR = Long terminal repeats. WPRE = Woodchuck post-transcription regulatory element. 
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Figure 3.28. Validation of ELF3-WT lentiviral vectors. 
(A) Schematic of the domain structure of wildtype (WT) ELF3 (371 amino acids long). (B) Lentiviral ELF3-WT 
overexpression vectors were validated by PCR for ELF3 expression (top panels), restriction digest to ensure the vectors 
were expression clones (middle panels) and HEK-293T transfection for GFP/YFP expression (bottom panels). pDest298-
ELF3-WT (GFP co-expression), restriction enzyme = EcoRI. pDest159-ELF3-WT (Venus-tag), restriction enzyme = PvuII. 
N = no template control. p159-E = p159 empty vector.  
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Figure 3.29. Validation of ELF3-ΔAT lentiviral vectors. 
(A) Schematic of ELF3 domain structure indicating regions containing nuclear localisation signal (NLS) sequences. Red 
line indicates deletion in the ΔAT mutant. (B) Lentiviral ELF3-ΔAT overexpression vectors were validated by PCR for ELF3 
expression (top panels), restriction digest to ensure the vectors were expression clones (middle panels) and HEK-293T 
transfection for GFP/YFP expression (bottom panels). pDest298-ELF3-ΔAT (GFP co-expression), restriction enzyme = 
BamHI. pDest159-ELF3-ΔAT (Venus-tag), restriction enzyme = BamHI. N = no template control. p298-E = p298 empty 
vector. p159-E = p159 empty vector. 
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3.5.3 Determining lentiviral titre of ELF3 overexpression vectors 
Lentiviral titre was determined by GFP expression using flow cytometry analysis. Whilst several studies use 
easy to transduce cell lines such as HEK-293 to determine viral titre, it was important to use a model that 
related to the primary prostate epithelial cells, which were ultimately to be used in experiments and are more 
difficult to transduce. Since there is variability in transduction efficiency between different patient samples, 
it was also important to titre in a model which would produce a consistent and comparable titre between 
different batches of virus. For these reasons, P4E6 cells were chosen as an appropriate model to titre in as 
they were produced in this lab from a patient sample and are therefore closely related to the basal cultures 
that are routinely grown and have a similar transduction efficiency. 
Viruses were concentrated using PEG-it solution and resuspended in PBS to avoid adding FCS containing 
media to primary cells as they are not ordinarily grown in this and would be induced to differentiate. A known 
number of P4E6 cells were transduced in suspension with 10-fold serial dilutions of concentrated virus 
between a range of 1:10 and 1:100,000. Cells were analysed at 48 hours post-transduction by flow cytometry 
on a CyAn ADP (Beckman Coulter). A summary of the gating strategy is shown in Figure 3.30. Viral titre 
was determined using dilutions which produced between 1 and 20% of GFP-positive P4E6 cells. Above 20% 
there may be an underestimation of the number of infectious particles, as cells may have been transduced 
more than once. The flow cytometer may also not be sensitive enough to detect the number of GFP-positive 
cells below 1%. pDest298 titres were in a range of 1.65x106-2.59x106 whilst pDest159 titres were in a range 
of 1x106-1.2x107 infectious particles/ml. 
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Figure 3.30. Gating strategy for lentiviral titration. 
P4E6 cells were transduced with serial dilutions of generated lentivirus. Lentiviral titre was determined by GFP-expression 
at 48 hours post-transduction using flow cytometry.  (A) Untransduced cells, (B) cells transduced with pDest298-ELF3-WT 
at a dilution of 1:100. Top panels show whole population (left) and singlets (right). Bottom panels indicate the GFP-positive 
population.  
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3.6 The effects of ELF3 overexpression on primary prostate epithelial cells 
3.6.1 Localisation of ELF3 in lentiviral transduced primary prostate epithelial cells  
Since reasonable ELF3 expression was present in all prostate cell lines tested (Section 3.1.1), investigation 
of the consequences of ELF3 overexpression was performed in primary prostate cells. As ELF3 was only 
expressed in the CB subpopulation of primary epithelial cultures (Section 3.2), the effects of ELF3 
overexpression on the population as a whole was examined.  
Primary prostate epithelial cells were transduced with pDest159-ELF3-WT and –ΔAT (in which the AT-hook 
domain containing a NLS has been deleted) vectors which possess a Venus-tag at the N-terminal of ELF3 
to validate the cellular localisation of ELF3. Cells were transduced with each virus at a ratio of two infectious 
particles for every one cell. In cells transduced with ELF3-WT virus, ELF3 was present in the nucleus of 
cells, demonstrated by the co-localisation with DAPI (Figure 3.31). However, in cells transduced with ELF3-
ΔAT virus, ELF3 was present in cytoplasm. This was the expected result and confirmed the ELF3-ΔAT virus 
could be used as a non-transcriptionally active control to identify any distinct cytoplasmic functions of ELF3 
in primary prostate cells.   
  
124 
 
 
 
 
Figure 3.31. ELF3 localisation in primary prostate epithelial cells. 
Lentiviral vectors conferring a YFP-tag at the N-terminal of ELF3 were used to determine the localisation of WT and mutant 
ELF3. Primary prostate cells were transduced with pDest159-GUS (control), pDest159-ELF3-WT (ELF3-WT) and 
pDest159-ELF3-ΔAT (ELF3-ΔAT) constructs at a ratio of two infectious particles for every individual cell. Representative 
confocal imaging of primary prostate cells. Blue = DAPI. Scale bar = 20μm.  
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3.6.2 ELF3 overexpression differentially alters the viability of primary normal and cancer prostate 
epithelial cells 
ELF3 overexpression was carried out on two cancer samples and 3 normal and cancer matched pairs from 
the same patients. Cell viability was analysed by alamarBlue over a six day time course. Cells were replated 
at the original seeding density after the reading on day 3. Overexpression of nuclear ELF3 (ELF3-WT) in 
primary normal epithelial cells showed a trend of decreased viability, whilst in cancer samples there was an 
increase in viability (Figure 3.32). Although not significant, overexpression of cytoplasmic ELF3 (ELF3-ΔAT) 
showed a similar trend on the viability of both normal and cancer primary prostate samples as ELF3-WT. 
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Figure 3.32. ELF3 overexpression differentially alters the viability of normal and cancer cells over 
time. 
Two cancer and three normal/cancer matched primary prostate pairs were transduced with control, ELF3-WT and ELF3-
ΔAT constructs at a ratio of two infectious particles for every individual cell. Cells were plated at 40% confluency on day 0 
of alamarBlue assay and the fluorescence was read at days 1-6. Cells were replated at the original density on day 3. (A) 
Normal, n=3. (B) Cancer, n=5. Control samples were normalised to 100% viability. Statistical significance was determined 
using a 2-way ANOVA with Tukey’s multiple comparison test. 
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3.6.3 ELF3 overexpression does not significantly alter primary prostate cell migration 
To assess the effects of ELF3 overexpression on the migratory capacity of primary prostate cells,  
quantitative phase imaging was carried out on two normal and cancer matched pairs using a VL21 platform. 
An Ibidi insert was used to ensure the gap was consistent between all wells. Each condition was carried out 
in triplicate and each well contained three regions of interest (ROI). Sample H681/17 L (cancer) does not 
have a control transduced condition in this instance as the culture became infected, however ELF3-WT and 
ELF3-ΔAT were compared. Full time lapse videos are shown in Appendix 3.1 (see attached CD). There is 
no consistent trend between samples. The control wound closed significantly faster in samples H681/17 R 
(normal) and H682/17 L (cancer), whereas the ELF3 overexpressing conditions closed faster than the 
control in sample H682/17 R (normal) (Figure 3.33). There was no significant difference between ELF3-WT 
and ELF3-ΔAT in any of the samples. The inconsistency in wound closure highlights the heterogeneity 
between patients. More patients would have to be tested in order to draw a clear conclusion.  
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Figure 3.33. The effects of ELF3 overexpression on primary prostate cell migration. 
Two normal/cancer matched primary prostate pairs were transduced with control, ELF3-WT and ELF3-ΔAT viruses at a 
ratio of two infectious particles for every individual cell. Cells were plated into Ibidi inserts to create a consistent gap in the 
centre and placed on a VL21 microscope to track wound closure at 35 minute intervals. The data was processed by 
Amanda Noble using Cell Analysis Toolbox (CAT) software and analysed and presented by myself. Graphs show area of 
the wounds at each 35 minute time frame. Accompanying videos found in Appendix 3.1. Statistical significance was 
determined using a 2-way ANOVA with Tukey’s multiple comparison test. 
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3.6.4 ELF3 overexpression alters the differentiation state of primary prostate epithelial cells 
The videos obtained from the migration analysis using quantitative phase imaging indicated there may be a 
change in cell subpopulation proportions with ELF3 overexpression (Figure 3.34). TA cells are generally 
smaller and fast moving, whilst CB cells are larger and more spread out (Frame et al., 2017). Therefore, in 
general, TA cells have a smaller median cell area and perimeter than CB cells. The quantitative phase 
imaging tracked each individual cell and recorded the median cell area and median cell perimeter for the 
duration of the time course.  
Figure 3.37 summarises the significance and trend of the data shown in Figures 3.35 (median cell area) and 
3.36 (median cell perimeter). Cell numbers ranged from 781 to 1640 for each individual ROI. The three ROIs 
from each well were combined as replicates and plotted. With the exception of sample H681/17 L (cancer) 
which did not have a control, results show that ELF3-WT cells tended to be smaller than control cells and 
ELF3-ΔAT cells. This indicates that ELF3-WT cells may have a larger proportion of TA cells. Furthermore, 
corresponding to this, ELF3-ΔAT cells tended to be larger than the control cells and ELF3-WT cells, thus 
indicating a larger proportion of CB cells. These findings were irrespective of diagnosis. 
To further investigate this observation, the two matched pairs from the imaging experiment together with a 
third matched pair, were stained with CD49b and analysed by flow cytometry. TA cells have high expression 
of CD49b (α2β1 integrin), whilst CB cells have low expression. Since the cells show a range of expression, 
median fluorescence was used to compare subpopulation proportions. In both the normal and cancer 
samples, there was a significant increase in CD49b expression in ELF3-WT cells relative to control cells and 
ELF3-ΔAT cells, indicative of a higher proportion of more primitive TA cells (Figure 3.38). There was no 
significant difference in CD49b expression in ELF3-ΔAT cells relative to control cells in both normal and 
cancer samples. However, two out of the three cancer samples did show a decrease in median fluorescence.  
Collectively, these data show that ELF3-WT transduced cells have a higher proportion of TA cells and ELF3-
ΔAT transduced cells have a higher proportion of CB cells, regardless of whether the cells where derived 
from normal or cancer regions.  
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Figure 3.34. Heterogeneity of primary prostate epithelial cells with ELF3 overexpression. 
Two normal/cancer matched primary prostate pairs were transduced with control, ELF3-WT and ELF3-ΔAT constructs at 
a ratio of two infectious particles for every individual cell. Panels show still frames of the quantitative phase imaging from a 
VL21 microscope. The data was processed by Amanda Noble using Cell Analysis Toolbox (CAT) software and analysed 
and presented by myself. A1, B1, C1 merely represents which well from the 6-well plate is in the image. 
131 
 
Figure 3.35. ELF3 overexpression significantly alters the median cell area of primary prostate 
epithelial cells.  
Two normal/cancer matched primary prostate pairs were transduced with control, ELF3-WT and ELF3-ΔAT constructs at 
a ratio of two infectious particles for every individual cell.  Quantitative phase imaging on a VL21 microscope was used to 
track individual cells. The data was processed by Amanda Noble using Cell Analysis Toolbox (CAT) software and analysed 
and presented by myself. Graphs show the median cell area where each data point is a single cell. Each condition was 
carried out in triplicate (denoted A1, A2 and A3 etc.) and each bar represents data from three regions of interest (ROI) within 
each replicate. Statistical significance is shown in Figure 3.37. 
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Figure 3.36. ELF3 overexpression significantly alters the median cell perimeter of primary prostate 
epithelial cells.  
Two normal/cancer matched primary prostate pairs were transduced with control, ELF3-WT and ELF3-ΔAT constructs at 
a ratio of two infectious particles for every individual cell.  Quantitative phase imaging on a VL21 microscope was used to 
track individual cells. The data was processed by Amanda Noble using Cell Analysis Toolbox (CAT) software and analysed 
and presented by myself. Graphs show the median cell perimeter where each data point is a single cell. Each condition 
was carried out in triplicate (denoted A1, A2 and A3 etc.) and each bar represents data from three regions of interest (ROI) 
within each replicate. Statistical significance is shown in Figure 3.37. 
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Figure 3.37. Statistical analysis of median cell area and median cell perimeter of primary prostate 
cells with ELF3 overexpression.  
Tables show statistical significance and trend of each primary sample from Figures 3.35 (median cell area) and 3.36 
(median cell perimeter). For simplicity, only corresponding triplicate wells for each condition were compared. Statistical 
significance was analysed using the Mann-Whitney test. 
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Figure 3.38. ELF3 overexpression alters the differentiation state of primary prostate cells. 
Three normal/cancer matched primary prostate pairs were transduced with control, ELF3-WT and ELF3-ΔAT constructs 
at a ratio of two infectious particles for every individual cell. Relative median fluorescence of CD49b staining was analysed 
by flow cytometry. Control cells were normalised to a median fluorescence of 100. Matching symbols indicate cells from 
the same patient. Statistical significance was determined using a 2-way ANOVA with Tukey’s multiple comparison test. 
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3.7 ELF3 regulatory networks 
3.7.1 ELF3 expression is upregulated by histone deacetylase inhibitor Vorinostat in primary 
prostate epithelial cells but does not induce a neuroendocrine phenotype 
Given that prostate tissue homogenate lysates did not express ELF3, and ELF3 was only expressed in CB, 
not TA cells, it was hypothesised that ELF3 may be epigenetically silenced in TA cells. To investigate this, 
primary prostate epithelial cell cultures were treated with three different doses of the HDAC inhibitor 
vorinostat (low = 0.625μM, medium = 2.5μM and high = 10μM) (Frame et al., 2017). Cells were harvested 
at 4 hours and 24 hours post-treatment for protein analysis by western blot. Compared to the untreated 
controls, ELF3 expression was induced by vorinostat treatment in both primary samples tested (Figure 
3.39A). ELF3 expression increased both with increasing concentration and duration of treatment with 
vorinostat.  
To determine in which cell populations ELF3 was upregulated, vorinostat treatment was administered to the 
selected TA and CB cell subpopulations as well as the whole population of patient sample H609/17 (Gleason 
3+4). The medium dose of 2.5μM for 24 hours was selected as the optimal treatment for significant ELF3 
upregulation. Whilst ELF3 was expressed at low levels in the untreated whole population or TA cells, there 
was significant ELF3 expression in the untreated CB population, confirming the expression pattern described 
in section 3.2.3. However, following vorinostat treatment, ELF3 was upregulated in all three cell populations 
(Figure 3.39B).  
HDAC inhibitors are known to induce a NE phenotype in PCa (Frigo and McDonnell, 2008). Furthermore, it 
has been demonstrated by a previous PhD student that treatment with HDAC inhibitors can result in the 
upregulation of NE cell markers in our primary prostate epithelial cell cultures (Oldridge E., unpublished 
data). Given the previous finding that ELF3 was expressed in a subset of high grade (Gleason >7) PCa’s 
shown by tissue microarray, it was hypothesised that this may be due to the emergence of a NE phenotype 
in some less differentiated PCa’s (Section 3.3.2). Whilst NE cells are present in the normal prostate, 
evidence shows the emergence of a NE phenotype in more advanced PCa (Terry and Beltran, 2014). 
Neuron specific enolase (NSE) was used as a marker of NE differentiation. Whilst there was an increase in 
NSE expression in sample H591/17 at the 24 hour time point with the high vorinostat dose, there was no 
increase in sample H598/17 with vorinostat treatment. However, a more elongated morphology was present 
following treatment (Figure 3.39C), as well as the formation of processes which is characteristic of NE cells 
(Abrahamsson, 1999). 
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Figure 3.39. ELF3 expression is upregulated in primary prostate epithelial cells following vorinostat 
treatment. 
(A) Primary prostate epithelial cell cultures were treated with three different doses of HDAC inhibitor vorinostat (L = 0.625μM, 
M = 2.5μM and H = 10μM). Cells were harvested at 4 hours and 24 hours after treatment for protein analysis. 30µg of 
protein was loaded per lane onto a 10% SDS gel, transferred onto a PVDF membrane and probed for the indicated 
proteins. GAPDH was used a loading control. Densitometry was carried out using Image J software. Numbers below blots 
indicate expression of ELF3 and NSE relative to the low dose (L) which was normalised to 1. (B) The TA and CB enriched 
subpopulations were treated with 2.5μM vorinostat for 24 hours before harvesting for protein analysis. WP = whole 
population. Numbers below blots indicate expression of ELF3 and NSE normalised to the low dose, 4 hour vorinostat 
treatment. (C) Brightfield images of sample H598/17 24 hours after vorinostat treatment. Scale bar = 100μm. 
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3.7.2 Global gene expression changes following ELF3 knockdown in prostate epithelial cell lines 
In order to assess the global effects of ELF3 knockdown, an Affymetrix Clariom D gene expression 
microarray was carried out (Eurofins Genomics, Wolverhampton UK). This next generation Affymetrix array 
can detect around 200,000 known transcripts from Ensembl. Sample sets consisted of BPH-1 and PC3 cells 
in biological triplicate (siSCR and siELF3). Each set was carried out in duplicate in order to extract both RNA 
for the microarray and also protein for validation of ELF3 knockdown and to also validate any differentially 
expressed genes of interest from the array at the protein level.  
The array data was analysed using TAC 4.0 software. The differential gene expression between siSCR and 
siELF3 samples of BPH-1 and PC3 cells was analysed both individually and collectively with a significance 
threshold of 2-fold increase or decrease and a p-value <0.05 (Table 3.3). Whilst the RNA expression of 
ELF3 was not significantly altered (Table 3.4), there was a significant downregulation of ELF3 at the protein 
level in all samples (Figure 3.40). PC3 cells had the most appreciable response to ELF3 knockdown, with a 
total of 2779 differentially expressed genes (including putative unannotated transcripts), compared with 
1440 genes in BPH-1 cells (Table 3.3). 675 genes were differentially expressed between siSCR and siELF3 
samples regardless of cell type, implying that ELF3 is involved in similar pathways in both cell lines (Table 
3.3) (Figure 3.41).  
 
Analysis Total genes Upregulated Downregulated 
BPH-1: siSCR (3) vs siELF3 (3) 1440 776 664 
PC3: siSCR (3) vs siELF3 (3) 2779 1848 931 
Both: siSCR (6) vs siELF3 (6) 675 355 320 
 
Table 3.3. Number of differentially expressed genes in each gene expression microarray analysis. 
GO analyses were carried out using DAVID and visualised using REVIGO. GO analysis of all sets revealed 
multiple terms associated with cell cycle-related processes and histone regulated processes (Figure 3.40) 
(Appendix 3.3). In agreement with this, several of the most significantly altered genes in both cell lines 
following ELF3 knockdown included cell cycle-related genes and histone genes. Most notably, the serine-
threonine protein kinase PLK1 was downregulated 7.5-fold in siELF3 samples compared to siSCR in both 
BPH-1 and PC3 cells combined. Furthermore, when BPH-1 and PC3 cells were analysed in separate 
analyses, PLK1 was downregulated 15.5-fold in BPH-1 cells and over 5.5-fold in PC3 cells. A list of 
differentially expressed cell-cycle related genes are shown in Appendix 3.4.  
The transcription of histone genes is regulated during the cell cycle, with a 35-fold increase during S phase 
and a subsequent 35-fold decrease upon entering G2 (Marzluff et al., 2002, Harris et al., 1991). This may 
explain the observed bias towards histone regulated processes in the GO analyses. PLK1 is involved in 
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several stages of the cell cycle, most notably during G2 and cytokinesis (de Gooijer et al., 2017, Petronczki 
et al., 2008). Other significantly altered genes from the microarray were also linked to G2 cell cycle phase 
and the PLK1 pathway, such as CDC25C and p21 (Appendix 3.4).  
The expression of other ETS transcription factors was assessed following ELF3 knockdown (Table 3.4). 
Here, there was a differential response between BPH-1 and PC3 cells. In BPH-1 cells, there was a 2-fold 
upregulation of ETS1 and ELF1, whilst in PC3 cells there was a 7-fold upregulation of ESE3 and a 2.5 fold 
upregulation of ETS2. PC3 cells also showed an almost 5-fold downregulation of ETV4. This indicates there 
may be distinct compensatory mechanisms for the loss of ELF3 between the cell lines.  
 
ETS Transcription 
Factors 
BPH-1 PC3 Both 
Gene 
ETS 
Subfamily 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
ELF3 ESE -1.78 0.09 -1.06 0.8396 -1.2 0.4737 
ESE3 ESE 1.32 3.18E-02 6.94 7.29E-06 2.77 0.4516 
ELF5 ESE -1.11 0.8197 1.28 0.2094 -1.01 0.8739 
ELF1 ELF 2.06 0.0345 1.51 0.0549 1.61 0.2949 
ELF2 ELF 1.06 0.7253 1.13 0.4599 1.08 0.8173 
ELF4 ELF -1.18 0.2635 -1.1 0.906 -1.31 0.0788 
ERG ERG -1.04 0.1453 1.01 0.9114 1.1 0.4003 
FLI1 ERG -1.1 0.3314 -1.66 0.3058 -1.23 0.2653 
FEV ERG 1.01 0.9598 1.24 0.2396 1.06 0.6011 
ERF ERF -1.27 0.0994 1.1 0.1774 -1.04 0.6698 
ETV3 ERF 1.36 0.015 1.73 0.0007 1.65 0.0073 
ETS1 ETS 2.21 4.78E-05 1.15 0.5584 1.46 0.0851 
ETS2 ETS 1.72 0.0287 2.54 0.0002 2.12 0.1448 
GABPA ELG 1.49 0.0142 1.76 0.0075 1.65 0.0331 
SPDEF PDEF -1.11 0.4906 1.41 0.0774 1.58 0.769 
ETV6 TEL 1.16 0.2277 1.01 0.867 1.29 0.6859 
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ETV7 TEL 1.49 0.1247 1.04 0.825 1.66 0.663 
SPI1 SPI -1.03 0.6846 1.16 0.985 -1.03 0.7397 
SPIB SPI 1 0.6875 1.01 0.9574 1.05 0.5418 
SPIC SPI 1.21 0.6362 -1.66 0.0256 -1.15 0.2898 
ELK1 TCF -1.46 0.0439 -1.07 0.72 -1.25 0.3695 
ELK3 TCF 3.53 0.1319 -1.18 0.0939 1.76 0.7782 
ELK4 TCF 1.19 0.06 1.4 0.0384 1.28 0.1032 
ETV4 PEA3 -1.45 0.0468 -4.91 4.84E-05 -2.88 0.1632 
ETV5 PEA3 -1.36 0.8792 -1.52 0.0496 -1.38 0.6811 
ETV1 PEA3 -1.1 0.6199 -1.06 0.3914 -1.46 0.8467 
ETV2 PEA3 -1.25 0.0958 -1.19 0.1595 -1.21 0.0525 
 
Table 3.4. Expression changes of ETS transcription factors following ELF3 knockdown. Highlighted 
boxes indicate genes with a significance threshold of 2-fold increase or decrease and a p-value 
<0.05. 
Other networks of interest identified by functional studies (Sections 3.4 and 3.6) were also investigated, 
including differentiation and EMT-associated genes (Table 3.5). PC3 cells showed an upregulation of the 
mesenchymal cell marker fibronectin and its receptor, integrin α5. However, there was also a 2-fold 
upregulation of epithelial cell marker E-cadherin. Both PC3 and BPH-1 cells exhibited an upregulation of the 
neuroendocrine cell marker NSE. There were no significant changes in gene expression found in 
basal/luminal cell markers or EMT-associated transcription factors in either cell line (Tables 3.5 and 3.6). 
Genes associated with the SC phenotype were also examined. However, the only significant change was a 
modest upregulation of CD49b in BPH-1 cells (Table 3.7). 
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Differentiation BPH-1 PC3 Both 
Gene Description Group 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
CDH1 E-cadherin E 1.13 0.2709 2.34 0.005 1.79 0.6553 
CTNNA1 
Alpha 1 
catenin 
E -1.04 0.5768 -1.06 0.6651 -1.07 0.9748 
CTNNA2 
Alpha 2 
catenin 
E -1.16 0.6181 -1.56 0.2072 -1.98 0.0083 
SDC1 Syndecan-1 E -1.2 0.4455 -1.31 0.0872 -1.25 0.4876 
CTNNB1 Beta catenin E/M -1.25 0.1436 1.04 0.9653 -1.06 0.7317 
VIM Vimentin M -1.4 0.9851 1.21 0.1469 1.02 0.9857 
CDH2 N-Cadherin M -2.79 0.0781 1.62 0.0077 -1.03 0.9682 
ITGA5 Integrin α5 M 1.81 0.0935 2.84 0.001 2.33 0.0239 
FN1 Fibronectin M -2.58 0.5795 3.64 0.0002 2.86 0.3618 
TP63 p63 B 1.09 0.6889 1.11 0.9957 1.13 0.9416 
KRT5 Cytokeratin 5 B -1.12 0.4817 -1.08 0.4656 -1.11 0.9766 
KRT14 Cytokeratin 14 B 2.08 0.2539 1.02 0.6336 1.6 0.7718 
KRT8 Cytokeratin 8 L -1.21 0.6864 1.2 0.034 1.26 0.6874 
KRT18 Cytokeratin 18 L -1.54 0.8863 -1.14 0.7831 -1.05 0.7718 
AR 
Androgen 
Receptor 
L -1.46 0.0801 -1.11 0.8565 -1.23 0.2166 
KLK3 PSA L -1.17 0.1616 1.03 0.6645 -1.09 0.5905 
NKX3-1 
NK3 
homeobox 1 
L 1.5 0.0304 1.27 0.1129 1.46 0.3081 
ENO2 
Neurone 
specific 
enolase 
NE 2.6 0.0436 7.21 
2.09E-
05 
3.53 0.0158 
SYP Synaptophysin NE -1.01 0.9912 -1.05 0.5319 1 0.8678 
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CHGA 
Chromogranin 
A 
NE -1.28 0.0722 -1.46 0.0984 -1.13 0.1963 
 
Table 3.5. Expression changes of genes involved in differentiation following ELF3 knockdown. E = 
epithelial, M = mesenchymal, B = basal, L = luminal, NE = neuroendocrine. Highlighted boxes 
indicate genes with significance threshold of 2-fold increase or decrease and a p-value <0.05. 
 
 
EMT Transcription Factors BPH-1 PC3 Both 
Gene Description 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
SNAI1 Snail 1.24 0.1636 1.27 0.1237 1.19 0.089 
SNAI2 Slug -1.11 0.3626 2.3 0.0915 1.39 0.553 
TWIST1 
Twist Family BHLH 
Transcription Factor 1 
-1.04 0.5925 1.66 0.0873 -1.11 0.5819 
TWIST2 
Twist Family BHLH 
Transcription Factor 2 
1.21 0.0886 1.32 0.1515 1.23 0.1012 
ZEB1 
Zinc Finger E-Box 
Binding Homeobox 1 
1.25 0.4184 -1.06 0.9053 1.19 0.9248 
ZEB2 
Zinc Finger E-Box 
Binding Homeobox 2 
-1.05 0.675 -1.07 0.7297 1.02 0.7351 
FOXC2 Forkhead Box C2 -1.08 0.5417 1.34 0.474 1.09 0.8927 
 
Table 3.6. Expression changes of transcription factors involved in epithelial-to-mesenchymal 
transition (EMT) following ELF3 knockdown. 
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Stem Cell Markers BPH-1 PC3 Both 
Gene Description 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
PSCA 
Prostate stem cell 
antigen 
1.46 0.0804 1.24 0.3098 1.32 0.0466 
NANOG Nanog homeobox -1.01 0.7987 1.1 0.9167 1.07 0.2411 
ALDH1A1 
Aldehyde 
dehydrogenase 1 
family, member A1 
1.52 0.4134 1.13 0.8367 1.03 0.9889 
ALDH1A3 
Aldehyde 
dehydrogenase 1 
family, member A3 
1.26 0.4657 1.19 0.4469 1.01 0.8824 
SOX2 SRY box 2 1.17 0.7479 -1.06 0.4364 -1.07 0.968 
POU5F1 
POU class 5 
homeobox 1 
-1.04 0.7425 1 0.8813 1.09 0.82 
NES Nestin 1.1 0.2663 -1.01 0.2414 1.14 0.9003 
MYC 
V-myc avian 
myelocytomatosis 
viral oncogene 
homolog 
1.14 0.394 -1.25 0.2376 -1.02 0.989 
ITGA2 
Integrin, alpha 2 
(CD49B) 
2.89 0.0047 1.48 0.3968 1.7 0.0613 
CD44  1.01 0.8094 1.04 0.2241 -1.04 0.7694 
ABCG2 
ATP binding 
cassette subfamily 
G member 2 
-1.54 0.557 -1.02 0.9041 1.14 0.9082 
 
Table 3.7. Expression changes of stem cell markers following ELF3 knockdown. Highlighted boxes 
indicate genes with significance threshold of 2-fold increase or decrease and a p-value <0.05. 
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Further analysis was carried out by Dr Alastair Droop to determine whether there was a differential response 
to ELF3 knockdown between BPH-1 and PC3 cells. Twelve known genes showed differential behaviour 
upon knockdown between the two cell lines (Table 3.8). Expression graphs are shown in Appendix 3.5 
(generated by Dr Alastair Droop). The analysis shows that there are a subset of genes which have 
comparable levels of expression between BPH-1 siSCR and PC3 siSCR, but with ELF3 knockdown there is 
a significant increase of expression in PC3 cells but not BPH-1. The most significant differentially expressed 
gene was LXN, which showed a small decrease in BPH-1 siELF3 cells but showed a significant increase 
PC3 siELF3 cells compared to their respective siSCR counterparts. An exception to this is ESE3 (also known 
as EHF) which has very high levels of expression in both BPH-1 siSCR and siELF3, whereas PC3 siSCR 
cells have relatively low expression with a significant increase in PC3 siELF3 cells.  
 
Gene Description Log Fold Change  P value 
LXN 
Zinc-dependent metallocarboxypeptidases 
inhibitor 
-2.28 7.88E-08 
GHR Growth hormone receptor -2.11 2.14E-07 
FBN1 Extracellular matrix glycoprotein  -2.13 3.85E-07 
PDGFA Platelet-derived growth factor subunit A -1.61 7.31E-07 
CSPG5 
Proteoglycan that may function as a neural 
growth and differentiation factor 
-2.44 3.25E-06 
CADM2 Cell adhesion molecule  -3.17 4.64E-06 
ESE3 Epithelial-specific ETS transcription factor -1.48 5.91E-06 
TMEM117 
Transmembrane protein 117 involved in 
stress-induced cell death pathway 
-2.41 7.40E-06 
SFMBT2 
Transcriptional repressor by binding to 
methylated lysines in histones 
-1.48 7.55E-06 
PDK4 
Mitochondrial protein involved in glucose 
metabolism 
-1.66 8.82E-06 
STC1 Calcium and phosphate regulator -2.13 1.54E-05 
TNFSF4 
Cytokine which mediates adhesion of 
activated T cells to endothelial cells 
-1.99 1.62E-05 
 
Table 3.8. Genes that show different behaviour upon ELF3 knockdown between BPH-1 and PC3 cells. 
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Figure 3.40. Validation of ELF3 knockdown at the protein level in array samples. 
Western blot indicating ELF3 protein expression 72 hours following ELF3 knockdown. 25µg of protein was loaded per lane 
onto a 10% SDS gel, transferred onto a PVDF membrane and probed for the indicated proteins. GAPDH was used a 
loading control. RNA extracted from duplicate samples were sent for Affymetrix gene expression microarray. M = mock, S 
= siSCR, E = siELF3. 
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Figure 3.41. Gene expression changes and gene ontology in prostate epithelial cells following ELF3 
knockdown. 
Differential gene expression of BPH-1 and PC3 cells with ELF3 knockdown was determined by an Affymetrix Clariom D 
microarray.  (A) Volcano plot indicating gene expression changes of siSCR vs siELF3 BPH-1 and PC3 cells collectively. 
Significance threshold included genes with a 2-fold increase or decrease and a p-value <0.05. Red = increased expression, 
green = decreased expression. (B) Gene ontology terms associated with significant differential gene expression changes 
between siSCR and siELF3 cells. Generated via the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) and visualised using REVIGO. 
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3.7.3 ELF3 knockdown alters the expression of key cell cycle regulatory genes in prostate epithelial 
cell lines at the protein level and results in a block at the G2 phase 
To validate results found in the gene expression microarray, several G2 phase proteins were tested by 
western blot using lysates from the BPH-1 and PC3 siELF3 cells (Figure 3.42). PLK1 and CDC25C were 
downregulated in both PC3 and BPH-1 cells at the protein level. The cyclin-dependent kinase (CDK) inhibitor 
p21 was also increased. These changes correlated with an arrest at the G2 checkpoint which was shown 
by a progressive accumulation of cells in the G2 phase during cell cycle analysis (Figure 3.43). Phospho-
histone H3 (PHH3) ICC staining was also carried out on BPH-1 cells to determine the number of cells in 
mitosis with siELF3 compared to siSCR. Representative images indicating the different stages of mitosis is 
shown in Figure 3.44A. Whilst 9% of mock and siSCR cells were positive for PHH3, only 3.8% of siELF3 
cells were undergoing mitosis, further indicating cell cycle arrest (Figure 3.44B).  
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Figure 3.42. ELF3 knockdown alters the expression of key cell cycle regulator genes. 
Protein expression (i) and densitometry analysis (ii) of G2 phase cell cycle-related genes in (A) BPH-1 cells and (B) PC3 
cells 72 hours following ELF3 knockdown. 25µg of protein was loaded per lane onto a 10% SDS gel, transferred onto a 
PVDF membrane and probed for the indicated proteins. GAPDH was used a loading control. Densitometry was carried 
out using Image J software. M = mock, S = siSCR, E = siELF3. Statistical significance was determined using a Student’s 
T-test (unpaired, two-tailed). 
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Figure 3.43. ELF3 knockdown causes a progressive accumulation of cells in the G2 phase of the cell 
cycle. 
Cell cycle analysis was carried out on (A) BPH-1 and (B) PC3 cells 24 hours post-transfection with mock, siSCR or siELF3 
for three consecutive days. Cells were treated with EdU for 4 hours and harvested and stained with propidium iodide before 
analysing by flow cytometry. Graphs represent the average of three biological replicates.  
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Figure 3.44. ELF3 knockdown reduces the number of BPH-1 cells in mitosis.  
BPH-1 cells were transfected with ELF3 (siELF3) and scrambled siRNA (siSCR), fixed in 4% paraformaldehyde at day 3 
post-transfection and stained with phospho-histone 3 (PHH3-S10) as a marker of mitosis. Blue = DAPI, red = PHH3-S10. 
(A) Representative images of cells in each stage of mitosis. (B) 220 cells were counted in each condition and presented as 
a percent PHH3-S10-positive.  
  
152 
3.7.4 ELF3 knockdown does not significantly alter the cell cycle in primary prostate epithelial cells 
To investigate whether the effects seen in prostate epithelial cell lines with ELF3 knockdown are mirrored in 
primary cells, ELF3 knockdown was optimised in primary prostate epithelial cells. Primary prostate samples 
were selected for CB cells as this is the subpopulation which expresses highest ELF3 protein (Section 3.2.3) 
CB cells were counted and plated onto 6 well plates for knockdown. Cells were harvested 72 hours post-
transfection for western blot analysis. A range of 70-99% knockdown was achieved in all samples tested 
(Figure 3.45). The same G2 cell cycle proteins were probed for in each knockdown sample as had been 
tested with the cell lines (Section 3.7.3) and also cyclin B1 and phosphorylated cyclin B1 (p-cyclin B1) as it 
is a substrate for PLK1. PLK1 was only detected in one sample (H589/17), and did decrease in siELF3 cells 
in this sample (Figure 3.46). CDC25C and p-cyclin B1 were not detected, however p21 was detected in all 
samples and treatments. This suggests that the cells are arresting and not reaching G2 phase of the cell 
cycle. An explanation for this could be that the primary cell density required for transfection meant that at 72 
hours, when the cells were harvested, the cells were confluent and may have ceased to proliferate. This 
was also reflected in the cell cycle analysis, where there was no change between siRNA treatments and few 
cells in G2 (Figure 3.46D). 
Colony forming assays were also set up but the cells did not form colonies in any treatment, indicating that 
the selection of CB cells was robust since they are less proliferative in the primary cultures (Collins et al., 
2001). Therefore, ELF3 knockdown does not promote de-differentiation into SC/TA cells which are more 
capable of forming colonies.  
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Figure 3.45. Efficiency of ELF3 knockdown in primary prostate committed basal cells. 
ELF3 knockdown was optimised in primary prostate epithelial cell cultures. CB cells were first enriched for by lack of 
adhesion to collagen-I coated plates after 20 minutes incubation. Cells were then plated at a density of 200,000 cells per 
well in a collagen-I coated 6-well plate. siRNA was transfected into cells using Oligofectamine transfection reagent 
(Invitrogen). Cells were harvested 72 hours post-transfection for protein analysis. 30µg of protein was loaded per lane onto 
a 10% SDS gel, transferred onto a PVDF membrane and probed for the indicated proteins. GAPDH was used a loading 
control. Densitometry was carried out using Image J software.  Samples included those derived from (A) BPH, (B) Gleason 
3+4 and (C) High Gleason (4+3 and 4+4) samples. M = mock, S = siSCR, E = siELF3, G = Gleason score. 
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Figure 3.46. ELF3 knockdown does not alter the cell cycle in primary prostate committed basal cells.  
Protein expression of G2 phase cell cycle-related genes in primary prostate committed basal cell cultures 72 hours post 
transfection with mock (M), siSCR (S) and siELF3 (E). 30µg of protein was loaded per lane onto a 10% SDS gel, transferred 
onto a PVDF membrane and probed for the indicated proteins. GAPDH was used a loading control. Densitometry was 
carried out using Image J software. Samples were derived from (A) BPH, (B) Gleason 3+4 and (C) High Gleason (4+3 and 
4+4) samples. (D) Representative histogram of cell cycle analysis 72 hours post-transfection. Red = mock, green = siSCR, 
blue = siELF3. 
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3.7.5 ELF3 overexpression has no effect on the cell cycle of primary prostate epithelial cells 
Since ELF3 knockdown has been shown to arrest prostate epithelial cells in G2, a complementary study 
using lentiviral ELF3 overexpression was next carried out. A normal/cancer matched pair was transduced 
with control, ELF3-WT and ELF3-ΔAT lentiviruses. A pulse-chase cell cycle analysis was carried out using 
EdU and propidium iodide staining to assess progression through the cell cycle. At the 24h time point a 
larger proportion of cells progressed to the G2 phase compared to 4h in all conditions (Figure 3.47). 
However, there was no clear difference in cell cycle phases between the control, ELF3-WT and ELF3-ΔAT 
conditions.  
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Figure 3.47. ELF3 overexpression does not have a distinct effect on cell cycle.  
Cell cycle analysis was carried out on a (A) cancer and (B) normal primary matched pair with ELF3 overexpression by flow 
cytometry. Cells were treated with EdU for 4 hours (pulse) and medium was then replaced in duplicate wells with normal 
growth medium and cells were harvested at 24 hours (chase) to assess progression through the cell cycle. 
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4. Discussion 
Deregulation of the ETS transcription factor family members is now recognised as a common feature in 
multiple cancers; with aberrant expression, loss of tumour suppressor function, inactivating mutations and 
the formation of fusion genes observed (Seth and Watson, 2005). Most notably, the TMPRSS2-ERG gene 
fusion is present in approximately 50% of PCas and in prostate CSCs (Tomlins et al., 2005, Polson et al., 
2013). However, the role of other ETS transcription factors in PCa is less well understood. Notably, there is 
now mounting evidence that the epithelial-specific ETS factors ELF3, ESE3, and PDEF play a role in PCa. 
Furthermore, these ETS factors also play a role in epithelial cell differentiation and consequently may be 
important regulators of the SC (and CSC) phenotype in the prostate (Archer et al., 2017). 
Existing literature at the beginning of this study was conflicting in terms of the role of ELF3 in the prostate. 
This consisted of one study which identified ELF3 as a driver of PCa and one which proposed it as a 
suppressor. In order to identify the genuine function of ELF3 it was important to consider the multiple cell 
populations present in the prostate. A gene expression microarray was previously carried out assessing the 
differential gene expression between prostate SCs and the more differentiated CB cells derived from benign 
and cancerous prostate tissue (Birnie et al., 2008). ELF3 was identified as significantly upregulated in the 
more differentiated CB cells of the prostate epithelium compared to SCs irrespective of diagnosis. This 
current study has been an in depth investigation into the expression pattern of ELF3 as well as its potential 
function in different cellular compartments of both normal and malignant prostate basal epithelial cells.   
4.1 Expression pattern of ELF3 in prostate cells and tissue 
This study details the most comprehensive ELF3 expression profile to date in prostate cell lines and primary 
prostate epithelial cell subpopulations. Longoni et al. described LNCaP, 22RV1 and Du145 cells as 
possessing low, intermediate and high ELF3 expression, respectively (Longoni et al., 2013), which agrees 
with our findings. In section 3.1.1, ELF3 expression was also determined in multiple other prostate cell lines, 
including those derived from normal and benign prostate, as well as primary and metastatic PCa. Whilst 
ELF3 was expressed in all cell lines tested, there was no clear pattern correlating with diagnoses. A study 
in colon cancer also observed a similar range of ELF3 expression amongst a panel of colon cell lines of 
normal, primary cancer and metastatic origin (Wang et al., 2014). Furthermore, we found no distinct 
correlation between ELF3 expression and prostate cell lines considered more basal/intermediate or more 
luminal.  
To determine the expression of ELF3 in the primary prostate, IHC staining of benign prostate tissue sections 
was carried out. This revealed that ELF3 expression was restricted to the basal epithelial cells of glands and 
was absent from luminal epithelial cells and the surrounding stroma (Section 3.3.2). As well as tissue IHC, 
ELF3 was not detected in lysates derived from the stromal cells of several patients (Section 3.2.2). This is 
unsurprising as ELF3 is described as an epithelial-specific transcription factor and is generally expressed in 
tissue with high epithelial cell content (Tymms et al., 1997). ELF3 expression however, can be induced in 
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several stromal-like cell lines following treatment with inflammatory stimuli (Rudders et al., 2001). 
Nevertheless, this does not appear to occur in the inflammatory setting of BPH. A study of the bladder found 
ELF3 to be expressed in the epithelial cells of human urothelium (Bock et al., 2014). In contrast to the 
prostate, ELF3 expression progressively increased as cells differentiated from the basal layer to the most 
superficial, differentiated cells. However, in the normal oral mucosa, like prostate, ELF3 is most highly 
expressed in the basal epithelium (AbdulMajeed et al., 2013). 
Western blot analysis was also carried out on enriched TA and CB epithelial subpopulations, which showed 
that ELF3 was consistently expressed in the CB subpopulation, with little or no detection in the TA cells 
(Section 3.2.2). This was evident in cells derived from both benign and cancerous tissue and there was no 
significant difference in expression between the two diagnoses. This agreed with the gene expression 
microarray which showed ELF3 was more highly expressed in CBs vs SCs at the RNA level irrespective of 
diagnosis (Section 3.2.1). Analysis of two independent breast cancer data sets also found ELF3 expression 
to be significantly lower in the CSC population compared to more differentiated subpopulations (Merino et 
al., 2016), suggesting its expression is linked to differentiation in both tissue types.  
Analysis of benign prostate tissue TMA’s showed that ELF3 protein was expressed in all sections that 
contained epithelial glands (Section 3.3.2), confirming the pattern of expression seen previously in individual 
patient sections. There were several patterns of expression observed in the PCa TMA analysed. Many 
cancer sections either showed no ELF3 staining, or high ELF3 expression in non-cancerous, AMACR-
negative glands, regardless of Gleason grade. Some more advanced, less differentiated cancers of Gleason 
grade ≥7 were positive for ELF3 expression. Longoni et al. showed that a subset of prostate tumours 
expressed higher ELF3 than normal prostate by qRT-PCR and IHC (Longoni et al., 2013). However, there 
was no further distinction between Gleason grades in that study. Analysis of two independent datasets also 
found increased ELF3 expression in metastatic tumours compared to primary prostate tumours, indicating 
that ELF3 expression may be associated with more advanced tumours (Longoni et al., 2013). Results from 
other tissues vary. In the colon, liver and lung, ELF3 expression appears to be associated with cancer 
progression and metastases (Wang et al., 2014, Nakarai et al., 2012, Zheng et al., 2018, Wang et al., 2018). 
In contrast, in oral and ovarian tissue, development of cancer is associated with a loss of ELF3 expression 
(AbdulMajeed et al., 2013, Yeung et al., 2017). 
Breast cancers can be classified into different subtypes according to molecular marker expression, including 
luminal and basal-like subtypes. Analysis from a genomic and transcriptomic study of 52 commonly used 
breast cancer cell lines divided the basal-like subgroup into two categories; basal A and basal B (Kao, 2009). 
Basal A cell lines were found to associate with ETS transcription factor pathways and expressed genes 
related to basal-like tumours. Basal B cell lines expressed genes related to mesenchymal and SC/progenitor 
cell properties and EMT. Notably, re-analysis of this data in a later study found that ELF3 was highly 
expressed in the basal A cell lines, with little or no expression in the basal B cell lines (Kar and Gutierrez-
Hartmann, 2017). This pattern of expression resembles what we have found in the prostate with regards to 
high ELF3 expression in CB cells but low in the SC/TA subpopulation. It should also be noted that basal-
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like breast cancers are associated with poor prognosis, further suggesting that ELF3 expression could be 
linked to more advanced disease. 
Whilst both similar and conflicting ELF3 expression patterns have been found in other tissues, multiple 
techniques have confirmed that ELF3 expression is restricted to the basal layer of the prostate epithelium. 
A larger patient cohort would be required to determine if there was a significant difference in ELF3 
expression with increasing Gleason grade in PCa. With regards to metastases, which has been discussed 
in other studies, tissue is difficult to obtain as prostate metastases are primarily to the bone and are therefore 
not readily available for study. 
4.2 Subcellular localisation of ELF3 
Determining the cellular localisation of a protein is important for understanding its function. A number of 
publications have examined the localisation of ELF3 in various tissues including bladder, colon, liver, breast 
and prostate tissues as well as cell lines. However, each has proposed differing cellular localisations 
(cytoplasmic, nuclear or pan-cellular), and subsequently roles, for ELF3. Whilst in urothelium, lung and 
ovarian epithelial cells ELF3 is almost exclusively nuclear (Bock et al., 2014, Wang et al., 2018, Yeung et 
al., 2017), there is evidence of cytoplasmic expression in other tissues. Abdulmajeed et al. found ELF3 to 
be exclusively cytoplasmic in the basal epithelium of oral mucosa tissue and cell lines, and in the colon 
tissue ELF3 appears to be pancellular (AbdulMajeed et al., 2013, Wang et al., 2014).  
We have shown by fractionated western blot that ELF3 is expressed in both the nucleus and cytoplasm of 
prostate epithelial cell lines of normal, benign and cancerous origin (Section 3.3.1). Furthermore, in prostate 
tissue sections, some patients exhibited exclusively cytoplasmic staining, whilst others showed expression 
in both the cytoplasm and nucleus (Section 3.3.2). In accordance with this, Longoni et al detected ELF3 in 
both the cytoplasm and nucleus of normal prostate and cancer tissue (Longoni et al., 2013). The authors 
also carried out immunofluorescence on DU145 and 22RV1 PCa cell lines. Whilst DU145 cells presented 
with a clear nuclear localisation, 22RV1 cells showed a more pan-cellular appearance, however no nuclear 
co-stain was carried out with these cells so this is difficult to determine.  
As a transcription factor, ELF3 requires efficient transport to the nucleus, which can be mediated through 
classical NLS (Gorlich and Kutay, 1999). Through deletions and mutations, multiple NLS motifs were 
identified within the AT-hook and ETS DNA-binding domains in the murine homologue of ELF3 (mElf3) (Do 
et al., 2006). This was further defined in human ELF3 by Prescott et al., who identified that a single NLS 
motif in the AT-hook domain was sufficient for nuclear translocation, as its deletion resulted in exclusively 
cytoplasmic expression in breast cell lines (Prescott et al., 2004, Prescott et al., 2011). Furthermore, two 
nuclear export signals (NES) were also found, suggesting that ELF3 is capable of translocating both to and 
from the nucleus. In fact, a study in colorectal cancer showed that treatment of HT-29 cells with TNF-α, a 
known upregulator of ELF3, resulted in the translocation of ELF3 from the cytoplasm to the nucleus (Brown 
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et al., 2004, Wu et al., 2008, Li et al., 2015). This process is true of many other transcription factors such as 
NF-κB and NFAT as well as fellow ETS factor ETS1 (Tsao et al., 2013). 
 Collectively the data indicates that ELF3 can be expressed in both the nucleus and cytoplasm of prostate 
epithelial cells and could therefore carry out distinct functions in both cellular compartments. Appropriately, 
the effects of ELF3 overexpression was investigated using two lentiviral constructs which resulted in 
expression in the separate cellular compartments to distinguish any overt distinct functions and will be 
discussed further in Section 4.4.  
4.3 ELF3 and the neuroendocrine phenotype 
The analysis of a PCa TMA showed that ELF3 was expressed in a subset of PCa’s with Gleason grade ≥7. 
However, ELF3 was not expressed in AMACR-positive regions of Gleason 6 PCa’s, likely due to the 
characteristic loss of the basal cell population in the development of PCa tumours (Parimi et al., 2014). As 
mentioned previously, ELF3 has been linked to the progression of advanced cancers of other tissues (Wang 
et al., 2014, Zheng et al., 2018, Wang et al., 2018). Additionally, the ETS factor ETS1 has been linked to 
Gleason grade and time to progression of CRPC (Li et al., 2012).  
Adenocarcinomas are the most common malignancy of the prostate. However, a subset of NE prostate 
neoplasms exist, which include carcinoid tumours, small cell carcinomas and large cell carcinomas. These 
classes of prostate tumours are generally very rare and are associated with poor prognosis (Parimi et al., 
2014). Several studies have shown that NE differentiation also occurs in conventional prostate 
adenocarcinomas, in association with more advanced disease. In particular, an increase in NE cells has 
been observed following ADT and has been suggested as a mechanism of treatment resistance and 
therefore linked to the emergence of CRPC (Hirano et al., 2004, Berruti et al., 2007, Sasaki et al., 2005, 
Terry and Beltran, 2014).  
The increase of NE cells following ADT is thought to occur via a process called NE transdifferentiation, 
whereby prostate epithelial adenocarcinoma cells acquire NE markers and properties. This phenomenon 
has been shown experimentally in vitro most extensively in LNCaP cells, but also PC3 cells (Bang et al., 
1994, Shen et al., 1997, Wright et al., 2003).  
HDAC inhibitors have been proposed as a potential PCa therapy due to the induction of cell death in AR-
positive cell lines (Rokhlin et al., 2006). However, they have also been shown to reduce AR expression and 
induce a NE phenotype in LNCaP and LAPC4 cells (Frigo and McDonnell, 2008). To determine whether 
ELF3 was associated with a NE phenotype in PCa we treated primary prostate epithelial cultures derived 
from tumours with the HDAC inhibitor vorinostat.  Vorinostat upregulated ELF3 in a concentration and time-
dependent manner in TA, CB and whole populations of basal epithelial cells (Section 3.7.1). Whilst the NE 
cell marker NSE increased with vorinostat treatment in one sample, this induction was not consistent in all 
samples tested. However, there was a distinct change in cell morphology following treatment, even in 
samples with no change in NSE levels, with the presence of dendritic-like processes characteristic of NE 
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cells (Abrahamsson, 1999). Literature shows that chromogranin A (ChrA) and synaptophysin are more 
specific markers of NE cells (Parimi et al., 2014), and whilst an antibody was tested for ChrA, it was found 
to be unsuitable for western blot.  
The origin of NE cells in prostate adenocarcinoma is not fully understood. Evidence suggests that the NE 
cells in the normal prostate likely arise from the same SC population that forms the epithelial cell hierarchy 
(Hudson, 2004). NE cells found in prostate adenocarcinomas have been proposed to be of cancerous 
luminal cell origin due to their expression of luminal CKs (Yuan et al., 2007). However, NE cells present in 
adenocarcinomas do not express AR or PSA and have also been shown to express the basal cell marker 
CK5 as well as luminal CKs (Hudson, 2004). Given the proliferative capabilities, differentiation and plasticity 
of prostate basal cells, as shown by their ability to undergo EMT, it is not unreasonable to assume they 
could also undergo transdifferentiation to NE cells. It should also be noted that transdifferentiation can be 
mediated in vitro by IL-1β (Spiotto and Chung, 2000, Chiao et al., 1999), which is a known activator of ELF3 
(Grall et al., 2005, Rudders et al., 2001, Longoni et al., 2013, Wu et al., 2008). 
In conclusion, despite our demonstration of ELF3-positivity in a subset of high Gleason grade PCa’s, there 
is currently not enough evidence to determine if ELF3 expression is associated with the NE phenotype. Of 
note, the treatment status of patients in the tested TMA is unknown. Obtaining more high grade, CRPC 
tissue sections, as well as investigation of additional markers, namely ChrA and synaptophysin, would be 
beneficial. However, CRPC patients generally do not undergo routine biopsies and tissue is only available 
from channel TURPs, which are rare. 
4.4 The role of ELF3 in the prostate and prostate cancer  
4.4.1 ELF3 and the stem cell phenotype 
When investigating a gene whose function is not fully elucidated, and its potential role in cancer initiation 
and progression, it is important to also consider what occurs in the non-cancer, normal setting. Appropriate 
prostate epithelial cell line models were chosen to initially investigate the role of ELF3 by considering the 
basal expression pattern found in primary prostate cells (Sections 3.2.2 and 3.3.2) and the levels of ELF3 
expression across the panel of prostate cell lines tested (Section 3.1.1). PC3 and BPH-1 cells were chosen 
because they are androgen-independent and do not have features of terminally differentiated luminal cells. 
They are typically called intermediate cells, having several basal epithelial markers, with some markers 
associated with more differentiated cells, but no androgen receptor expression. They also express significant 
but modifiable levels of ELF3 and are derived from benign and cancer patients respectively. 
Since ELF3 is expressed in the CB population of primary prostate basal cells and absent from SC and 
luminal cell populations and also taking into consideration that ELF3 has been ascribed both tumour 
suppressive and oncogenic roles in literature, we therefore originally hypothesised that knockdown of ELF3 
could either: 1) cause de-differentiation and initiate SC-like characteristics, or 2) promote differentiation and 
reduce SC-like characteristics. We found that ELF3 knockdown significantly reduced the colony forming 
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ability of BPH-1 cells by 80% and PC3 cells by 65%. (Section 3.4.4). There was also a significant decrease 
in cell viability (Section 3.4.2) and migration (Section 3.4.3). These findings demonstrate that cells with ELF3 
knockdown display a less malignant phenotype, do not acquire SC characteristics, and are therefore unlikely 
to be undergoing de-differentiation.  
The findings from the loss of function studies of ELF3 raised the possibility that induction of ELF3 expression 
could drive the opposite and promote a malignant cell phenotype, as described in the prostate by Longoni 
et al. One study has proposed that ELF3 expression specifically promotes a SC phenotype in lung 
adenocarcinoma cell lines (Ali et al., 2016). They showed that ELF3 is activated by protein kinase C-iota via 
phosphorylation in its PNT domain, which promoted nuclear localisation and activation of the NOTCH3 
promoter. ELF3 knockdown reduced oncosphere growth and cell viability and decreased the number of 
asymmetric divisions characteristic of SC/CSCs. 
To study the overexpression of ELF3 in prostate cells we wanted to address the complex nature of its cellular 
localisation. The data showed that ELF3 was expressed in both the cytoplasm and nucleus of prostate 
epithelial cells (discussed in Section 4.2). Furthermore, other studies have shown that ELF3 carries out 
functions other than conventional transcriptional regulation in the nucleus. Prescott et al. used a series of 
deletion mutants of ELF3 to investigate its cellular localisation (Prescott et al., 2004, Prescott et al., 2011). 
Cytoplasmic localisation of ELF3 resulted in transformation of the non-tumorigenic breast cell line MCF-12A. 
This was found to be mediated by the SAR domain of ELF3, suggesting this is a non-transcriptional function. 
These effects were also eliminated by tagging a NLS onto the cytoplasmic ELF3 mutant. Prof Gutierrez-
Hartmann kindly gifted us the ELF3-ΔAT plasmid which expressed full length ELF3 with an AT-hook domain 
deletion which resulted in cytoplasmic expression due to the deletion of an essential NLS. ELF-ΔAT 
(cytoplasmic) and ELF3-WT (nuclear) were cloned into lentiviral constructs to investigate the function of 
ELF3 in the distinct cellular compartments in primary prostate epithelial cells (Sections 3.5 and 3.6.1). ELF3 
is the sole ETS factor containing an AT-hook domain, which is primarily found in a subset of high mobility 
group proteins which are regulators of chromatin structure (Reeves, 2000). To date, the AT-hook domain 
has been ascribed functions only within the nucleus and has been shown to be important in ELF3-mediated 
transcriptional activation in a promoter-dependent manner (Kopp et al., 2007). Therefore, deletion of this 
domain should not interfere with any function ELF3 could potentially carry out in the cytoplasm. 
Overexpression of ELF3 in primary prostate basal cells showed inconclusive findings. In wound closure 
assays, two samples, one cancer and one normal derived from different patients, the control wound closed 
faster than the ELF-WT and ELF3-ΔAT wounds, whilst the third sample showed the opposite. Further 
samples would have to be tested in order to deduce what effect overexpression of ELF3 has on the migratory 
potential of primary cells. Longoni et al. showed that ELF3 overexpression in the PCa cell lines LNCaP and 
22RV1 induced a more malignant phenotype including increased colony formation and migration (Longoni 
et al., 2013). However, these cell lines possess a luminal phenotype (Table 3.1) and our data has shown 
that ELF3 is not endogenously expressed in luminal cells in primary prostate tissue (Section 3.3.2). Data of 
Longoni et al. may therefore not be representative of what occurs in vivo. To distinguish induction of SC 
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characteristics, colony forming assays were attempted, however due to interference of non-transduced cells 
the data was deemed unreliable. Transduced GFP-positive cells could have been selected using 
fluorescence-activated cell sorting (FACS), however colony forming ability has been shown to be negatively 
affected following this procedure in our lab. An antibiotic selection marker would have been a more suitable 
set up for colony forming assays in this instance.  
To explore the wider consequences of lack of ELF3 expression, an Affymetrix Clariom D microarray was 
carried out on BPH-1 and PC3 cells with ELF3 knockdown in triplicate (Section 3.7.2). Data was analysed 
by individual cell line and also collectively, to identify ELF3-regulated pathways which are important in both 
cell lines. The expression of a number of classical SC/CSC markers were investigated, however there was 
no significant difference in expression with ELF3 knockdown in either cell line. There was an approximately 
3-fold increase of CD49b in BPH-1 cells, but this alone is insufficient to suggest induction of a SC phenotype, 
particularly considering the outcomes of functional assays.  
Collectively, the data suggests that whilst ELF3 knockdown inhibits a malignant cell phenotype, there is no 
decrease in classical SC markers to suggest ELF3 is involved in promoting such a phenotype. Furthermore, 
more studies on the consequences of ELF3 overexpression would have to be performed to distinguish true 
SC biological characteristics, such as colony formation.  
4.4.2 ELF3 as a regulator of the cell cycle 
Since we found that ELF3 knockdown did not cause cleaved caspase-3-induced apoptosis, this suggested 
that the observed decrease in viable cell number may be due to reduced proliferation (Section 3.4.2). 
Previous studies have highlighted ELF3 as a cell cycle regulator in breast and non-small cell lung carcinoma 
(NSCLC) cell lines. ELF3 knockdown resulted in an accumulation of cells in the G1 phase and, in breast 
cancer cells, a reduction in cyclin D1 (Kar and Gutierrez-Hartmann, 2017, Wang et al., 2018). GO analysis 
from the microarray revealed that the differentially expressed genes were involved in processes related to 
the cell cycle and histone regulation. PLK1 was one of the most significantly differentially expressed genes, 
and was amongst the highest fold changes in all three analyses (BPH-1, PC3 and combined), suggesting it 
may be highly regulated by ELF3. PLK1 is involved in G2 and cytokinesis stages of the cell cycle, both of 
which were highlighted in the GO anaylsis, (de Gooijer et al., 2017, Petronczki et al., 2008). As mentioned 
previously, histone gene expression is highly regulated during the cell cycle, and this may account for the 
bias towards histone-regulated processes in the GO analysis. There were also significant changes in 
expression of genes upstream and downstream of the PLK1 pathway, including CDC25C, cyclin B1, p21 
and FOXM1.   
Of note, increased PLK1 expression has been detected in PCa (Weichert et al., 2004). Moreover, there is a 
correlation of increased PLK1 in PCa tumours with NE differentiation (Grobholz et al., 2005), further 
suggesting there could be a link between ELF3 expression and NE differentiation as discussed in Section 
4.3. Contradictory to this, both cell lines in this study showed a significant increase in NSE expression 
following ELF3 knockdown, particularly PC3 cells which showed an over 7-fold induction. However, there 
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was no change in other NE markers such as ChrA or synaptophysin. PC3 cells represent aggressive PCa 
and are known to inherently express some NE markers (Tai et al., 2011). Nevertheless, this increase in NE 
phenotype does not coincide with results from functional studies, as siELF3 cells showed a decrease in 
malignant phenotype. 
Multiple candidate G2 cell cycle proteins were validated at the protein level (Section 3.7.3). There was a 
significant decrease in PLK1 and CDC25C as well as an increase in CDK inhibitor p21 with ELF3 
knockdown. This was also validated at the functional level, where there was an accumulation of BPH-1 and 
PC3 siELF3 cells in the G2 phase over time. Furthermore, PHH3-S10 staining confirmed there were fewer 
siELF3 cells undergoing mitosis compared to mock and siSCR. This conclusively validates ELF3 as a cell 
cycle regulator in prostate epithelial cell lines regardless of diagnosis. It would be interesting to determine 
whether ELF3 is a direct regulator of PLK1, either transcriptionally, which could be observed using a 
luciferase-reporter assay, chromatin immunoprecipitation (ChIP) or electrophoretic mobility shift assay 
(EMSA), or at the protein level by co-immunoprecipitation (co-IP). In relation to this, PDEF (another 
epithelial-specific ETS factor), can bind to and inhibit the FOXM1 promoter in TRAMP mouse cells (Cheng 
et al., 2014). PLK1 is a FOXM1 target gene and was also showed decreased expression in the ELF3 
knockdown microarray.  
ELF3 knockdown was optimised in primary prostate cultures enriched for CB cells to determine the effects 
on cell cycle. However, whilst significant knockdown in this challenging model was achieved, there was no 
significant, consistent effect on cell cycle phase or the expression of G2 cell cycle proteins (Section 3.7.4). 
This could largely be due to unsuitable experimental set up for cell cycle analysis. The cells were virtually 
fully confluent at the 72h time point following transfection and cells were therefore not rapidly proliferating, 
as indicated by the high levels of p21 across all samples. A stable knockdown via lentivirus transduction and 
selection may be more suited in this instance as the starting cell density for experiments can be optimised 
more readily than following transient transfection.  
4.4.3 The differential role of ELF3 in benign and cancerous prostate 
In the overexpression studies, ELF3-ΔAT and ELF3-WT showed the same trend in effects on the cell viability 
of both normal and cancer primary prostate samples, although this was only significant at one time point in 
the ELF3-WT and further samples would be beneficial to confirm this (Section 3.6.2). The trend showed an 
increase in cell viability of cancer samples and decreased cell viability of normal samples. This could suggest 
that ELF3 differentially affects cell proliferation between the normal and cancer setting. In accordance with 
this, Prescott et al. found that transiently overexpressing ELF3 in breast cell lines resulted in nuclear 
localisation and exerted differential effects on normal and cancer cell lines (Prescott et al., 2004). 
Specifically, nuclear ELF3 promoted apoptosis in normal breast cell lines but not cancer. Whilst we found 
no change in expression of the apoptosis marker cleaved caspase-3 in cells with ELF3 knockdown, this has 
not been tested in primary prostate cells with ELF3 overexpression. Some studies have linked ELF3 
expression to apoptosis, particularly in the inflammatory setting (Feng et al., 2016, Li et al., 2015). Other 
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studies have also shown that nuclear translocation of ELF3 induces apoptosis in a transcription-dependent 
manner (Lee et al., 2008, Longoni et al., 2013), which suggests ELF3 may require specific stimuli to promote 
apoptosis. 
In the microarray, PC3 cells possessed almost double the number of significantly altered genes (1848 
upregulated, 931 downregulated) compared to BPH-1 (776 upregulated, 664 downregulated). This is 
interesting as PC3 cells showed a more modest response in colony forming and migration assays compared 
to BPH-1 cells. Given that the degree of knockdown was similar in both cell lines, this result further implies 
that PC3 cells may be upregulating compensatory pathways to cope with ELF3 knockdown, which in turn 
suggests that ELF3 may be an important regulator in cancer.  
Following the unbiased analysis of GO terms, changes in expression of other ETS factors were also 
assessed. Interestingly, PC3 cells showed a significant 7-fold upregulation of ESE3. ETS factors are known 
to display redundancy among their functions (Oikawa and Yamada, 2003, Hollenhorst et al., 2007). 
Therefore ESE3 upregulation may represent one compensatory mechanism for PC3 cells. As mentioned in 
Section 1.8.3.3, ESE3 is an epithelial-specific ETS factor belonging to the same subfamily as ELF3 and they 
share 84% homology within their ETS DNA-binding domain (Kas et al., 2000). However, each has a distinct 
PNT domain, suggesting that whilst they may bind to similar target genes, their effects could ultimately vary, 
depending on the protein-protein interactions achieved via their PNT domains. In the prostate, ESE3 has 
been found to possess tumour suppressor functions. One study demonstrated that ESE3 can upregulate 
the expression of Nkx3.1; a tumour-suppressor commonly lost in PCa partly by heterozygous deletion of the 
gene located at chromosome 8p21.2 (Bowen et al., 2000, Vocke et al., 1996, Kunderfranco et al., 2010). 
Further studies by the same group have identified that loss of ESE3 promotes a SC phenotype due in part 
to its repression of IL-6 and the STAT3 pathway (Albino et al., 2012, Albino et al., 2016). ESE3 expression 
is also lost in cancers of other tissues (Tugores et al., 2001). Given these observations, it is surprising that 
PC3 cells would upregulate ESE3 in response to ELF3 knockdown. However, ESE3 displays a similar 
expression pattern to ELF3 in the normal prostate and is therefore most highly expressed in basal epithelial 
cells (Tugores et al., 2001). Given the homology between ELF3 and ESE3 and the plethora of regulation 
that ETS factors exhibit, ESE3 could potentially alter its function in this context to partially restore colony 
forming and migratory abilities. 
4.4.4 The role of ELF3 in differentiation and EMT 
BPH-1 siELF3 cells showed a more overt morphological change when compared to PC3 siELF3 cells. BPH-
1 cells were more tightly packed together which was evident in brightfield images and IF of tubulin and 
phalloidin (Section 3.4.5). There was also a progressive increase of basal marker CK5 and decrease of 
luminal marker CK18 shown by western blot and ICC, indicating cells were becoming more basal. On the 
other hand, PC3 cells showed an initial decrease in CK18, however this was not sustained, and CK5 was 
only detected at low levels in all conditions by ICC. This shift in CK expression could be due to death of the 
more differentiated CK18 positive cells that cease to divide. 
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Differentiation status was also investigated in primary prostate cells after ELF3 overexpression. Using two 
methods, quantitative phase imaging and flow cytometry, we showed that irrespective of diagnosis, ELF3-
WT cultures had a higher proportion of more primitive TA cells compared to ELF3-ΔAT cultures, which had 
a higher proportion of CB cells (Figure 4.1). This indicates that nuclear ELF3 may be required to maintain 
prostate epithelial cells in the basal state, and downregulation of expression may contribute to CB cell 
commitment of differentiation to luminal cells. Knockout of murine Elf3 results in 30% lethality, highlighting 
its importance in development (Ng et al., 2002). Furthermore, the surviving mice displayed several 
abnormalities of the epithelial cell-rich small intestine, including the inability to undergo proper terminal 
differentiation. ELF3 has also been linked to differentiation in many human studies. For instance, Brembeck 
et al. showed ELF3 repressed the basal keratin 4 and upregulated the late differentiation marker SPRR2A 
in oesophageal squamous carcinoma cell lines (Brembeck et al., 2000). In the bladder, ELF3 has been 
shown to be a regulator of differentiation in the urothelium, as knockdown of ELF3 prevents differentiation 
and expression of late differentiation marker uroplakin3a (Bock et al., 2014). Several studies have also 
showed that ELF3 is upregulated in primitive cell lines following induced differentiation by retinoic acid (Park 
et al., 2014, Cheong et al., 2010, Kim and Lotan, 2004). This also coincides with the expression pattern of 
ELF3 we have found in prostate basal subpopulations, whereby SCs express low ELF3 which is upregulated 
upon basal cell differentiation. Our findings indicate that a delicate balance of ELF3 expression is required 
to maintain the proper differentiation and homeostasis of the prostate epithelial hierarchy and increased 
ELF3 may feedback to increase progenitor cell numbers. 
E-cadherin and active β-catenin expression were also examined as epithelial and EMT markers, 
respectively. Both cell lines showed an increase in E-cadherin and active β-catenin, albeit they were 
upregulated in PC3 siELF3 cells at a later time point than BPH-1 siELF3 cells. Active β-catenin was localised 
to the cell membrane in both cell types. In the nucleus, β-catenin can activate the Wnt signalling pathway 
and promote EMT. However, the observed localisation indicates that rather than acting as a driver of EMT, 
it was likely acting as an adaptor to E-cadherin in the cell membrane adhesion complex (Shin et al., 2010, 
Tian et al., 2011). This coincides with the increased cell-cell contacts and compact colony formation 
observed in BPH-1 cells with ELF3 knockdown. ELF3 has been shown to bind and co-localise with β-catenin 
in the cytoplasm of colon cancer cells via its ETS domain (Yang and Lee, 2016). This raises the possibility 
that ELF3 sequesters β-catenin in the cytoplasm of prostate epithelial cells and therefore loss of ELF3 
liberates the protein.  
From findings in the functional assays and literature, other pathways of interest were also investigated from 
the gene expression microarray, such as EMT. PC3 cells with ELF3 knockdown showed an upregulation of 
fibronectin and its receptor integrin α5, which are associated with mesenchymal cells. PC3 cells have an 
invasive cell phenotype and inherently express markers of EMT such as vimentin to a certain degree (Singh 
et al., 2003). However, there was no change in mesenchymal cell marker expression in BPH-1 cells. There 
was also a 2-fold upregulation of E-cadherin in PC3 cells, which agrees with the previous western blot 
findings. There was also no significant change in EMT transcription factor expression. Several recent studies 
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have explored the role of ELF3 in EMT with conflicting findings. In colorectal and breast cancer, ELF3 has 
been shown to negatively regulate ZEB1, a key driver of EMT (Liu et al., 2018, Sinh et al., 2017). Studies in 
ovarian cancer and NSCLC have also found ELF3 expression to negatively regulate EMT by decreasing cell 
proliferation, anchorage independent growth, migration and invasion, as well as reducing expression of 
classical EMT markers such as vimentin and Snail (Yeung et al., 2017, Lou et al., 2018). Conflicting studies 
in breast, NSCLC and hepatocellular carcinoma have shown ELF3 to promote EMT. In hepatocellular 
carcinoma, ELF3 promotes ZEB1 expression by binding to miR-141-3p and repressing its action on ZEB1 
(Zheng et al., 2018). In NSCLC, ELF3 promotes EMT marker expression through activation of the PI3K/Akt 
and ERK signalling pathways (Wang et al., 2018). Finally, a study by Schedin et al. showed that 
overexpression of ELF3 in a normal breast cell line resulted in sphere formation which resembled tumours 
with an EMT phenotype compared to normal glandular spheres formed by control cells (Schedin et al., 
2004).  
Whilst ELF3 knockdown reduced colony formation, cell viability and migration, there was no overt differential 
expression of EMT transcription factors or mesenchymal cell markers in the microarray. Though, there was 
an increase in E-cadherin and active β-catenin at the cell membrane, demonstrating that cells are becoming 
more epithelial. The experimental and gene expression data shows that ELF3 knockdown induces functional 
changes which were in part due to reduced cell proliferation via cell cycle arrest at G2. However, EMT is a 
dynamic process, and fluctuation of ELF3 expression levels clearly influences the epithelial phenotype. 
Therefore, it would be interesting to investigate the expression of EMT markers at the protein level to fully 
confirm whether ELF3 is a regulator of EMT in prostate epithelial cells.  
 
 
Figure 4.1. ELF3 expression in the prostate epithelial hierarchy. 
A summary of ELF3 expression manipulation carried out in prostate epithelial cells. ELF3 is endogenously expressed in 
the CB subpopulation (blue), whilst ELF3-WT overexpression via lentiviruses induces a proportional shift towards the TA 
subpopulation (green). 
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4.5 Targeting ETS factors in cancer  
4.5.1. Direct targeting of ETS factors 
Various methods of targeting ETS factors have been investigated either at the transcriptional, mRNA or 
protein levels. For instance, triplex-forming oligonucleotides (TFOs) are single-stranded oligonucleotides 
that bind to specific sequences in DNA and form triple helices, interrupting the transcription of the targeted 
gene. They bind to long homopurine sequences, which are commonly found in gene promoter regions and 
enhance both the specificity and stability of the interaction. A TFO targeted to ETS2 resulted in decreased 
colony forming ability and induced apoptosis in DU145 cells (Carbone et al., 2004). Since ETS2 is a regulator 
of telomerase activation in breast cancer cells (Dwyer and Liu, 2010), this type of therapy could potentially 
abrogate the self-renewal capacity of CSCs. The control experiments in this study revealed that the ETS2 
TFO was highly target gene-specific and presented an appealing prospect for future gene-targeted therapies 
(Carbone et al., 2003). However, a suitable delivery method and the potential for long-term mutagenic effects 
are significant limitations. 
A small molecule inhibitor of ETS factor fusion protein EWS-FLI1 in Ewing’s sarcoma has been tested on 
ERG-fusion positive VCaP cells and ETV1-fusion positive LNCaP cells (Rahim et al., 2011). The inhibitor, 
YK-4-279, decreased the migratory and invasive properties associated with ERG and ETV1 overexpression 
in PCa, without altering their protein levels in vitro. The fusion negative cell line (PC3) was unresponsive to 
treatment, suggesting the inhibitor is selectively targeting the overexpressed ETS factors. Whether YK-4-
279 will also target essential ETS factors and cause off-target toxic effects in vivo still needs to be 
investigated. 
A major consideration is that direct targeting of a transcription factor is likely to result in off-target side effects, 
especially given the wide variety of functions ETS factors perform in different types of cells and tissues 
(Figure 4.2). ETS factor knockouts in mice generally result in at best detrimental effects or even lethality 
(Bartel et al., 2000). As only a limited number of target genes are likely to cause the oncogenic effects, or 
alternatively block tumour suppressors, the toxicity induced by blocking transcription factors must therefore 
be carefully monitored. Targeting unique cancer-associated molecules such as TMPRSS2-ERG mRNA 
would avoid such complications and specifically target cancer cells. A good example of this in practice is 
imatinib, a small molecule inhibitor of the BCR-ABL fusion protein which has revolutionised the treatment of 
fusion positive chronic myeloid leukaemia (CML) as well as other cancers (Nadal and Olavarria, 2004). 
TMPRSS2-ERG is a complex target since the mRNA presents as multiple different splice variants in each 
patient and the translated protein formed only consists of ERG. Shao et al. designed siRNA molecules 
specific for the unique junctions of two isoforms of TMPRSS2-ERG mRNA, including the most common 
isoform TMPRSS2 exon 1-ERG exon 4 and TMPRSS2 exon 2-ERG exon 4 which is associated with 
aggressive disease (Shao et al., 2012). The efficiency in knocking down the fusion gene was tested in vivo 
via liposomal nanovectors, which have also been successfully tested in murine models of breast and ovarian 
cancer (Landen et al., 2005, Halder et al., 2006). The siRNAs were able to reduce growth of established 
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VCaP xenograft tumours with no effect on normal ERG levels and no toxicity observed in the mice. Since 
prostate CSCs express TMPRSS2-ERG, knocking it down might inhibit cell growth. Whilst this approach is 
appealing, its effect on the function and longevity of fusion positive prostate CSCs would need to be 
monitored before it could be considered curative. Furthermore, CSC liposome uptake into every tumour cell 
and their potential to degrade the siRNA through resistance mechanisms would also need to be investigated. 
 
 
Figure 4.2. The benefits and disadvantages of inhibiting ETS factors in cancer. 
The inhibition of aberrantly expressed ETS transcription factors in cancer would prevent their binding to the promoter 
regions of target genes. This would subsequently lead to the repression of cancer-associated target genes normally 
upregulated by said ETS factor in cancer. Alternatively, this may also alleviate the suppression of repressed tumour 
suppressor genes. This will lead to many beneficial, tumour-specific effects. However, given the importance of ETS factors 
in normal tissue homeostasis, there will also be toxic, off-target effects to normal cells. Taken from (Archer et al., 2017). 
4.5.2. Indirect targeting of ETS factors 
An alternative and almost certainly less toxic method of preventing the aberrant effects of ETS factors in 
cancer is to indirectly target the specific factor and thus target the oncogenic effect. ETS factors are known 
to regulate gene expression via interactions with co-regulatory proteins (Li et al., 2000). Since multiple ETS 
factors are able to bind to the same target genes, targeting the protein-protein interactions should be a more 
selective way of inhibiting their effects in cancer without interfering with the normal binding of other ETS 
factors. Several synthetic molecules have been constructed which interfere with the interaction between 
ELF3 and one of its co-activators, Sur2 (Shimogawa et al., 2004, Asada et al., 2003, Lee et al., 2009). The 
ELF3-Sur2 interaction is required for the activation of the growth factor HER2 (Moasser, 2007). The use of 
ELF3-Sur2 inhibitors downregulated HER2 expression with a concomitant decrease in cell proliferation and 
increase in apoptosis in cell line models of breast cancer, gastric cancer and HNSCC. Furthermore, the 
ELF3-Sur2 inhibitors sensitised breast cancer cell lines to tamoxifen and also worked synergistically with 
the currently used treatments for gastric cancer and HNSCC (Nam et al., 2013, Kim et al., 2012, Zhang et 
al., 2013). Thus, determining the interacting partners of ETS factors which are important in driving tumour 
progression may be a more viable route for cancer therapeutics. 
In order to inhibit the negative effects of a specific ETS factor in cancer without hindering its normal roles in 
target and surrounding tissues, the induced transcriptome of the factor is an essential tool. The ability to 
evaluate precisely which target genes are important for cancer initiation and progression, and identifying 
key co-regulators would be instrumental in developing ETS factor targeting therapies. Although time-
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consuming, this is the only way, short of finding a cancer-specific and targetable molecule, to maintain the 
equilibrium between positive and negative ETS factor function. ChIP-chip technology, where whole genome 
analysis can identify all the binding sites of a specific ETS factor within the genome in different types of cells 
would be a primary tool for this analysis (Buck and Lieb, 2004). 
4.5.3. Expression of suppressive ETS factors 
With regards to PCa, PDEF and ESE3 are candidate tumour suppressors that could be exploited for gene 
therapy. The classical example of a tumour suppressor is transcription factor p53, which is mutated in over 
50% of all human cancers, making it an attractive therapy target. Re-introduction of wildtype p53 has been 
investigated using non-replicative adenoviruses in multiple cancers including prostate (Hong et al., 2014, 
Stegh, 2012, Yang et al., 1995). Clinical trials have produced promising results in different cancers 
particularly in combination with conventional chemotherapy and radiotherapy (Xie et al., 2010, Li et al., 
2009). Notably, loss of functional p53 has also been linked to enhancement of the CSC phenotype (Prabhu 
et al., 2012). Therefore, reintroduction of p53 may abrogate the CSC population and could explain the 
success of the viral transduction approach in combination with traditional cancer therapies. Re-expression 
of PDEF or ESE3 would only be beneficial for the subtype of PCas that have lost PDEF or ESE3 expression. 
If PDEF and ESE3 loss are truly maintaining cells in a de-differentiated state then their re-expression, e.g. 
via a viral vector, could promote differentiation of the tumour cells. This should also differentiate the CSCs 
into a cell type that is more susceptible to conventional treatments. 
4.5.4 Differentiation therapy 
In order to cure PCa, we must take into account the cellular heterogeneity of the disease, a challenge which 
current therapy strategies have been unable to surmount. This is reflected in the limited survival rates of 
patients prescribed the next-generation drugs which typically only target luminal cells. The effects of the 
aberrantly expressed epithelial-specific ETS factors in PCa appear to maintain the cancer cells in a more 
SC-like state (Archer et al., 2017). We and others have observed this stem-like phenotype in advanced 
metastatic tumours (Rane et al., 2015, Pellacani et al., 2014, Smith et al., 2015). This will confer drug-
resistance mechanisms and inevitably tumour recurrence following treatment, as these cells retain their 
proliferative potential and hence tumour renewal potency. The premise of differentiation therapy is to 
manipulate CSCs and progenitor cells to drive them towards differentiation and lose their stem-like abilities, 
resulting in differentiated cells with limited proliferative capacity characteristic of the bulk of a prostate 
tumour. Although an attractive theory, the design of effective differentiation therapies has been limited (Rane 
et al., 2012). The most notable success has been with acute promyelotic leukaemia (APL) which is 
characterised by an accumulation of progenitor cells caused by a block in differentiation (de The et al., 1991, 
Grignani et al., 1993). Differentiation is restored in APL via all-trans retinoic acid treatment which is now part 
of the standard APL therapy regime (Huang et al., 1988, Sanz et al., 2009). If differentiation therapy were 
to be successful in PCa it would have to be combined with conventional cytotoxic treatments to kill the bulk 
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tumour cells as well as the differentiated and now vulnerable CSCs, which would eradicate all tumour cells 
and prevent recurrence. 
4.6 Concluding remarks 
The regulatory potential of ETS factors most likely explains the conflicting findings in literature of ELF3 
biological functions such as tumour suppressor vs. oncogene or even more specifically activation vs. 
repression of the same gene. This could involve interaction with various co-factors, or under specific stimuli. 
The possible redundancy found between ETS factors adds an additional layer of complexity when studying 
these proteins. Studies in ELF3 and other discussed ETS factors have also shown that function is extremely 
context-dependent, with regards to tissue type, cell type and pathology. Consequently, defining the correct 
cell type to study ELF3 expression was integral to determining its genuine function in the prostate.  
Whilst established cell lines are easily manipulated and provide a suitable means to explore mechanisms 
and theories, they do not fully represent the complexity of a tumour and how the cells interact and 
differentiate. To illustrate this, multidimensional scaling of cell lines and primary cells shows distinct 
clustering, demonstrating that they are very different, and both should be employed appropriately within a 
study (Figure 4.3). By utilising the fractionated cell populations from primary patient tumours, this study has 
for the first time provided a comprehensive account of ELF3 expression in the prostate, including individual 
subpopulations. Furthermore, we have described a novel role for ELF3 as a regulator of the cell cycle in 
prostate basal cells as well as generating an effective tool for studying ELF3 overexpression. We have 
generated data that implies that ELF3 almost certainly carries out additional functions in the prostate, of 
which we could only begin to unravel in the duration of this study. This includes the regulation of primary 
prostate epithelial cell differentiation, potential regulation of β-catenin function, and providing a survival 
benefit in cancer vs. normal cells and a possible link to advanced prostate tumours.  
Collectively, these findings suggest ELF3 may be an oncogene in the PCa setting. However, given ELF3 is 
also a regulator of the cell cycle and potentially differentiation in normal prostate epithelial cells, this would 
need to be taken into consideration in the context of developing therapies. The gene expression microarray 
of cells with ELF3 knockdown provided a useful repository of information and a similar investigation into the 
genome-wide changes caused by ELF3 overexpression would be invaluable in defining further roles and 
unveiling important signalling pathways regulated by ELF3, and whether it or its downstream effectors could 
ultimately be manipulated to improve PCa treatment.  
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Figure 4.3. Multidimensional scaling of prostate epithelial cells. 
Multidimensional scaling (MDS) of prostate primary cells, BPH-1 and PC3 cell lines. Cell line sample sets were in biological 
triplicate and included untransfected, mock transfected, siSCR and siELF3 of BPH-1 and PC3 cells. Primary cells represent 
several individual patients. Produced by Alastair Droop.  
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Appendices 
Appendix 3.1: Videos of migration assay of primary prostate cells with ELF3 
overexpression (see attached CD). 
Appendix 3.2: ELF3 knockdown does not induce apoptosis in primary prostate 
committed basal cells. 
Primary prostate committed basal cell lysates harvested 72 hours post-transfection were probed for cleaved 
caspase 3 as a marker of apoptosis. S = staurosporine-treated BPH-1 cells (1μM for 24 hours). 
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Appendix 3.3: Gene ontology (GO) terms associated with siSCR vs siELF3 in BPH-1 
and PC3 cells combined. Top 35 terms with highest p-values shown.   
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Term P-value Genes 
GO:0006334 Nucleosome 
assembly 
3.75E-13 
HIST2H3A, HIST1H3J, HIST1H1E, HIST1H1D, HIST1H2BF, 
HIST2H3C, HIST1H2BM, HIST1H1T, HIST1H2BN, HIST1H4A, 
HIST1H2BL, HIST1H2BJ, NAA60, HIST1H3A, HIST1H3B, 
HIST1H4E, HIST1H3C, HIST1H4C, H2AFX, HIST1H3F, 
ASF1B, HIST2H3PS2, HIST1H4J 
GO:0000183 Chromatin 
silencing at rDNA 
1.45E-09 
HIST2H3A, HIST1H3J, HIST1H4A, HIST1H3A, HIST1H3B, 
SUV39H1, HIST1H4E, HIST1H3C, HIST1H4C, HIST1H3F, 
HIST1H4J, HIST2H3C 
GO:0006335 DNA replication-
dependent nucleosome 
assembly 
4.76E-09 
HIST1H3J, HIST1H4A, IPO4, HIST1H3A, HIST1H3B, 
HIST1H4E, HIST1H3C, HIST1H4C, ASF1B, HIST1H3F, 
HIST1H4J 
GO:0006342 Chromatin 
silencing 
1.74E-07 
HIST1H2AB, HIST2H2AB, HIST1H2AG, HIST1H2AE, 
MORF4L2, HIST1H2AI, H2AFX, HIST1H2AJ, HIST1H2AM, 
HIST1H2AL, BAHD1 
GO:0032200 Telomere 
organization 
2.74E-07 
HIST1H3J, HIST1H4A, HIST1H3A, HIST1H3B, HIST1H4E, 
HIST1H3C, HIST1H4C, HIST1H3F, HIST1H4J 
GO:0045815 Positive 
regulation of gene expression, 
epigenetic 
4.81E-07 
HIST2H3A, HIST1H3J, POLR2F, HIST1H4A, HIST1H3A, 
HIST1H3B, HIST1H4E, HIST1H3C, HIST1H4C, HIST1H3F, 
HIST1H4J, HIST2H3C 
GO:0045814 Negative 
regulation of gene expression, 
epigenetic 
4.99E-07 
HIST2H3A, HIST1H3J, HIST1H4A, HIST1H3A, HIST1H3B, 
HIST1H4E, HIST1H3C, HIST1H4C, HIST1H3F, HIST1H4J, 
HIST2H3C 
GO:0031047 Gene silencing 
by RNA 
1.06E-06 
HIST2H3A, HIST1H3J, NUP133, POLR2F, POM121, 
HIST1H4A, NUP210, HIST1H3A, HIST1H3B, HIST1H4E, 
HIST1H3C, HIST1H4C, HIST1H3F, HIST1H4J, HIST2H3C 
GO:0051290 Protein 
heterotetramerization 
1.04E-05 
HIST1H3J, HIST1H4A, HIST1H3A, HIST1H3B, HIST1H4E, 
HIST1H3C, HIST1H4C, HIST1H3F, HIST1H4J 
GO:0007059 Chromosome 
segregation 
6.16E-05 
KIF11, SPAG5, INCENP, NAA60, CENPF, SKA3, CENPW, 
CENPE, NDC80, RCC1 
GO:0007062 Sister chromatid 
cohesion 
7.29E-05 
ITGB3BP, KIF22, NUP133, MAD2L1, PLK1, INCENP, CENPF, 
CENPE, NDC80, AURKB, CDCA5, CENPI 
GO:0007067 Mitotic nuclear 
division 
8.57E-05 
ITGB3BP, KIF22, KIF11, KIF15, CENPF, NDC80, AURKB, 
RCC1, HMGA2, CDC25C, REEP4, CCNB2, PLK1, INCENP, 
SKA3, CENPW, MAD2L2, CDCA5, TUBB3 
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GO:0051301 Cell division 1.24E-04 
ITGB3BP, KIF14, CKS1B, KIF11, PSRC1, KIF18B, CENPF, 
NDC80, CENPE, RCC1, HMGA2, CDC25C, REEP4, CCNB1, 
NCAPH, MAD2L1, CCNB2, NCAPG, SPAG5, CENPW, SKA3, 
MAD2L2, CDCA5 
GO:0060968 Regulation of 
gene silencing 
1.27E-04 HIST1H3J, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3F 
GO:0044267 Cellular protein 
metabolic process 
2.47E-04 
HIST2H3A, HIST1H3J, HIST1H4A, GSN, HIST1H3A, 
HIST1H3B, HIST1H4E, HIST1H3C, HIST1H4C, HIST1H3F, 
HIST1H4J, HIST2H3C 
GO:0051726 Regulation of 
cell cycle 
3.80E-04 
CCNB1, ADARB1, CCNB2, TSC1, DTL, PLK1, FOXM1, SKP2, 
CENPF, BOP1, CDC25C, MYBL2 
GO:0006336 DNA replication-
independent nucleosome 
assembly 
4.78E-04 HIST1H4A, IPO4, HIST1H4E, HIST1H4C, ASF1B, HIST1H4J 
GO:0008283 Cell proliferation 5.95E-04 
CKS1B, TSPAN1, KIF15, MET, HDGF, PIM1, SKP2, CENPF, 
PRKDC, BOP1, AURKB, PIM2, CDC25C, MXD1, ISG20, 
TGFB2, LRP1, PLK1, NAA60, MELK, ERCC1, USP13 
GO:0034080 CENP-A 
containing nucleosome 
assembly 
7.90E-04 
ITGB3BP, HIST1H4A, HIST1H4E, CENPW, HIST1H4C, 
HIST1H4J, CENPI 
GO:0006886 Intracellular 
protein transport 
0.001300515 
STX3, TBC1D3G, TBC1D3H, COPZ1, CTSA, TBC1D3B, 
BCAP31, AP1S3, STX12, IPO4, TBC1D13, RHOB, TOMM22, 
STX11, TBC1D3, VPS39 
GO:0007080 Mitotic 
metaphase plate congression 
0.002509116 KIF14, CCNB1, KIF22, PSRC1, CENPE, CDCA5 
GO:0016233 Telomere 
capping 
0.002660512 HIST1H4A, HIST1H4E, PRKDC, HIST1H4C, HIST1H4J 
GO:0000086 G2/M transition 
of mitotic cell cycle 
0.003025545 
CCNB1, CCNB2, CEP250, PLK1, FOXM1, SKP2, CALM3, 
OPTN, CDC25C, MELK, HMMR 
GO:0000209 Protein 
polyubiquitination 
0.003113594 
WSB1, PSMB4, C18ORF25, DTL, RNF165, TRIM69, TPP2, 
SKP2, RBCK1, RNF24, RNF181, RNF213, CBFB 
GO:0051310 Metaphase plate 
congression 
0.003190695 KIF22, CENPF, CENPE, NDC80 
GO:0000070 Mitotic sister 
chromatid segregation 
0.003648786 MAD2L1, PLK1, SPAG5, KIF18B, NDC80 
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GO:0000278 Mitotic cell cycle 0.003964187 E2F4, CEP250, CENPF, KIF18B, CENPW, CENPE 
GO:0007018 Microtubule-
based movement 
0.004995467 KIF23, KIF14, KIF22, KIF4A, KIF11, KIF15, KIF18B, CENPE 
GO:0006977 DNA damage 
response, signal transduction 
by p53 class mediator 
resulting in cell cycle arrest 
0.005278038 CCNB1, E2F1, CDKN1B, E2F4, E2F7, ARID3A, CDC25C 
GO:0007077 Mitotic nuclear 
envelope disassembly 
0.005392878 CCNB1, NUP133, POM121, CCNB2, PLK1, NUP210 
GO:0006303 Double-strand 
break repair via 
nonhomologous end joining 
0.005709232 
HIST1H4A, C7ORF49, HIST1H4E, PRKDC, H2AFX, 
HIST1H4C, HIST1H4J 
GO:0045653 Negative 
regulation of megakaryocyte 
differentiation 
0.010547239 HIST1H4A, HIST1H4E, HIST1H4C, HIST1H4J 
GO:0098609 Cell-cell 
adhesion 
0.011251182 
HSP90AB1, HIST1H3J, DIAPH3, WASF2, HSPA1A, GIPC1, 
ESYT2, EPB41L1, HNRNPK, CCNB2, HIST1H3A, HIST1H3B, 
HIST1H3C, NDRG1, HIST1H3F 
GO:0071456 Cellular 
response to hypoxia 
0.01233504 
CCNB1, E2F1, STC2, CPEB2, SUV39H1, BNIP3, NDRG1, 
ADAM8 
GO:0016255 Attachment of 
GPI anchor to protein 
0.012898059 PIGK, GPAA1, PIGT 
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Appendix 3.4: Expression changes of cell cycle-related genes following ELF3 
knockdown from gene expression microarray. Highlighted boxes indicate genes with 
significance threshold of 2-fold increase or decrease and a p-value <0.05. NS = not 
significant. 
Cell Cycle - significant only BPH-1 PC3 Both 
Gene Description 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
Fold 
Change 
P-Val 
PLK1 Polo-like kinase 1 -15.56 0.0001 -5.59 1.16E-06 -7.53 4.24E-07 
CCNB2 Cyclin B2 -13.21 0.0001 -8.27 9.34E-07 -8.22 2.27E-06 
SKP2 
S-phase kinase-
associated protein 
2 
-5.07 2.62E-06 -6.2 5.65E-05 -5.32 0.0022 
CDCA5 
Cell cycle division 
associated 5 
-2.36 0.0036 -3.17 0.007 -2.98 0.0062 
CKS1BP7 
CDC28 protein 
kinase regulatory 
subunit 1B 
pseudogene 7 
-2.3 0.0366 -2.09 0.0014 -2.91 0.0154 
CKS1B 
CDC28 protein 
kinase regulatory 
subunit 1B 
-2.7 0.0202 -2.4 0.0002 -2.79 0.0232 
CENPF 
Centromere 
protein F 
-3.8 0.0024 -2.15 0.0036 -2.83 0.0024 
CDC25C 
Cell division cycle 
25C 
-2.34 0.0008 -2.27 0.0006 -2.42 2.39E-05 
AURKB Aurora kinase B -2.68 0.0046 -2.55 0.009 -2.23 0.0045 
CCNB2 Cyclin B2 -13.21 0.0001 -8.27 9.34E-07 -8.22 2.27E-06 
CDCA5 Soronin -2.36 0.0036 -3.17 0.007 -2.98 0.0062 
MAD2L2 
MAD2 mitotic 
arrest deficient-like 
2 (yeast) 
-2.9 8.80E-06 -3.96 9.56E-06 -3.31 2.35E-08 
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CENPW 
Centromere 
protein W 
-2.22 0.0334 -2.04 0.0222 -2.03 0.0095 
FOXM1 Forkhead box M1 -2.27 0.0125 NS NS -2.4 0.0141 
CEP128 
Centrosomal 
protein 128kDa 
-2.6 0.0014 NS NS -2.98 0.0029 
CENPE 
Centromere 
protein E 
-3.62 0.0044 NS NS -2.15 0.0013 
INCENP 
Inner centromere 
protein 
-2.62 0.0011 NS NS -2.36 0.001 
CCNC Cyclin C 2.69 0.0028 NS NS 2.29 0.0086 
CKS1BP3 
CDC28 protein 
kinase regulatory 
subunit 1B 
pseudogene 3 
NS NS -2.21 0.0004 -2.3 0.0453 
SKA3 
Spindle and 
kinetochore 
associated 
complex subunit 3 
NS NS -2.38 0.0008 -2.06 0.0019 
PPP2R1B 
Protein 
phosphatase 2, 
regulatory subunit 
A, beta 
NS NS 2.74 1.65E-05 2.87 6.97E-05 
CDKN1B 
Cyclin-dependent 
kinase inhibitor 1B 
NS NS 3.84 7.47E-06 2.13 0.0368 
PPP2R5B 
Protein 
phosphatase 2, 
regulatory subunit 
B, beta 
4.75 0.0207 3.04 0.0002 NS NS 
CDKL5 
Cyclin-dependent 
kinase-like 5 
2.21 0.0173 2.22 0.0007 NS NS 
181 
CKS1B 
CDC28 protein 
kinase regulatory 
subunit 1B 
-2.7 0.0202 -2.4 0.0002 NS NS 
NDC80 
Kinetochore 
complex 
component 
NS NS NS NS -2.19 0.0098 
PRC1 
Protein regulator of 
cytokinesis 1 
NS NS NS NS -2.02 0.001 
CCNB1 Cyclin B1 NS NS NS NS -2.59 0.004 
CENPI 
Centromere 
protein I 
NS NS NS NS -2.13 0.0093 
CDK6 
Cyclin-dependent 
kinase 6 
-5.26 3.41E-05 NS NS NS NS 
BUB1B 
mitotic checkpoint 
ser/thr kinase B 
-2.56 0.0067 NS NS NS NS 
CDKN3 
Cyclin-dependent 
kinase inhibitor 3 
-2 0.0284 NS NS NS NS 
CCNY Cyclin Y -2.5 0.0008 NS NS NS NS 
ANAPC11 
Anaphase 
promoting complex 
subunit 11 
-2.16 0.0005 NS NS NS NS 
MKI67 Ki67 -2.04 0.0374 NS NS NS NS 
CCNJL cyclin J-like 2.13 0.0338 NS NS NS NS 
PAK4 
p21 protein 
(Cdc42/Rac)-
activated kinase 4 
-2.05 0.0005 NS NS NS NS 
CDCA7 
cell division cycle 
associated 7 
-2.22 0.0008 NS NS NS NS 
CDCA2 
cell division cycle 
associated 2 
-2.48 0.0006 NS NS NS NS 
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CDCA3 
cell division cycle 
associated 3 
-2.75 0.0143 NS NS NS NS 
CDK5 
Cyclin-dependent 
kinase 5 
NS NS -2.78 0.0003 NS NS 
CDKN1A 
Cyclin-dependent 
kinase inhibitor 1A 
(p21, Cip1) 
NS NS 6.94 8.41E-06 NS NS 
ANAPC1 
Anaphase 
promoting complex 
subunit 1 
NS NS -2.5 0.0015 NS NS 
BRCA1 
Breast cancer type 
1 susceptibility 
protein 
NS NS -2.7 0.0013 NS NS 
CDK2 
Cyclin-dependent 
kinase 2 
NS NS -3.08 0.0315 NS NS 
PLK4 Polo-like kinase 4 NS NS -2.83 0.0037 NS NS 
CENPM 
Centromere 
protein M 
NS NS -2.2 0.0049 NS NS 
DSCC1 
DNA replication 
and sister 
chromatid 
cohesion 1 
NS NS -2.27 0.0311 NS NS 
CCNG2 Cyclin G2 NS NS 5.14 0.0019 NS NS 
CDKN2C 
Cyclin-dependent 
kinase inhibitor 2C 
NS NS 2.51 0.0032 NS NS 
CDKL4 
cyclin-dependent 
kinase-like 4 
NS NS 2.36 0.0025 NS NS 
CDK19 
cyclin-dependent 
kinase 19 
NS NS 2.18 0.0431 NS NS 
CDKL1 
cyclin-dependent 
kinase-like 1 
NS NS -2.47 0.0001 NS NS 
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(CDC2-related 
kinase) 
CDK5 
cyclin-dependent 
kinase 5 
NS NS -2.78 0.0003 NS NS 
CDCA4 
cell division cycle 
associated 4 
NS NS -2.92 0.0065 NS NS 
CENPB 
centromere protein 
B 
NS NS -2.02 0.0153 NS NS 
CENPN 
centromere protein 
N 
NS NS -2.16 0.0081 NS NS 
CENPP 
centromere protein 
P 
NS NS -2.23 0.0001 NS NS 
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Appendix 3.5: Expression graphs of genes that show different behaviour upon ELF3 
knockdown between BPH-1 and PC3 cells from gene expression microarray. Norm = 
siSCR, kd = siELF3. Graphs generated by Alastair Droop. 
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Abbreviations 
3D-CRT  Three-dimensional conformal radiation therapy 
ADT   Androgen-deprivation therapy 
AML   Acute myeloid leukaemia 
APL   Acute promyelotic leukaemia 
AR   Androgen receptor  
ARB   Angiotensin II type I receptor blocker 
ARE   Androgen response elements 
BCA   Bicinchoninic acid assay 
BM   Basement membrane 
bp   Base pairs  
BPE   Bovine pituitary extract 
BPH   Benign prostatic hyperplasia 
BSA   Bovine serum albumin 
CAF   Cancer-associated fibroblasts 
CARN   Castration-resistant Nkx3.1-expressing cells 
CB   Committed basal 
cDNA   Complementary DNA 
ChIP   Chromatin immunoprecipitation 
ChrA   Chromogranin A 
CK   Cytokeratin 
CML   Chronic myeloid leukaemia 
Co-IP   Co-immunoprecipitation 
CPPS   Chronic pelvic pain syndrome 
CRC   Colorectal cancer 
CRPC   Castration-resistant prostate cancer 
CSC   Cancer stem cell 
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CT   Threshold cycle 
D10   DMEM + 10% FCS + 2 mM L-Glutamine 
DAB   Diaminobenzidene 
DAPI  4′,6-diamidino-2-phenylindole 
DAVID   Database for Annotation, Visualization and Integrated Discovery 
DDT   Dithiothreitol 
DES   Diethylstilbestrol 
DHT   Dihydrotestosterone 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTP   Deoxyribonucleotide triphosphate 
E.coli   Escherichia coli 
EBRT   External beam radiation therapy 
ECL   Enhanced chemiluminescence 
EDTA   Ethylenediaminetetraacetic acid 
EGF   Epidermal growth factor 
EGTA   Ethylene glycol-bis(β-aminoethyl ether 
EMSA   Electrophoretic mobility shift assay 
EMT   Epithelial-to-mesenchymal transition 
ER   Oestrogen receptor 
ETS   E26 transformation-specific 
FACS   Fluorescence activated cell sorting 
FCS   Foetal calf serum 
FDA   U.S. Food and Drug Administration 
FISH   Fluorescent in situ hybridisation 
g   Gram 
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GnRH   Gonadotrophin-releasing hormone  
GO   Gene ontology 
GUS   β-glucoronidase 
H7   Ham’s F-12 + 7% FCS + 2 mM L-Glutamine 
HDAC   Histone deacetylase 
HIER   Heat-induced epitope retrieval 
HIFU   High-intensity focused ultrasound 
HMW-CK  High molecular weight cytokeratin 
HNSCC   Head and neck squamous cell carcinoma 
Hr  Hour 
HRP   Horseradish peroxidase 
IAP   Inhibitor of apoptosis 
ICC   Immunocytochemistry 
IHC   Immunohistochemistry 
IMRT   Image-guided intensity-modulated radiation therapy 
K2   KSFM media + 2% FCS + 2 mM L-Glutamine + BPE + EGF 
kDa   Kilo Dalton 
KSFM   Keratinocyte Serum-Free Medium 
L   Left lobe (in relation to primary samples) 
LB   Lysogeny broth 
MACS   Magnetic-activated cell sorting 
MDS   Multidimensional scaling 
mElf3   Murine ELF3 homologue 
MET   Mesenchymal-to-epithelial transition 
mg   Milligram 
MgCl2   Magnesium chloride 
ml   Millilitre 
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mM   Millimolar 
MRI   Magnetic resonance imaging 
mRNA   Messenger RNA 
Na4P2O7  Sodium pyrophosphate tetrabasic 
NaCl   Sodium chloride 
NaF   Sodium fluoride 
NaVO4   Sodium orthovanadate 
NE   Neuroendocrine 
NES   Nuclear export signal 
ng   Nanogram 
NLS   Nuclear localisation signal 
nm   Nanometre 
NSCLC   Non-small cell lung cancer 
NSE   Neurone specific enolase 
PAGE   Polyacrylamide gel electrophoresis 
PAP   Prostatic acid phosphatase 
PBS   Phosphate buffered saline 
PCa   Prostate cancer 
PCR   Polymerase chain reaction 
PDEF   Prostate-derived ETS factor 
PDT   Photodynamic therapy 
PFA   Paraformaldehyde 
PHH3   Phospho-histone H3 
PIN   Prostatic intraepithelial neoplasia 
PNT   Pointed domain 
PrECs   Normal prostate epithelial cells (cell line) 
PSA   Prostate specific antigen 
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qRT-PCR  Quantitative reverse-transcriptase PCR 
R   Right lobe (in relation to primary samples) 
R10   RPMI + 10% FCS + 2 mM L-Glutamine 
R5   RPMI + 5% FCS + 2 mM L-Glutamine 
RIPA   Radioimmunoprecipitation assay buffer 
RNA   Ribonucleic acid 
ROS   reactive oxygen species 
RP   radical prostatectomy  
RP   Replated 
RPM   Revolutions per minute 
RPMI   Roswell Park Memorial Institute medium 
RT   Reverse transcriptase 
SC   Stem cell 
SCM   Stem cell media 
SDS   Sodium dodecyl sulfate 
siELF3   ELF3 siRNA 
siRNA   Small interfering RNA 
siSCR   Scrambled siRNA 
T-25   25cm2 tissue culture flask 
T-75   75cm2 tissue culture flask 
TA   Transit amplifying 
TAC   Transcriptome analysis software 
TAE   Tris base + acetic acid + EDTA buffer 
TBP   TATA-binding protein 
TBS   Tris-buffered saline  
TBST   TBS + Tween-20 
TFO   Triplex-forming oligonucleotides 
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TMA   Tissue microarray 
TRUS   Transrectal ultrasound 
TURP   Transurethral resection of the prostate 
v/v   Volume per volume 
w/v   Weight per volume 
WHTH   Winged-helix-turn-helix 
WT  Wildtype  
μg   Microgram 
μl   Microlitre 
μm   Micrometre 
μM   Micromolar 
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